Transcript
  • SOUTH BAYLO UNIVERSITY

    Investigation of Simultaneous Acupuncture Treatment on Hypertension and Bi-Syndrome:

    Case Series

    ๊ณ ํ˜ˆ์••๊ณผ ๋น„์ฆ์˜ ๋™์‹œ์น˜๋ฃŒ์— ๊ด€ํ•œ ์ž„์ƒ์‚ฌ๋ก€

    by

    Jonathan B. Kim

    A RESEARCH PROJECT SUBMITTED

    IN PARTIAL FULFILLMENT OF THE

    REQUIREMENTS FOR THE DEGREE

    Doctor of Acupuncture and Oriental Medicine

    June 2018

  • Copyright

    by

    Jonathan B. Kim

    2018

  • i

    Investigation of Simultaneous Acupuncture Treatment on Hypertension and Bi-Syndrome:

    Case Series

    ๊ณ ํ˜ˆ์••๊ณผ ๋น„์ฆ์˜ ๋™์‹œ์น˜๋ฃŒ์— ๊ด€ํ•œ ์ž„์ƒ์‚ฌ๋ก€

    Jonathan B. Kim

    SOUTH BAYLO UNIVERSITY, LOS ANGELES, 2018

    RESEARCH ADVISOR: Shan Qin Cui, OMD, L.Ac.

    ABSTRACT

    The purpose of this study was to investigate and better understand the effects of

    simultaneous acupressure treatment on patients with hypertension and Bi-syndrome. The

    subjects in this study were 7 Bi syndrome participants with systolic blood pressure of 140

    mmHg or higher. Participants were treated with both traditional acupuncture which are the

    points of Thi Chong (LR3), Zu San Li (ST36), He Gu (LI4), Quhi (LI11), and auricular

    acupuncture point therapy by affixing vaccaria seeds to the points of Sympathetic, Lower

    Blood Pressure Groove, Kidney, Liver, Endocrine and Neurogate. Moreover, Kunlun

    (BL60), Wan Shun Yi, Wan Shun Er, Zheng Jing, Ma Kuai Shui for Low Back Pain,

    Tiaokou (ST38), Shen Guan, Zu Qian Jin, Zu Wu Jin for Shoulder Pain, and Liangqiu

    (ST34), Dubi (ST35), Xiyan (EX36), Xuehai (SP10), Quguan (LV8), Xiyangguan (GB34)

    for Knee Pain were used. The treatments were conducted twice a week for four weeks to

    each patient, the needling treatments were kept for 30 minutes exactly.

  • ii

    Changes in blood pressure were measured once immediately before and after each

    treatment. Furthermore, data were evaluated using Visual Analogue Scale (VAS), Changes

    in blood pressure, Oswestry Disability Index (ODI), Shoulder Pain and Diability Index

    (SPADI), and Osteoarthritis Index (WOMAC). Data from eight consecutive treatments

    were evaluated by Paired Samples Test for pretest and posttest records and by Independent

    Samples Test for statistical significance between factors. From the results obtained,

    significant effects of lowering systolic (SBP), diastolic blood pressure (DBP), and VAS

    were observed.

    It was concluded that simultaneous acupuncture treatment on hypertension and Bi-

    syndrome can be effectively applied to patients and the results suggest that it could be

    widely used for blood pressure regulation and pain control.

    Keywords: acupuncture, hypertension, high blood pressure, bi-syndrome

  • iii

    TABLE OF CONTENTS

    ABSTRACT i

    LIST OF TABLES iv

    LIST OF FIGURES vii

    I. INTRODUCTION 1

    II. OBJECTIVES 9

    III. LITERATURE REVIEW 10

    IV. MATERIALS AND METHODS 27

    V. RESULTS AND DISCUSSION 44

    VI. CONCLUSIONS 120

    REFERENCES 122

  • iv

    LIST OF TABLES

    Table 1. Location and Indication of Acupuncture Points 36

    Table 2. Location and Indication of Auricular Points 37

    Table 3. Acupuncture Points Used for the Treatment of Lower Back Pain 38

    Table 4. Acupuncture Points Used for the Treatment of Shoulder Pain 39

    Table 5. Acupuncture Points Used for the Treatment of Knee Pain168) 40

    Table 6. Demographic Characteristics of the Subjects 45

    Table 7. Change of Systolic Blood Pressure 47

    Table 8. Change of Diastolic Blood Pressure 48

    Table 9. The Effect of Treatment on the Change of VAS 51

    Table 10. Cumulative Effect of Systolic Blood Pressure 55

    Table 11. Cumulative Effect of Diastolic Blood Pressure 56

    Table 12. SYS Treatment Rate (%) 57

    Table 13. DI Treatment Rate (%) 58

    Table 14. Cumulative Effect of VAS 64

    Table 15. VAS Treatment Rate (%) 65

    Table 16. Long Lasting Effect of Systolic Blood Pressure 70

    Table 17. Long Lasting Effect of Diastolic Blood Pressure 71

  • v

    Table 18. Long Lasting Effect of VAS 72

    Table 19. Change of VAS, SYS, and DI Blood Pressure by Taking Medication 74

    Table 20. Change of VAS, SYS, and DI Blood Pressure by Duration of Hypertension 79

    Table 21. Change of VAS, Systolic, and Diastolic Blood Pressure by Age 84

    Table 22. Change of VAS, Systolic, and Diastolic Blood Pressure by Gender 88

    Table 23. Change of VAS, Systolic, and Diastolic Blood Pressure by History 93

    Table 24. Everage of VAS, Systolic, and Diastolic Blood Pressure by Bi 97

    Table 25. Model Summary and Parameter Estimates for VAS 100

    Table 26. Model Summary and Parameter Estimates for Systolic Pressure 101

    Table 27. Model Summary and Parameter Estimates for Diastolic Pressure 102

    Table 28. Time course change of ODI score 104

    Table 29. Model Summary and Parameter Estimates 105

    Table 30. The Change of ODI Pain Scale 107

    Table 31. Cumulative Effect of ODI Pain Scale 108

    Table 32. Time course change of SPADI score 109

    Table 33. Model Summary and Parameter Estimates 110

    Table 34. The Change of SPADI Pain Scale 111

  • vi

    Table 35. The Cumulative Effect of SPADI Pain Scale 112

    Table 36. Time course change of WOMAC score 113

    Table 37. Model Summary and Parameter Estimates 114

    Table 38. The Change of WOMAC Pain Scale 115

    Table 39. The Cumulative Effect of WOMAC Pain Scale 116

  • vii

    LIST OF FIGURES

    Figure 1. Dng Bang Sterilized Needles 28

    Figure 2. Vaccaria Press Seeds 28

    Figure 3. Upper Arm Blood Pressure Monitor 29

    Figure 4. Visual Analogue Scale (VAS) 30

    Figure 5. ์—ฐ๊ตฌ ์„ค๊ณ„๋„ (Schemetic Diagram of Study Design) 34

    Figure 6. Ear Acupuncture Points 41

    Figure 7. Ear Nerve Distribution 42

    Figure 8. Change of Systolic Blood Pressure 49

    Figure 9. Change of Diastolic Blood Pressure 49

    Figure 10. Change of VAS (Visual Analogue Scale) 52

    Figure 11. Cumulation Effect of Systolic Blood Pressure 59

    Figure 12. Cumulation Effect of Systolic Blood Pressure 59

    Figure 13. Cumulative Effect of Diastolic Blood Pressure 60

    Figure 14. Cumulative Effect of Diastolic Blood Pressure 60

    Figure 15. SYS Treatment Rate (%) 61

    Figure 16. DI Treatment Rate (%) 61

  • viii

    Figure 17. SYS Treatment Rate (%) 62

    Figure 18. DI Treatment Rate (%) 62

    Figure 19. Cumulative Effect of VAS 66

    Figure 20. Cumulative Effect of VAS 66

    Figure 21. VAS Treatment Rate (%) 67

    Figure 22. VAS Treatment Rate (%) 67

    Figure 23. Difference of VAS and Blood Pressure by Taking Prescribed Medication 75

    Figure 24. Difference of Blood Pressure by Taking Prescribed Medication 75

    Figure 25. Change of Systolic Blood Pressure by Taking Prescribed Medication 76

    Figure 26. Change of Diastolic Blood Pressure by Taking Prescribed Medication 76

    Figure 27. Difference of VAS by Taking Prescribed Medication 77

    Figure 28. Change of VAS by Taking Prescribed Medication 78

    Figure 29. Difference of VAS and Blood Pressure by Duration of Hypertension 80

    Figure 30. Difference of Blood Pressure by Duration of Hypertension 80

    Figure 31. Change of Systolic Blood Pressure by Duration of Hypertension 81

    Figure 32. Change of Diastolic Blood Pressure by Duration of Hypertension 81

    Figure 33. Difference of VAS by Duration of Hypertension 82

  • ix

    Figure 34. Change of VAS by Duration of Hypertension 83

    Figure 35. Difference of VAS and Blood Pressure by Age 84

    Figure 36. Difference of Blood Pressure by Age 85

    Figure 37. Change of Systolic Blood Pressure by Age 85

    Figure 38. Change of Diastolic Blood Pressure by Age 86

    Figure 39. Differenc of VAS by Age 87

    Figure 40. Change of VAS by Age 87

    Figure 41. Difference of VAS and Blood Pressure by Gender 89

    Figure 42. Difference of Blood Pressure by Gender 89

    Figure 43. Change of Systolic Blood Pressure by Gender 90

    Figure 44. Change of Diastolic Blood Pressure by Gender 90

    Figure 45. Difference of VAS by Gender 91

    Figure 46. Change of VAS by Gender 92

    Figure 47. Difference of VAS and Blood Pressure by History 93

    Figure 48. Difference of Blood Pressure by History 94

    Figure 49. Change of Systolic Blood Pressure by History 94

    Figure 50. Change of Diastolic Blood Pressure by History 95

  • x

    Figure 51. Difference of VAS by History 96

    Figure 52. Change of VAS by History 96

    Figure 53. Change of Systolic Blood Pressure by Bi 98

    Figure 54. Change of Diastolic Blood Pressure by Bi 98

    Figure 55. Change of VAS by Bi 99

    Figure 56. Regression of VAS 101

    Figure 57. Regression of Systolic Blood Pressure 102

    Figure 58. Regression of Diastolic Pressure 103

    Figure 59. Regression of LBP (ODI) 105

    Figure 60. ODI, SPADI, WOMAC Pain Level 106

    Figure 61. Regression of Shoulder Pain (SPADI) 110

    Figure 62. Regression of Knee Pain (WOMAC) 114

  • xi

    ACKNOWLEGEMENT

    ์ง€๋‚œ 3 ๋…„์˜ ์ƒํ™œ์€ ์ œ๊ฐ€ ์–ผ๋งˆ๋‚˜ ๋ถ€์กฑํ•œ์ง€ ๋งŽ์ด ๋˜๋Œ์•„๋ณผ ์ˆ˜ ์žˆ๊ฒŒ ํ•ด์ค€

    ์‹œ๊ฐ„์ด์—ˆ์Šต๋‹ˆ๋‹ค. ๋ถ€์กฑํ•œ ์ œ๊ฐ€ ๋ฌด์‚ฌํžˆ ๋ฐ•์‚ฌ์ƒํ™œ์„ ๋งˆ์น˜๊ธฐ๊นŒ์ง€๋Š” ์ฃผ๋ณ€์˜ ๋งŽ์€

    ๋„์›€์˜ ์†๊ธธ์ด ์žˆ์—ˆ๊ธฐ์— ๊ฐ€๋Šฅํ•˜์˜€์Šต๋‹ˆ๋‹ค. ๋จผ์ € ๋…ผ๋ฌธ์˜ ์ฃผ์ œ ์„ ํƒ์— ๋„์›€์„

    ์ฃผ์‹  ์ตœ์„ ๊ธˆ ๊ต์ˆ˜๋‹˜๊ณผ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ๋ฅผ ๋ถ„์„ํ•˜๊ณ  ํ•ด์„ํ•˜๋Š”๋ฐ ๋„์›€์„ ์ฃผ์‹  ์„œํ˜ธ์˜

    ๊ต์ˆ˜๋‹˜๊ป˜ ์ง„์‹ฌ์œผ๋กœ ๊ฐ์‚ฌ ๋“œ๋ฆฌ๋ฉฐ, ์ƒ๋‹ด ๋ฐ ์กฐ์–ธ์„ ํ•ด์ฃผ์‹  ๊น€์ˆ˜๊ฒฝ ๊ต์ˆ˜๋‹˜๊ณผ

    ํ—ˆ์„ฑํ™” ๊ต์ˆ˜๋‹˜๊ป˜ ๊ฐ์‚ฌ ๋“œ๋ฆฝ๋‹ˆ๋‹ค. ๋˜ํ•œ ์–‘๋ฐฉ๊ณผ ํ•œ๋ฐฉ์˜ ์ง€์‹์œผ๋กœ ์ด๋Œ์–ด ์ฃผ์‹ 

    ๊น€์„œ๊ฒฝ ๊ต์ˆ˜๋‹˜ ๊ณผ ์ดํ•œ์˜ฅ ๊ต์ˆ˜๋‹˜๊ป˜ ๊ฐ์‚ฌ ๋“œ๋ฆฝ๋‹ˆ๋‹ค. ๊ทธ๋ฆฌ๊ณ  ์ด ๋…ผ๋ฌธ์ด

    ์™„์„ฑ๋˜๊ธฐ๊นŒ์ง€ ๋„์™€์ฃผ์‹  ๋ชจ๋“  ๋ถ„๋“ค๊ป˜ ๊ฐ์‚ฌ ๋“œ๋ฆฝ๋‹ˆ๋‹ค. ๋งˆ์ง€๋ง‰์œผ๋กœ ํ•ญ์ƒ ์˜†์—์„œ

    ํ•จ๊ป˜ ํ•ด์ค€ ์•„๋‚ด์—๊ฒŒ๋„ ๊ฐ์‚ฌ๋ฅผ ์ „ํ•ฉ๋‹ˆ๋‹ค.

  • 1

    I. INTRODUCTION

    ๊ทผ๋ž˜ ๊ณ ํ˜ˆ์••์˜ ๋ฐœ์ƒ๋นˆ๋„๋Š” ์ง€์†์ ์œผ๋กœ ์ฆ๊ฐ€ํ•˜๊ณ  ์žˆ๋Š” ์ถ”์„ธ์ด๋ฉฐ ๊ณ ํ˜ˆ์••์€

    ๋‡Œ์ค‘ํ’, ์‹ฌ๋ถ€์ „, ๊ด€์ƒ๋™๋งฅ ์งˆํ™˜ ๋“ฑ ์น˜๋ช…์ ์ธ ํ•ฉ๋ณ‘์ฆ์„ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ

    ๋ณด๋‹ค ์ ๊ทน์ ์ธ ํ™˜์ž ๊ด€๋ฆฌ์™€ ์น˜๋ฃŒ๊ฐ€ ์š”๊ตฌ๋˜๊ณ  ์žˆ๋‹ค1). ๊ณ ํ˜ˆ์••์€ ์„ฑ์ธ์˜ 30%

    ์ •๋„์—์„œ ๋ฐœ๊ฒฌ๋  ์ •๋„๋กœ ๋งค์šฐ ํ”ํ•œ ์งˆํ™˜์ด๊ณ , ์—ญํ•™์กฐ์‚ฌ๋ฅผ ํฌํ•จํ•œ ์ž„์ƒ์—ฐ๊ตฌ๋ฅผ

    ํ†ตํ•ด ์ ๊ทน์ ์ธ ํ˜ˆ์••์กฐ์ ˆ์ด ์‹ฌํ˜ˆ๊ด€๊ณ„ ํ•ฉ๋ณ‘์ฆ๊ณผ ์‚ฌ๋ง๋ฅ ์„ ๊ฐ์†Œ์‹œํ‚ฌ ์ˆ˜ ์žˆ์Œ์ด

    ์ฆ๋ช…๋จ์— ๋”ฐ๋ผ ์ ๊ทน์ ์œผ๋กœ ์น˜๋ฃŒํ•˜์—ฌ์•ผ ํ•˜๋Š” ์งˆํ™˜์œผ๋กœ ๋Œ€๋‘๋˜์—ˆ๋‹ค. ๋˜ํ•œ

    ์‹ฌ๊ฐํ•œ ์ˆœํ™˜๊ธฐ ๊ณ„ํ†ต์˜ ํ•ฉ๋ณ‘์ฆ์„ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ๋Š” ์งˆํ™˜์œผ๋กœ์จ ์ƒํ™œ์ˆ˜์ค€์ด

    ํ–ฅ์ƒ๋˜๊ณ  ์˜ํ•™์˜ ๋ฐœ๋‹ฌ๋กœ ์ธํ•˜์—ฌ ํ‰๊ท ์ˆ˜๋ช…์ด ์—ฐ์žฅ๋จ์— ๋”ฐ๋ผ ์œ ๋ณ‘๋ฅ ์ด ์ ์ฐจ

    ๋†’์•„์ง€๊ณ  ์žˆ๋‹ค2). ์ด๋Ÿฐ ์ตœ๊ทผ ์ธ๊ตฌ ๊ณ ๋ นํ™” ํ˜„์ƒ์˜ ์‹ฌํ™”๋กœ ๊ตญ๋ฏผ๋“ค์˜ ์ฃผ์š” ์งˆ๋ณ‘

    ์–‘์ƒ์ด ๊ณผ๊ฑฐ ๊ธ‰์„ฑ๊ธฐ ์งˆํ™˜ ์ค‘์‹ฌ์—์„œ ๊ณ ํ˜ˆ์••, ๋‹น๋‡จ, ์•”, ๋‡Œ์กธ์ค‘ ๋“ฑ ๋งŒ์„ฑ ํ‡ดํ–‰์„ฑ

    ์งˆํ™˜์œผ๋กœ ๋ณ€ํ™”ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ๋ณ€ํ™”์— ๋ถ€์‘ํ•˜๊ธฐ ์œ„ํ•œ ๋…ธ๋ ฅ์œผ๋กœ ํ•œ๋ฐฉ์„

    ํฌํ•จํ•œ ๋ณด์™„ ๋Œ€์ฒด์˜๋ฃŒ์— ๋Œ€ํ•œ ํ•„์š”์„ฑ์ด ์ฆ๋Œ€๋˜๊ณ  ์žˆ๋‹ค3). ํ•œ์˜ํ•™์€ ์งˆํ™˜

    ์ค‘์‹ฌ์œผ๋กœ ๋ณด๋Š” ์„œ์–‘์˜ํ•™๊ณผ๋Š” ๋‹ฌ๋ฆฌ ์ฆ์ƒ ์ค‘์‹ฌ์œผ๋กœ ์ธ์ฒด์˜ ์งˆ๋ณ‘์„ ๊ด€์ฐฐํ•˜์—ฌ

    ๋ณ€์ฆํ•˜๊ณ  ์น˜๋ฃŒ๋ฒ•์„ ๊ฒฐ์ •ํ•œ๋‹ค. ๊ทธ๋Ÿฌ๋ฏ€๋กœ ๋˜‘๊ฐ™์€ ์งˆํ™˜์ด๋ผ๋„ ํ™˜์ž์˜ ์ฒด์งˆ๊ณผ

    ์ฆ์ƒ์— ๋”ฐ๋ผ ๋‹ค์–‘ํ•œ ๋ณ‘๋ฆฌ๊ธฐ์ „์„ ๊ฐ€์งˆ ์ˆ˜ ์žˆ๊ณ  ์น˜๋ฃŒ๋ฒ• ์—ญ์‹œ ๋‹ฌ๋ผ์งˆ ์ˆ˜๋ฐ–์—

    ์—†๋‹ค. ํŠนํžˆ, ๊ณ ํ˜ˆ์••์€ ์ธ์ฒด์˜ ์ „์‹ ์งˆํ™˜์œผ๋กœ์„œ ํ•œ์˜ํ•™์ ์œผ๋กœ๋Š” ์Œ์–‘๊ณผ ๊ธฐํ˜ˆ์˜

    ๋ถ€์กฐํ™”๋กœ ์ธํ•œ ์ฆ์ƒ ์ค‘ ํ•˜๋‚˜์ด๋‹ค.

    ๊ณ ํ˜ˆ์••์€ ๋งŒ์„ฑ ์ˆœํ™˜๊ธฐ๊ณ„ ์งˆํ™˜ ์ค‘ ๊ฐ€์žฅ ๋ฐœ์ƒ๋นˆ๋„๊ฐ€ ๋†’์€ ์งˆํ™˜์œผ๋กœ1,4)

  • 2

    ๋ณธ์ธ์ด ์ž๊ฐํ•˜๋Š” ๋šœ๋ ทํ•œ ์ฆ์ƒ์ด ์—†๊ณ , ์ง„๋‹จ ํ›„์— ํ‰์ƒ ์•ฝ๋ฌผ์„ ๋ณต์šฉํ•˜๋ฉฐ,

    ํ™˜์ž๊ฐ€ ์ƒํ™œ์Šต๊ด€์˜ ๋ณ€ํ™”๋ฅผ ์š”๊ตฌ ๋ฐ›์œผ๋ฏ€๋กœ, ํ™˜์ž ์Šค์Šค๋กœ๊ฐ€ ์ค‘๋„์— ์น˜๋ฃŒ๋ฅผ

    ํฌ๊ธฐํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์•„ ํ•ฉ๋ณ‘์ฆ์— ์˜ํ•œ ์‚ฌํšŒ์  ๋ถ€๋‹ด์ด ์ค‘์š”ํ•œ ๋ฌธ์ œ๊ฐ€ ๋˜๊ณ 

    ์žˆ๋‹ค5). ๋งŒ์„ฑ ์‹ ์งˆํ™˜, ์‹ ๋™๋งฅ ํ˜‘์ฐฉ์ฆ, ์ˆ˜๋ฉด ๋ฌดํ˜ธํก์ฆ, ์ผ์ฐจ์„ฑ

    ์•Œ๋„์Šคํ…Œ๋ก ์ฆ(primary aldosteronism)๋“ฑ์ด ํ”ํ•œ ์›์ธ์ด๋ฉฐ, ๊ฐˆ์ƒ‰์„ธํฌ์ข…, ์ฟ ์‹ฑ

    ์ฆํ›„๊ตฐ(Cushing syndrome), ๋ถ€๊ฐ‘์ƒ์„  ๊ธฐ๋Šฅํ•ญ์ง„์ฆ ๋“ฑ๋„ ๊ทธ ์›์ธ์ด ๋œ๋‹ค6).

    ์‚ฌํšŒ์™€ ์ธ๊ตฌ ๊ตฌ์กฐ์˜ ๋ณ€ํ™”์— ๋”ฐ๋ฅธ ๋…ธ์ธ๊ณผ ๋งŒ์„ฑ์งˆํ™˜์˜ ์ฆ๊ฐ€์— ๋”ฐ๋ผ ํ˜„

    ์˜๋ฃŒ๊ณ„์—์„œ ๊ณ ํ˜ˆ์••์˜ ๊ด€๋ฆฌ๋Š” ์ค‘์š”ํ•œ ๋ฌธ์ œ๋กœ ๋Œ€๋‘๋˜๊ณ  ์žˆ๋Š” ์‹ค์ •์ด๋ฉฐ7) ๊ณ ํ˜ˆ์••

    ๊ด€๋ จ ๊ตญ์™ธ์—ฐ๊ตฌ์—์„œ๋Š” ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••์˜ ์ƒ์Šน์€ ์„ธ๊ณ„์ ์ธ ๊ฑด๊ฐ•์œ„ํ—˜์š”์†Œ๋กœ, ์ˆ˜์ถ•๊ธฐ

    ํ˜ˆ์••์˜ ์ฆ๊ฐ€์œจ์€ 25๋…„๊ฐ„ ํฌ๊ฒŒ ์ฆ๊ฐ€ํ•˜์˜€์œผ๋ฉฐ, ๊ทธ๋กœ ์ธํ•ด

    ์žฅ์• ๋ณด์ •์†์‹ค์—ฐ์ˆ˜(Disability-Adjusted Life Years, DALYs) ๋ฐ ์‚ฌ๋ง ์ฆ๊ฐ€์™€

    ๊ด€๋ จ์ด ์žˆ๋‹ค๊ณ  ๋ณด๊ณ ํ•˜์˜€๋‹ค8).

    ๋ฏธ๊ตญ Framingham Heart Study์—์„œ๋Š” ๊ณ ํ˜ˆ์••์ด ์žˆ๋Š” ๋Œ€์ƒ์ž๋Š”

    ์ •์ƒํ˜ˆ์••์„ ๊ฐ€์ง€๊ณ  ์žˆ๋Š” ์‚ฌ๋žŒ์— ๋น„ํ•ด ๋™๋งฅ๊ฒฝํ™”์„ฑ์งˆํ™˜์˜ ์œ„ํ—˜์ด 2-3๋ฐฐ ์ •๋„

    ์ฆ๊ฐ€ํ•˜๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค9). ํŠนํžˆ, ๊ณ ํ˜ˆ์•• ํ™˜์ž๋Š” ํ•ฉ๋ณ‘์ฆ์ด๋‚˜ ๋™๋ฐ˜ ์งˆํ™˜,

    ์ง„๋‹จ์— ๋Œ€ํ•œ ์ธ์‹ ๋ฐ ํ•ญ๊ณ ํ˜ˆ์••์ œ์— ์˜ํ•œ ๋ถ€์ž‘์šฉ์œผ๋กœ ์ธํ•ด ์‚ถ์˜ ์งˆ์ด

    ์ €ํ•˜๋˜๊ณ 10), ๊ทธ๋กœ ์ธํ•ด ์‹ฌํ˜ˆ๊ด€ ๋ฌธ์ œ๋‚˜ ํ•ฉ๋ณ‘์ฆ์˜ ์œ„ํ—˜์— ๋…ธ์ถœ๋˜๋Š”

    ์ทจ์•ฝ์ง‘๋‹จ์ด๊ธฐ ๋•Œ๋ฌธ์—, ๊ณ ํ˜ˆ์•• ํ™˜์ž์˜ ์‚ถ์˜ ์งˆ์— ๋Œ€ํ•œ ๊ด€์‹ฌ์„ ๊ฐ–๋Š” ๊ฒƒ์€

    ์ค‘์š”ํ•˜๋‹ค11). ๊ณ ํ˜ˆ์•• ํ™˜์ž์˜ 90% ์ด์ƒ์ด ๋ณธํƒœ์„ฑ ๊ณ ํ˜ˆ์••์œผ๋กœ12) ํ˜ˆ์•• ์ƒ์Šน์˜

    ์›์ธ์€ ํ˜ˆ๊ด€๋ฒฝ ์ €ํ•ญ์ฆ๊ฐ€์™€ ํ˜ˆ์•ก์˜ ๋ถ€ํ”ผ์ฆ๊ฐ€13)์ด๋ฉฐ ์›์ธ์€ ์—ฐ๋ น, ์„ฑ๋ณ„, ์ธ์ข…,

  • 3

    ๊ฐ€์กฑ๋ ฅ ๋“ฑ์˜ ์ธ๊ตฌํ•™์ , ์œ ์ „์  ์š”์ธ๊ณผ ์ฒด์ค‘ ๋“ฑ์˜ ์ƒ๋ฆฌ์  ์š”์ธ, ํ™˜๊ฒฝ์ 

    ์š”์ธ๋“ค์˜ ๋ณตํ•ฉ์ ์ธ ์ž‘์šฉ์— ์˜ํ•œ ๊ฒƒ์œผ๋กœ ๊ฐ€์žฅ ์ค‘์š”ํ•œ ํ™˜๊ฒฝ์  ์œ„ํ—˜์š”์ธ์œผ๋กœ๋Š”

    ๋†’์€ ์‹์—ผ์„ญ์ทจ, ์•Œ์ฝ”์˜ฌ ์„ญ์ทจ, ๋น„๋งŒ, ์ ์€ ์‹ ์ฒดํ™œ๋™ ๋“ฑ์„ ๋“ค ์ˆ˜ ์žˆ๋‹ค14).

    ๋ฏธ๊ตญ ์ œ 7์ฐจ ํ•ฉ๋™ ์œ„์›ํšŒ(Joint National Committee on Detection

    Pressure, JNC-VII)์˜ ๋ณด๊ณ ์— ์˜ํ•˜๋ฉด 120mmHg/80mmHg ๋ฏธ๋งŒ์ธ ๊ฒฝ์šฐ๋ฅผ

    ์ •์ƒ์œผ๋กœ ๋ถ„๋ฅ˜ํ•˜๊ณ , 120~139mmHg/80~89mmHg์— ์†ํ•˜๋Š” ๊ฒฝ์šฐ๋ฅผ ์ „๊ณ ํ˜ˆ์••,

    140mmHg/90mmHg ์ด์ƒ์ธ ๊ฒฝ์šฐ๋ฅผ ๊ณ ํ˜ˆ์••์œผ๋กœ ๋ถ„๋ฅ˜ํ•œ๋‹ค15). ๊ณ ํ˜ˆ์••์€ ๊ทธ

    ์›์ธ์— ๋”ฐ๋ผ ๋ณธํƒœ์„ฑ(์ผ์ฐจ์„ฑ, ์›๋ฐœ์„ฑ) ๊ณ ํ˜ˆ์••๊ณผ ์ด์ฐจ์„ฑ(์†๋ฐœ์„ฑ) ๊ณ ํ˜ˆ์••์œผ๋กœ

    ๊ตฌ๋ถ„ํ•  ์ˆ˜ ์žˆ๋‹ค. ์„ค๋ช…ํ•  ๋งŒํ•œ ์›์ธ์ด ์—†๋Š” ๊ฒฝ์šฐ๋ฅผ ๋ณธํƒœ์„ฑ ๊ณ ํ˜ˆ์••์ด๋ผ๊ณ 

    ํ•˜๋Š”๋ฐ, ๋‹ค์–‘ํ•œ ์œ ์ „์  ์š”์ธ๊ณผ ํ™˜๊ฒฝ์  ์š”์ธ์˜ ๋ณต์žกํ•œ ์ƒํ˜ธ์ž‘์šฉ์œผ๋กœ

    ๋ฐœ์ƒํ•œ๋‹ค16). ๊ณ ํ˜ˆ์••์€ ์‹ฌํ˜ˆ๊ด€๊ณ„ ์งˆํ™˜, ํŠนํžˆ ๊ด€์ƒ๋™๋งฅ ์งˆํ™˜๊ณผ ๋‡Œ์กธ์ค‘์˜ ํ•ฉ๋ณ‘์ฆ

    ๋ฐœ์ƒ์— ๊ฐ€์žฅ ์ค‘์š”ํ•œ ์œ„ํ—˜์ธ์ž๋กœ ๋„๋ฆฌ ์•Œ๋ ค์ ธ ์žˆ์œผ๋ฉฐ ๊ณ ํ˜ˆ์•• ํ™˜์ž์—์„œ

    ๊ฐ•์••์น˜๋ฃŒ๋ฅผ ํ•˜๊ฒŒ ๋˜๋ฉด ์ด๋Ÿฌํ•œ ํ•ฉ๋ณ‘์ฆ ๋ฐœ์ƒ์„ ํ˜„์ €ํžˆ ์ค„์ผ ์ˆ˜ ์žˆ๋‹ค๋Š” ๊ฒƒ์ด ๊ทธ

    ์ค‘์š”ํ•œ ์ž„์ƒ์  ์˜๋ฏธ๋ผ ํ•˜๊ฒ ๋‹ค. ๋ฏธ๊ตญ์˜ ๊ฒฝ์šฐ์—๋Š” 55์„ธ ์ด์ „์— ์ •์ƒ ํ˜ˆ์••์ด์—ˆ๋˜

    ์ธ๊ตฌ์˜ 90%์—์„œ ์ƒ์•  ์ค‘ ๊ณ ํ˜ˆ์••์ด ์œ ๋ฐœ๋œ ๊ฒƒ์œผ๋กœ ์กฐ์‚ฌ๋˜์—ˆ์„ ๋งŒํผ ๊ณ ํ˜ˆ์••์€

    ์œ ๋ณ‘๋ฅ ์ด ๋†’์€ ์งˆํ™˜์ด๊ธฐ๋„ ํ•˜๋‹ค17). ์ด์ฒ˜๋Ÿผ ๋‹จ์ผ ์งˆํ™˜์œผ๋กœ์„œ ์ด๋ณด๋‹ค ๋†’์€

    ์œ ๋ณ‘์œจ์„ ๋ณด์ด๋Š” ์งˆํ™˜์€ ์—†๊ณ , ๋‚˜์ด๊ฐ€ ๋“ค์–ด๊ฐ์— ๋”ฐ๋ผ ์œ ๋ณ‘๋ฅ ์ด ํ˜„๊ฒฉํžˆ ์ฆ๊ฐ€ํ•ด

    ํ˜„๋Œ€ ๊ณ ๋ นํ™” ์‚ฌํšŒ์—์„œ ๊ณ ํ˜ˆ์•• ๊ด€๋ฆฌ๋Š” ์ค‘์š”ํ•œ ๋ณด๊ฑด์˜๋ฃŒ ๋ฌธ์ œ ์ค‘ ํ•˜๋‚˜์ด๋‹ค.

    ์ตœ๊ทผ ์‹ฌํ˜ˆ๊ด€๊ณ„์งˆํ™˜์˜ ๋ฐœ์ƒ๊ณผ ์‚ฌ๋ง๋ฅ ์„ ๋‚ฎ์ถ”๊ธฐ ์œ„ํ•ด ํ˜ˆ์••์„ ์ •์ƒ ์ˆ˜์ค€์œผ๋กœ

    ์ฒ ์ €ํ•˜๊ฒŒ ๊ด€๋ฆฌํ•  ๊ฒƒ์„ ๊ฐ•์กฐํ•˜๋Š” ์—ฐ๊ตฌ ๊ฒฐ๊ณผ๊ฐ€ ๋ณด๊ณ ๋˜๊ณ  ์žˆ์œผ๋ฉฐ18,19)ํ˜ˆ์••์กฐ์ ˆ์—

  • 4

    ๋Œ€ํ•œ ์น˜๋ฃŒ๋ฒ•์œผ๋กœ๋Š” ํ˜ˆ์••๊ฐ•ํ•˜์ œ๋ฅผ ์‚ฌ์šฉํ•˜๋Š” ์•ฝ๋ฌผ์š”๋ฒ•๊ณผ ์šด๋™, ์‹์ด์š”๋ฒ•,

    ์ด์™„์š”๋ฒ• ๋“ฑ์˜ ๋น„์•ฝ๋ฌผ์š”๋ฒ•์ด ์žˆ๋‹ค4,20). ํ˜ˆ์••๊ฐ•ํ•˜์ œ๋Š” ์ž‘์šฉํ•˜๋Š” ์›๋ฆฌ์— ๋”ฐ๋ผ

    ๊ณ ํ˜ˆ์••์˜ ์น˜๋ฃŒ์—๋Š” ์ด๋‡จ์ œ์™€ ๋ฒ ํƒ€ ์ฐจ๋‹จ์ œ ๋“ฑ๊ณผ ๊ฐ™์€ ๊ธฐ์กด์— ๋„๋ฆฌ ์‚ฌ์šฉ๋˜์–ด ์˜จ

    ํ•ญ๊ณ ํ˜ˆ์••์ œ ์ด์™ธ์— ์•ŒํŒŒ ์ฐจ๋‹จ์ œ, ์ง€์†ํ˜• ์นผ์Š˜ ์ฐจ๋‹จ์ œ, ์•ˆ์ง€์˜คํ…์‹ โ…ก ์ˆ˜์šฉ์ฒด

    ์ฐจ๋‹จ์ œ(ARB), ์•ˆ์ง€์˜คํ…์‹  ์ „ํ™˜ํšจ์†Œ ์–ต์ œ์ œ ๋ฐ ์ตœ๊ทผ์— ์†Œ๊ฐœ๋˜๊ณ  ์žˆ๋Š”

    ์•ˆ์ง€์˜คํ…์‹  ์ˆ˜์šฉ์ฒด ์ฐจ๋‹จ์ œ ๋“ฑ ๋งŽ์€ ์•ฝ์žฌ๋“ค์ด ์ž„์ƒ์—์„œ ์‚ฌ์šฉ๋˜๊ณ  ์žˆ๋‹ค21,22).

    ๋˜ํ•œ ํ˜ˆ์••์•ฝ ์ค‘์—์„œ๋„ ๋‚ดํ”ผ์„ธํฌ๊ธฐ๋Šฅ ๊ฐœ์„ ํšจ๊ณผ๊ฐ€ ์žˆ๋Š” ๊ฒƒ์œผ๋กœ ๋ณด๊ณ ๋˜๊ณ  ์žˆ๋Š”

    angiotensin-converting enzyme(ACE) inhibitors๋‚˜ angiotensinII type1

    receptor blockers(ARBs)์˜ ๋™๋งฅ๊ฒฝํ™” ์–ต์ œ๊ธฐ๋Šฅ์ด ์ฃผ๋ชฉ๋ฐ›๊ณ  ์žˆ๋‹ค23-25). ํ•˜์ง€๋งŒ,

    ์•ฝ๋ฌผ์น˜๋ฃŒ ๋ฐ ์ƒํ™œ๋ฐฉ์‹์˜ ๋ณ€ํ™” ๋“ฑ์ด ๋ณธํƒœ์„ฑ ๊ณ ํ˜ˆ์••์— ํšจ๊ณผ๊ฐ€ ์žˆ๋‹ค๊ณ  ๋ฐํ˜€์ ธ

    ์žˆ์ง€๋งŒ26-28), ์น˜๋ฃŒ์— ๋Œ€ํ•œ ํ™˜์ž์˜ ๋‚ฎ์€ ์ˆœ์‘๋„, ์˜๋ฃŒ๊ด€๋ฆฌ์— ๋Œ€ํ•œ ์ ‘๊ทผ์ด

    ์–ด๋ ค์šด ์ , ํ˜น์€ ๊ฒฝ์ œ์  ๋ถ€๋‹ด ๋•Œ๋ฌธ์— ์ ์ ˆํžˆ ์กฐ์ ˆ ๋ฐ ๊ด€๋ฆฌ๋˜์ง€ ์•Š๋Š” ๋น„์œจ์ด

    ๋†’๋‹ค29)๋Š” ์ ์ด ํ•œ๊ณ„์ ์œผ๋กœ ์ง€์ ๋œ๋‹ค. ํŠนํžˆ ์ด๋“ค์€ ์žฅ๊ธฐ๊ฐ„ ๋ณต์šฉํ•ด์•ผ ํ•˜๊ธฐ

    ๋•Œ๋ฌธ์— ์•ฝ์˜ ์ข…๋ฅ˜์— ๋”ฐ๋ผ์„œ ์ฒด์œ„์„ฑ ์ €ํ˜ˆ์••, ์ €์นผ๋ฅจํ˜ˆ์ฆ, ๊ธฐ์นจ, ๋‘ํ†ต, ํ˜„๊ธฐ์ฆ,

    ๋ถ€์ข…, ์‹์š•๋ถ€์ง„ ๋“ฑ์˜ ๋ถ€์ž‘์šฉ์„ ๋™๋ฐ˜ํ•  ์ˆ˜ ์žˆ๋‹ค30).

    ๊ณ ํ˜ˆ์•• ์น˜๋ฃŒ์— ์žˆ์–ด ์žฅ๊ธฐ๊ฐ„์˜ ์•ฝ๋ฌผ๋ณต์šฉ, ์•ฝ๋ฌผ์˜ ๋ถ€์ž‘์šฉ์— ๋Œ€ํ•œ ๋ฌธ์ œ๋Š”

    ์ตœ๊ทผ ์ง€์†์ ์œผ๋กœ ์ œ๊ธฐ๋˜์–ด ์™”๊ณ  ๊ทธ ๋Œ€์•ˆ์œผ๋กœ ๋น„์•ฝ๋ฌผ์š”๋ฒ•์— ๋Œ€ํ•œ ๊ด€์‹ฌ๋„

    ๋†’์•„์ง€๊ณ  ์žˆ๋Š” ์ถ”์„ธ์ด๋‹ค31,32). ํ•œ์˜ํ•™์—์„œ๋„ ๊ณ ํ˜ˆ์•• ์กฐ์ ˆ์— ๊ด€ํ•œ ์ž„์ƒ ์—ฐ๊ตฌ๋„

    ์ ์ฐจ ๋Š˜์–ด๋‚˜๊ณ  ์žˆ๋‹ค. ํšจ๋Šฅ๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ์•ˆ์ „์„ฑ์ด ํ™•๋ณด๋œ ํ•œ์•ฝ์žฌ๋ฅผ ์ด์šฉํ•œ

    ์‹ฌํ˜ˆ๊ด€๊ณ„ ์งˆํ™˜์— ํšจ๊ณผ์ ์ธ ๊ธฐ๋Šฅ์„ฑ ์‹ํ’ˆ ๋ฐ ์˜์•ฝํ’ˆ์˜ ๊ฐœ๋ฐœ์ด ์ ˆ์‹คํžˆ ์š”๊ตฌ๋˜๊ณ 

  • 5

    ์žˆ์œผ๋ฉฐ, ์„ธ๊ณ„์ ์œผ๋กœ ์ฒœ์—ฐ๋ฌผ ์œ ๋ž˜ ์น˜๋ฃŒ์ œ์— ๊ด€ํ•œ ์—ฐ๊ตฌ์— ๊ด€์‹ฌ์ด ๋ชจ์•„์ง€๊ณ 

    ์žˆ๋‹ค33). ํ•œ๋ฐฉ๋ณ‘์› ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ํ•œ ์—ฐ๊ตฌ๋“ค์ด ์ ์  ์ฆ๊ฐ€ํ•˜๊ณ  ์žˆ๊ณ 34),

    ํ•œ์•ฝ๋„ ACEํ™œ์„ฑ ์–ต์ œ ๋ฐ ํ˜ˆ์ค‘ ANP(Atrial Natriuretic Peptide) ๊ฐ์†Œ ๋“ฑ์˜

    ํ•ญ๊ณ ํ˜ˆ์••์•ฝ๊ณผ ๊ฐ™์€ ๊ฐ•์•• ํšจ๊ณผ๋ฅผ ๊ฐ€์ง„ ๋‹จ๋ฏธ ์•ฝ์žฌ๋‚˜ ๋ณตํ•ฉ ์ฒ˜๋ฐฉ ๊ฐ™์€ ๋‹ค์–‘ํ•œ

    ์ฒ˜๋ฐฉ์ด ๋งŽ์ด ์—ฐ๊ตฌ๋˜๊ณ  ์žˆ๋‹ค35). ๊ฒฐ๊ตญ ํ•œ์˜ํ•™์  ์ด๋ก ์„ ํ† ๋Œ€๋กœ ์นจ, ๋œธ, ํ•œ์•ฝ

    ๋“ฑ์„ ์ ์ ˆํ•˜๊ฒŒ ์ด์šฉํ•˜์—ฌ ์ „์‹ ์ ์ธ ์Œ์–‘๊ณผ ๊ธฐํ˜ˆ์˜ ์กฐํ™”๋ฅผ ๋„๋ชจํ•˜๋ฉด ์ž์—ฐ์Šค๋Ÿฝ๊ฒŒ

    ํ˜ˆ์••์ด ์กฐ์ ˆ๋จ์„ ๊ธฐ๋Œ€ํ•  ์ˆ˜ ์žˆ๋‹ค36).

    ํ•œ์˜ํ•™์—์„œ ๊ณ ํ˜ˆ์••์ด๋ผ๋Š” ๋ณ‘๋ช…์ด ๊ธฐ๋ก๋œ ๊ณ ์„œ์˜ ๋‚ด์šฉ์€ ์—†์œผ๋‚˜ ๋‘ํ†ต,

    ํ˜„ํ›ˆ, ํ•ญ๊ฐ•, ์ด๋ช…, ์‹ฌ๊ณ„, ํ‰๋ฏผ ๋“ฑ์˜ ๊ณ ํ˜ˆ์•• ๊ด€๋ จ ์ฆ์ƒ์œผ๋กœ ๋ฏธ๋ฃจ์–ด ๋ณด์•„ ํ˜„ํ›ˆ

    ๊ฐ„์–‘์ƒํ•ญ ๋‘ํ†ต ํ•ญ๊ฐ• ๋“ฑ์˜ ๋ฒ”์ฃผ์— ์†ํ•œ๋‹ค๊ณ  ๋ณผ ์ˆ˜ ์žˆ๋‹ค15). ์นจ์š”๋ฒ•์€ ๊ฐ์ข…

    ์นจ๊ตฌ๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ์ฒดํ‘œ์ƒ์˜ ์ผ์ •ํ•œ ๋ถ€์œ„์— ๋ฌผ๋ฆฌ์  ์ž๊ทน์„ ๊ฐ€ํ•˜์—ฌ ๊ฒฝ๊ธฐ์šดํ–‰์„

    ์กฐ์ ˆ์‹œ์ผœ ์งˆ๋ณ‘์„ ์˜ˆ๋ฐฉ, ์™„ํ™”, ์น˜๋ฃŒํ•˜๋Š” ํ•œ๋ฐฉ์˜๋ฃŒ๊ธฐ์ˆ ์˜ ํ•œ ๋ถ„์•ผ์ด๋‹ค37).

    ์นจ์น˜๋ฃŒ๋Š” ์ด์ „์˜ ์—ฌ๋Ÿฌ ๊ฐ€์ง€ ์—ฐ๊ตฌ๋ฅผ ํ†ตํ•ด์„œ ๊ณ ํ˜ˆ์••์— ํšจ๊ณผ๊ฐ€ ์žˆ๋Š” ๊ฒƒ์œผ๋กœ

    ๋ณด๊ณ ๋˜์—ˆ์œผ๋ฉฐ, ๋˜ํ•œ ๋‘ ์ฐจ๋ก€์˜ ์ด์ค‘๋งน๊ฒ€ ๋ฌด์ž‘์œ„๋ฐฐ์ • ์ž„์ƒ์‹œํ—˜์„ ํ†ตํ•ด์„œ

    ๊ฐ•์••ํšจ๊ณผ๊ฐ€ ๋ณด๊ณ ๋œ ๋ฐ” ์žˆ๋‹ค38-41). ๋ฌธ42), ์ด43), ์œ 44), ๊น€45)์€ ์•ฝ์นจ(่—ฅ้ผ)์ด

    ๊ณ ํ˜ˆ์•• ๋ฐฑ์„œ(็™ฝ้ผ )์˜ ํ˜ˆ์••์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ์— ๋Œ€ํ•˜์—ฌ, ์ด46)๋Š” ๊ณ ํ˜ˆ์•• ์น˜๋ฃŒ์—

    ์ƒ์‘๋˜๋Š” ์ฒด๊ฐ„๋ถ€(้ซ”ๅนน้ƒจ)๊ฒฝํ˜ˆ์— ๋Œ€ํ•˜์—ฌ, ์ •47)์€ ๊ฒฝํ˜ˆ(็ถ“็ฉด)์˜ ์ž์นจ(ๅˆบ้ผ)์ด

    ๊ณ ํ˜ˆ์•• ๋ฐฑ์„œ(็™ฝ้ผ )์—๋ฏธ์น˜๋Š” ์˜ํ–ฅ์— ๋Œ€ํ•˜์—ฌ, ํ•œ48,49)์€ ๊ณ ํ˜ˆ์•• ํ™˜์ž์—์„œ ๊ฐ

    ์นจ๋ฒ•(้ผๆณ•)์˜ ํ˜ˆ์••๊ฐ•ํ•˜ ํšจ๊ณผ์— ๋Œ€ํ•œ ๋ณด๊ณ ๊ฐ€ ์žˆ์—ˆ๊ณ , ์ตœ๊ทผ ํƒœ๊ณ„ํ˜ˆ(ๅคช่ฐฟ็ฉด)์—

    ๋Œ€ํ•˜์—ฌ ๊น€50)์€ ์•ฝ์นจ(่—ฅ้ผ)์ด ์‹ ์žฅ๊ธฐ๋Šฅ(่…Ž่‡ŸๆฉŸ่ƒฝ)์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ์— ๋Œ€ํ•˜์—ฌ,

  • 6

    ๊น€51)์˜ ํ•ญ์‚ฐํ™” ํšจ๊ณผ์— ๋Œ€ํ•œ ๋ณด๊ณ ๊ฐ€ ์žˆ์—ˆ์œผ๋ฉฐ, ํƒœ๋ฐฑ(ๅคช็™ฝ)์— ๋Œ€ํ•˜์—ฌ ๋ฌธ42)์˜

    ๋ณด๊ณ ๊ฐ€ ์žˆ๋‹ค. ๋˜ํ•œ ๋‡Œํ˜ˆ๋ฅ˜์™€ ๊ด€๋ จ๋œ ์—ฐ๊ตฌ๋กœ๋Š” ์ •52), ๊น€53), ์ด54), ๋ฐ•55), ์ž„56),

    ์‹ 57,58), ์•ˆ59)์˜ ๋ณด๊ณ ๊ฐ€ ์žˆ์—ˆ์œผ๋ฉฐ, ํ˜ˆ์••๊ณผ ๋‡Œํ˜ˆ๋ฅ˜๋Ÿ‰์— ๊ด€๋ จ๋œ ์—ฐ๊ตฌ๋กœ๋Š”

    ๊น€60,61)์˜ ๋ณด๊ณ ๊ฐ€ ์žˆ๋‹ค.

    ์ด์นจ์š”๋ฒ•์€ ์™ธ์ด(ๅค–่€ณ)์— ์กด์žฌํ•˜๋Š” ์ดํ˜ˆ(่€ณ็ฉด)์„ ์ž๊ทนํ•˜์—ฌ ๋‹ค๋ฅธ

    ์‹ ์ฒด๋ถ€์œ„์— ๋‚˜ํƒ€๋‚œ ๋ณ‘๋ฆฌ์  ์†Œ๊ฒฌ์„ ๊ฐœ์„ ์‹œํ‚ค๋Š” ์น˜๋ฃŒ๋ฐฉ๋ฒ•์ด๋‹ค. ํ•œ์˜ํ•™์—์„œ๋Š”

    "์‹ ์ฃผ์ด(่…Žไธป่€ณ), ์‹ ์žฌ๊ทœ์œ„์ด(่…Žๅœจ็ซ…็ˆฒ่€ณ)", "์‹ ๊ธฐํ†ต์–ด์ด(่…Žๆฐฃ้€šๆ–ผ่€ณ),

    ์‹ ํ™”์น™์ด๋Šฅ๋ฌธ์˜ค์Œ์˜(่…Žๅ’Œๅ‰‡่€ณ่ƒฝ่žไบ”้Ÿณ็Ÿฃ)"์ด๋ผ ํ•˜๋ฉด์„œ ๊ท€์˜ ์ƒ๊น€์ƒˆ, ๋ชจ์–‘ ๋ฐ

    ์งˆํ™˜ ๋“ฑ์„ ๋ณด๊ณ  ์‹ ์žฅ(่…Ž่‡Ÿ)์˜ ๊ธฐ๋Šฅ์„ฑ์‡ ๋ฅผ ํŒŒ์•…ํ•˜์˜€๋‹ค. ๋˜ํ•œ "์ด์ž์ข…๋งฅ์ง€์†Œ์ทจ์•ผ

    (่€ณ่€…ๅฎ—่„ˆไน‹ๆ‰€่šไนŸ)"๋ผ ํ•˜๋ฉด์„œ 12 ๊ฒฝ๋ฝ์ด ์ง๊ฐ„์ ‘์ ์œผ๋กœ ์ด๋ถ€(่€ณ้ƒจ)๊ณผ

    ์—ฐ๊ณ„๋˜์–ด ์žˆ๊ณ , ๊ธฐํƒ€ ์‹ฌ, ๊ฐ„, ํ, ์œ„์žฅ ๋“ฑ๋„ ์ด๋ถ€(่€ณ้ƒจ)์— ์˜ํ–ฅ์„ ์ฃผ๊ณ  ์žˆ๋‹ค๊ณ 

    ์–ธ๊ธ‰ํ•˜๊ณ  ์žˆ๋‹ค62,63). ์ด์นจ์€ ์™ธ์ด์˜ ์ด๊ฐœ์— ๋ถ„ํฌ๋˜์–ด ์žˆ๋Š” ๊ฒฝํ˜ˆ์„ ์ž๊ทนํ•˜์—ฌ

    ์‹ ์ฒด์˜ ๋‹ค๋ฅธ ๋ถ€์œ„์— ๋‚˜ํƒ€๋‚˜๋Š” ์ฆ์ƒ์„ ๊ฐœ์„ ํ•˜๋Š” ์น˜๋ฃŒ์š”๋ฒ•์œผ๋กœ, ํ•œ์˜ํ•™ ์ด๋ก ์„

    ๊ทผ๊ฑฐ๋กœ ์ž„์ƒ์—์„œ ๊ด‘๋ฒ”์œ„ํ•˜๊ฒŒ ํ™œ์šฉ๋˜๊ณ  ์žˆ๋Š” ์‹ ์นจ์š”๋ฒ•์ด๋‹ค64). ์ด์นจ์š”๋ฒ•

    (่€ณ้ผ็™‚ๆณ•)์€ ๋ฏธ์นจ(ๅพฎ้ผ)์š”๋ฒ•์˜ ์ผ์ข…์œผ๋กœ ๊ท€ ํ‘œ๋ฉด์— ๋ฐฐ์—ด๋œ ๋‡Œ์™€ ์—ฐ๊ฒฐ๋˜์–ด

    ๋‡Œ์˜ ๋ณ‘๋ฆฌ์  ํ˜„์ƒ์„ ๊ฐœ์„ ํ•˜๋Š” ์ฒด์„ฑ๊ฐ๊ฐ์˜ ํ‘œํ˜„์œผ๋กœ ๊ทผ๊ณจ๊ฒฉ๊ณ„ ์งˆํ™˜ ์ด๋‚˜

    ์‹ฌ์žฅ์งˆํ™˜์ด ์žˆ๋Š” ํ™˜์ž๋ฅผ ์ง„๋‹จํ•˜๋Š”๋ฐ ์‚ฌ์šฉ๋˜๊ณ  ์ตœ๊ทผ์—๋Š” ๊ธˆ์—ฐ, ๋น„๋งŒ, ์•ฝ๋ฌผ์ค‘๋…

    ๋“ฑ์˜ ์น˜๋ฃŒ์—๊นŒ์ง€ ์‘์šฉ๋˜๊ณ  ์žˆ๋‹ค65-69). ์น˜๋ฃŒ์›๋ฆฌ๋Š” ์ดํ˜ˆ์— ์ฃผ๋Š” ์ž๊ทน์ด

    ๋‡Œํ•˜์ˆ˜์ฒด๊ณ„ํ†ต์— ํฅ๋ถ„์„ ์ผ์œผ์ผœ ์ฒด์•ก์ค‘์˜ ํ˜ธ๋ฅด๋ชฌ ํ‰ํ˜•์„ ์กฐ์ ˆํ•˜๊ณ  ๋ฐฉ์–ด๊ธฐ๋Šฅ์„

    ์ฆ๊ฐ•์‹œ์ผœ ์งˆ๋ณ‘์„ ์น˜์œ ํ•œ๋‹ค70). ํŠนํžˆ ์ด์นจ์š”๋ฒ•(่€ณ้ผ็™‚ๆณ•)์€ ์ด๊ณฝ(่€ณๅป“)์— ์œ„์น˜ํ•œ

  • 7

    ํ˜ˆ์œ„(็ฉดไฝ)์˜ ์ž๊ทน์„ ํ†ตํ•˜์—ฌ ์ธ์ฒด ๊ฐ๋ถ€์˜ ์งˆ๋ณ‘์„ ์น˜๋ฃŒํ•˜๋Š”

    ๋ถ„๊ตฌ์ˆ ๋ฒ•(ๅˆ†ๅ€้“–ๆณ•)์œผ๋กœ ๊ณ ๋Œ€(ๅคไปฃ) ํ•œ์˜ํ•™(้Ÿ“้†ซๅญธ)์„ ๊ทผ๊ฑฐ๋กœ ๊ด‘๋ฒ”ํ•˜๊ฒŒ ์ž„์ƒ์—

    ํ™œ์šฉ๋˜๋Š” ์‹ ์นจ์š”๋ฒ•(ๆ–ฐ้ผ็™‚ๆณ•)์œผ๋กœ์„œ71) ์œ , ๊น€72)์€ ๊ณ ํ˜ˆ์••์˜ ์น˜๋ฃŒ์— ๋Œ€ํ•œ

    ์ด์นจ(่€ณ้ผ)์˜ ์„ ํ˜ˆ์›์น™(้ธ็ฉดๅŽŸๅ‰‡)์„ ์—ฌ์„ฏ ๊ฐ€์ง€๋กœ ๋ถ„๋ฅ˜ํ•˜๊ธฐ๋„ ํ•˜์˜€๋‹ค.

    ๊ณ ํ˜ˆ์••์€ ๊ทธ ์งˆ๋ณ‘ ์ž์ฒด๋กœ ์ƒ๊ธฐ๋Š” ์œ„ํ—˜์„ฑ๋ณด๋‹ค 2์ฐจ์ ์œผ๋กœ ์‹ฌ์žฅ, ๋‡Œํ˜ˆ๊ด€๊ณ„,

    ์‹ ์žฅ ๋“ฑ์—์„œ ๋ฐœ์ƒํ•˜๋Š” ํ•ฉ๋ณ‘์ฆ์ด ์šฐ๋ฆฌ ๋ชธ์— ์‹ฌ๊ฐํ•œ ์œ„ํ•ด(ๅฑๅฎณ)๋ฅผ ๊ฐ€ํ•  ์ˆ˜

    ์žˆ๋‹ค๋Š” ์ ์„ ๊ณ ๋ คํ–ˆ์„ ๋•Œ ์ „์ธ์  ๊ด€์ ์—์„œ ๋ฐ”๋ผ๋ณด๋Š” ํ•œ์˜ํ•™์€ ๋ถ„๋ช… ๊ทธ ๋Œ€์•ˆ์ด

    ๋  ์ˆ˜ ์žˆ์„ ๊ฒƒ์ด๋ผ๊ณ  ์‚ฌ๋ฃŒ๋œ๋‹ค. ๋˜ํ•œ ๊ณ ๋ น ์นœํ™”์  1์ฐจ ์˜๋ฃŒ๊ธฐ๊ด€์ธ ํ•œ์˜์›์€

    ์ ‘๊ทผ์„ฑ์—์„œ ๋งŒ์„ฑ์งˆํ™˜์˜ ๊ด€๋ฆฌ์  ์ธก๋ฉด์— ์šฐ์ˆ˜ํ•œ ์žฅ์ ์„ ์ง€๋‹ˆ๊ณ  ์žˆ์–ด ํ•œ์˜ํ•™์˜

    ๊ณ ํ˜ˆ์•• ์น˜๋ฃŒ๋ฅผ ์ฒด๊ณ„ํ™”์‹œํ‚ค๊ณ  ๋ณด๊ธ‰ํ•จ์œผ๋กœ์จ ๋ณด๋‹ค ํ™œ์„ฑํ™”์‹œํ‚ฌ ํ•„์š”์„ฑ์ด ์žˆ๋‹ค.

    ๊ทธ๋Ÿฌ๋‚˜ ๊ณ ํ˜ˆ์••์— ๋Œ€ํ•œ ์นจ์น˜๋ฃŒ ๋ฐ ์ด์••์š”๋ฒ•์˜ ํ˜ˆ์••๊ฐ•ํ•˜ ํšจ๊ณผ์— ๋Œ€ํ•œ ์—ฐ๊ตฌ๋Š”

    ๊ธฐ์กด์˜ ์ฒด๊ณ„์  ๋ฌธํ—Œ๊ณ ์ฐฐ(systematic review: SR) ๋ฐ ์ž„์ƒ์—ฐ๊ตฌ๋ฅผ ํ†ตํ•œ ์—ฌ๋Ÿฌ

    ๋…ผ๋ฌธ์—์„œ ์•Œ ์ˆ˜ ์žˆ์ง€๋งŒ73-75) ์ง€์†์ ์ธ ์ž„์ƒ์—ฐ๊ตฌ์™€ ์น˜ํ—˜๋ก€๋ฅผ ํ†ตํ•œ ๊ฒ€์ฆ์ด

    ํ•„์š”ํ•จ์€ ๋ฌผ๋ก  ์ข€ ๋” ๊ตฌ์ฒด์ ์ธ ๊ณ ํ˜ˆ์••๊ณผ ํ†ต์ฆ์น˜๋ฃŒ์™€์˜ ์ƒ๊ด€๊ด€๊ณ„์— ๋Œ€ํ•œ

    ์—ฐ๊ตฌ๊ฐ€ ๋’ค๋”ฐ๋ผ์•ผ ํ•  ๊ฒƒ์œผ๋กœ ์‚ฌ๋ฃŒ๋œ๋‹ค. ๋˜ํ•œ ๋น„์ฆ์„ ๋™๋ฐ˜ํ•œ ๊ณ ํ˜ˆ์•• ํ™˜์ž๋ฅผ

    ๋Œ€์ƒ์œผ๋กœ ๋น„์ฆ์น˜๋ฃŒ ๋ฐ ๊ณ ํ˜ˆ์•• ์น˜๋ฃŒ๋ฅผ ํ•จ๊ป˜ ์‹ค์‹œํ•˜๋ฉด์„œ ์•„์ง๊นŒ์ง€ ๋น„์ฆ์น˜๋ฃŒ๊ฐ€

    ๊ณ ํ˜ˆ์•• ์น˜๋ฃŒ์— ์–ด๋– ํ•œ ์˜ํ–ฅ์„ ๋ผ์น˜๋Š”์ง€ ๋Œ€ํ•œ ์ž„์ƒ์—ฐ๊ตฌ๊ฐ€ ์ „ํ˜€ ์—†๋‹ค. ์ด์— ๋ณธ

    ์—ฐ๊ตฌ์—์„œ๋Š” ๋น„์ฆ์„ ๋™๋ฐ˜ํ•œ ๊ณ ํ˜ˆ์•• ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ๋น„์ฆ์น˜๋ฃŒ์™€ ํ•จ๊ป˜ ์ „ํ†ต์นจ๊ณผ

    ์ด์••์š”๋ฒ•์„ ๋ณ‘ํ–‰ํ•˜์—ฌ ๊ณ ํ˜ˆ์••์„ ์น˜๋ฃŒํ•จ์œผ๋กœ์จ ์น˜๋ฃŒ ์ „๊ณผ ํ›„์˜ ํ˜ˆ์••๋ณ€ํ™”์™€

    ๊ณ ํ˜ˆ์••๊ณผ ๋น„์ฆ์˜ ์ƒ๊ด€๊ด€๊ณ„๋ฅผ ๋ถ„์„ํ•จ์œผ๋กœ์จ ํ–ฅํ›„ ์ž„์ƒ์—์„œ์˜ ํ™œ์šฉ ๋ฐ ๊ด€๋ จ

  • 8

    ์—ฐ๊ตฌ์— ๋„์›€์ด ๋˜๊ณ ์ž ํ•˜๋ฉฐ ๋ณธ ์„ ํ–‰์—ฐ๊ตฌ๋ฅผ ๋ฐ”ํƒ•์œผ๋กœ ๊ณ ํ˜ˆ์••๊ณผ ๋น„์ฆ์˜

    ๋™์‹œ์น˜๋ฃŒ๊ฐ€ ๊ณ ํ˜ˆ์••๊ณผ ๋น„์ฆ ์น˜๋ฃŒ์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ์— ๋Œ€ํ•œ ์ดˆ๋ณด์ ์ธ ์ž๋ฃŒ๋ฅผ

    ์ œ์‹œํ•˜๊ณ ์ž ํ•œ๋‹ค.

  • 9

    II. OBJECTIVES

    ๋ณธ ์—ฐ๊ตฌ์˜ ๋ชฉ์ ์€ ๊ณ ํ˜ˆ์••๊ณผ ๋น„์ฆ์„ ํ•จ๊ป˜ ์น˜๋ฃŒ์‹œ์— ๊ณ ํ˜ˆ์••๊ณผ ๋น„์ฆ ์น˜๋ฃŒ์—

    ๋ฏธ์น˜๋Š” ๋ณ€ํ™”๋ฅผ ์•Œ์•„๋ณด๊ณ ์ž ํ•œ๋‹ค. ๋ณธ ์—ฐ๊ตฌ์˜ ์ˆ˜ํ–‰์„ ์œ„ํ•œ ์„ธ๋ถ€ ๋ชฉํ‘œ๋Š” ๋‹ค์Œ๊ณผ

    ๊ฐ™๋‹ค:

    Objective 1. ๋งคํšŒ ์น˜๋ฃŒ ์ „๊ณผ ์น˜๋ฃŒ ์งํ›„์˜ ํ˜ˆ์••์„ ์ธก์ •ํ•˜์—ฌ ๋งค๋ฒˆ

    ์น˜๋ฃŒํšจ๊ณผ๋ฅผ ์—ฐ๊ตฌํ•œ๋‹ค.

    Objective 2. 1์ฐจ ์น˜๋ฃŒ ์ „ ์ธก์ •ํ•œ ํ˜ˆ์••๊ณผ ๋งคํšŒ ์น˜๋ฃŒ ํ›„ ํ˜ˆ์••์„ ์ธก์ •ํ•˜์—ฌ

    ๋ˆ„์  ์น˜๋ฃŒํšจ๊ณผ๋ฅผ ๋น„๊ตํ•œ๋‹ค.

    Objective 3. ๋งคํšŒ ์น˜๋ฃŒ ํ›„ ์ธก์ •ํ•œ ํ˜ˆ์•• ๊ฒฐ๊ณผ๋ฅผ ๊ทธ ๋‹ค์Œ ์น˜๋ฃŒ ์ „ ์ธก์ •ํ•œ

    ํ˜ˆ์••๊ณผ ๋น„๊ตํ•˜์—ฌ ์น˜๋ฃŒ ์ง€์† ํšจ๊ณผ๋ฅผ ์—ฐ๊ตฌํ•œ๋‹ค.

    Objective 4. 1์ฐจ ์น˜๋ฃŒ์ „ ์ธก์ •ํ•œ ์ตœ์ดˆ ํ˜ˆ์••๊ณผ ์น˜๋ฃŒ ๋งˆ์ง€๋ง‰์˜ ํ˜ˆ์••์„

    ์ธก์ •ํ•˜์—ฌ ์ตœ์ข… ์น˜๋ฃŒํšจ๊ณผ๋ฅผ ์—ฐ๊ตฌํ•œ๋‹ค.

    Objective 5. ํ†ต์ฆ์˜ ์น˜๋ฃŒ ์ „ํ›„์˜ VAS, ์„ค๋ฌธ์ง€๋ฅผ ํ†ตํ•œ ODI, SPADI,

    WOMAC ๋ฅผ ์ธก์ •ํ•˜์—ฌ ํ†ต์ฆ ์น˜๋ฃŒํšจ๊ณผ๋ฅผ ์—ฐ๊ตฌ๋ถ„์„ํ•œ๋‹ค.

  • 10

    III. LITERATURE REVIEW

    ๊ณ ํ˜ˆ์••์€ ์ฃผ์š” ์‚ฌ๋ง ์งˆํ™˜ 1, 2์œ„๋ฅผ ์ฐจ์ง€ํ•˜๋Š” ๋‡Œํ˜ˆ๊ด€ ์งˆํ™˜๊ณผ ์‹ฌ์žฅ์งˆํ™˜์˜

    ์ฃผ์›์ธ์œผ๋กœ ๋ณด๋‹ค ์ ๊ทน์ ์ธ ํ™˜์ž ๊ด€๋ฆฌ์™€ ์น˜๋ฃŒ๊ฐ€ ์š”๊ตฌ๋˜๊ณ  ์žˆ๊ณ 15) ํ˜„

    ์˜๋ฃŒ๊ณ„์—์„œ๋„ ์ค‘์š”ํ•œ ๋ฌธ์ œ๋กœ ๋Œ€๋‘๋˜๊ณ  ์žˆ๋Š” ์‹ค์ •์ด๋‹ค7). ์—ฐ๋ น์ด ์ฆ๊ฐ€ํ•˜๋ฉด์„œ

    ํ˜ˆ์••์€ ํ•จ๊ป˜ ์ƒ์Šนํ•˜๋Š”๋ฐ ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••์€ 70, 80์„ธ๊ฐ€ ์ง€๋‚˜๋„๋ก ๊ณ„์† ์ƒ์Šนํ•˜์ง€๋งŒ

    ์ด์™„๊ธฐ ํ˜ˆ์••์€ 50-60์„ธ๋  ๋•Œ๊นŒ์ง€๋Š” ์ƒ์Šนํ•˜๊ณ  ๊ทธ ํ›„์—๋Š” ์ ์ฐจ ๋‚ฎ์•„์ง€๋Š”

    ๊ฒฝํ–ฅ์ด ์žˆ๋‹ค. ๋”ฐ๋ผ์„œ ๋…ธ๋…„์ธต์—์„œ์˜ ํ˜ˆ์••์€ ์ฒญ์žฅ๋…„์ธต์—์„œ ๋ณด๋‹ค ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••์€

    ๋†’์ง€๋งŒ ์ด์™„๊ธฐ ํ˜ˆ์••์€ ์ƒ๋Œ€์ ์œผ๋กœ ๋‚ฎ์€ ํ˜„์ƒ, ์ฆ‰ ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••๊ณผ ์ด์™„๊ธฐ

    ํ˜ˆ์••๊ณผ์˜ ์ฐจ์ด์ธ ๋งฅ์••(pulse pressure)์ด ํฐ๊ฒƒ์ด ํŠน์ง•์ด๋‹ค76). ํŠนํžˆ ๋…ธ์ธ์˜

    ๊ณ ํ˜ˆ์••์€ 95% ์ด์ƒ์ด ๋ณธํƒœ์„ฑ ๊ณ ํ˜ˆ์••์œผ๋กœ ์ƒ๋‹น๊ธฐ๊ฐ„ ๋ฌด์ฆ์ƒ ์ƒํƒœ๋กœ

    ์ง„ํ–‰๋˜๋ฏ€๋กœ ์งˆ๋ณ‘์˜ ์‹ฌ๊ฐ์„ฑ์„ ์ธ์‹ํ•˜์ง€ ๋ชปํ•˜์—ฌ ์กฐ๊ธฐ๋ฐœ๊ฒฌ์ด ์–ด๋ ต๊ณ  ๊ณ ํ˜ˆ์••์„

    ๋…ธํ™”๋กœ ์ธํ•œ ๋‹น์—ฐํ•œ ๊ฒฐ๊ณผ๋กœ ๊ฐ„์ฃผํ•˜๋Š” ๊ฒฝํ–ฅ์ด ์žˆ๊ธฐ ๋•Œ๋ฌธ์— ์ž๊ฐ€๊ด€๋ฆฌ๋ฅผ ํ•˜์ง€

    ์•Š์•„ ํ•ฉ๋ณ‘์ฆ์ด ๋ฐœ์ƒํ•˜๊ฑฐ๋‚˜ ์žฌ๋ฐœํ•˜๊ณ  ์งˆ๋ณ‘์ด ์•…ํ™”๋˜์–ด ์กฐ๊ธฐ ์‚ฌ๋ง์„ ์ดˆ๋ž˜ํ•˜๋Š”

    ๊ฒฝํ–ฅ์ด ์žˆ๋‹ค77). ํŠนํžˆ ํ˜ˆ์••์˜ ์ธก์ •๋Œ€์ƒ์ด ๋˜๋Š” ์ „์‹  ๋™๋งฅ์••์€ ์ฃผ์š” ์žฅ๊ธฐ ์ฆ‰ ๋‡Œ,

    ์•ˆ๊ตฌ, ์‹ ์žฅ ๋ฐ ์‹ฌ์žฅ์„ ๊ด€๋ฅ˜ํ•˜๊ธฐ์— ์ถฉ๋ถ„ํ•œ ์••๋ ฅ์„ ์œ ์ง€ํ•˜๊ณ , ํ˜ˆ๊ด€์ด ์†์ƒ ๋ฐ›์ง€

    ์•Š์„ ์ •๋„๋กœ ํ˜ˆ์••์„ ์œ ์ง€ํ•˜๋Š”๊ฒŒ ์ค‘์š”ํ•˜๋‹ค78).

    ๊ณ ํ˜ˆ์••์€ ๋ฏธ๊ตญ์ธ๊ตฌ์˜ 24% ์—์„œ ๋ฐœ๊ฒฌ๋  ์ •๋„๋กœ ๋งค์šฐ ํ”ํ•œ ์งˆํ™˜์ด๊ณ ,

    ๊ด€์ƒ๋™๋งฅ์งˆํ™˜, ๋‡Œ์กธ์ค‘, ์‹ ๋ถ€์ „๊ณผ ๊ฐ™์€ ์‹ฌ๊ฐํ•œ ํ•ฉ๋ณ‘์ฆ์˜ ์ฃผ์š” ์œ„ํ—˜์ธ์ž์ด๊ธฐ

    ๋•Œ๋ฌธ์—, ์—ญํ•™์กฐ์‚ฌ๋ฅผ ํฌํ•จํ•œ ์ž„์ƒ์—ฐ๊ตฌ์—์„œ ์ ๊ทน์ ์ธ ํ˜ˆ์••์กฐ์ ˆ์ด ์‹ฌํ˜ˆ๊ด€๊ณ„

  • 11

    ํ•ฉ๋ณ‘์ฆ๊ณผ ์‚ฌ๋ง๋ฅ ์„ ๊ฐ์†Œ์‹œํ‚ฌ ์ˆ˜ ์žˆ๋‹ค๊ณ  ํ•˜์˜€๋‹ค79). ๊ณ ํ˜ˆ์••์€ ํ™˜์ž ๋ณธ์ธ์ด

    ์ž๊ฐํ•˜๋Š” ๋šœ๋ ทํ•œ ์ฆ์ƒ์ด ์—†๊ณ , ์ง„๋‹จ ํ›„์— ํ‰์ƒ ์•ฝ๋ฌผ์„ ๋ณต์šฉํ•˜๋ฉฐ, ํ™˜์ž๊ฐ€

    ์ƒํ™œ์Šต๊ด€์˜ ๋ณ€ํ™”๋ฅผ ์š”๊ตฌ ๋ฐ›์œผ๋ฏ€๋กœ, ํ™˜์ž ์Šค์Šค๋กœ๊ฐ€ ์ค‘๋„์— ์น˜๋ฃŒ๋ฅผ ํฌ๊ธฐํ•˜๋Š”

    ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์•„ ํ•ฉ๋ณ‘์ฆ์— ์˜ํ•œ ์‚ฌํšŒ์  ๋ถ€๋‹ด์ด ์ค‘์š”ํ•œ ๋ฌธ์ œ๊ฐ€ ๋˜๊ณ  ์žˆ๋‹ค5). ํ˜ˆ์••

    ์ƒ์Šนํ›„ ์ฒซ 10~20๋…„์€ ๋Œ€๋ถ€๋ถ„ ๋ฌด์ฆ์ƒ์œผ๋กœ ๊ฒฝ๊ณผํ•˜์ง€๋งŒ ๊ณ ํ˜ˆ์••์€ ๋™๋งฅ๊ฒฝํ™”์ฆ์„

    ์ด‰์ง„์‹œํ‚ค๊ณ  ๊ฐ์ข… ์‹ฌํ˜ˆ๊ด€ ์งˆํ™˜์˜ ๋ฐœ๋ณ‘๋ฅ ์„ ๋†’์ด๋Š” ๋“ฑ ๊ทธ ์‚ฌ์ด์—๋„ ์‹ฌํ˜ˆ๊ด€

    ์žฅ์• ๋Š” ์ง„ํ–‰๋˜๊ณ  ์žˆ๋‹ค๊ณ  ๋ณด๋Š” ๊ฒฌํ•ด๊ฐ€ ์žˆ๋‹ค80). ๋˜ํ•œ, ๊ณ ํ˜ˆ์••์€ ํ‘œ์ ์žฅ๊ธฐ์—

    ํ˜„์ €ํ•œ ํ•ฉ๋ณ‘์ฆ์ด ๋‚˜ํƒ€๋‚˜๊ธฐ ์ „๊นŒ์ง€๋Š” ์ฆ์ƒ์ด ์—†์–ด ์ง„๋‹จ๋˜์ง€ ๋ชปํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€

    ๋งŽ์œผ๋ฉฐ, ๊ณ ํ˜ˆ์•• ์ง„๋‹จ์ด ์ด๋ฃจ์–ด์ง„ ์ดํ›„์—๋„ ์น˜๋ฃŒ๋ฅผ ๋ฐ›์ง€ ์•Š๊ฑฐ๋‚˜ ์น˜๋ฃŒ๋ฅผ

    ์ค‘๋‹จํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์•„, ๋ณ„๋„์˜ ๊ณ ํ˜ˆ์•• ๊ด€๋ฆฌ๋ฅผ ์œ„ํ•œ ๋…ธ๋ ฅ์ด ์—†์œผ๋ฉด, ๊ณ ํ˜ˆ์••

    ํ™˜์ž์˜ ์ ˆ๋ฐ˜์€ ์ง„๋‹จ๋˜์ง€ ์•Š๊ณ , ์ง„๋‹จ๋œ ํ™˜์ž์˜ ์ ˆ๋ฐ˜์€ ์น˜๋ฃŒ๋ฐ›์ง€ ์•Š์œผ๋ฉฐ,

    ์น˜๋ฃŒ๋ฐ›๊ณ  ์žˆ๋Š” ํ™˜์ž์˜ ์ ˆ๋ฐ˜์€ ํ˜ˆ์••์กฐ์ ˆ์ด ์ ์ ˆํ•˜์ง€ ๋ชปํ•˜๋‹ค๋Š” '์ ˆ๋ฐ˜์˜

    ๋ฒ•์น™(rule of halves)'์ด ์ ์šฉ๋˜๊ณ  ์žˆ๋‹ค81).

    ํ˜ˆ์••์ด๋ž€ ๋™๋งฅ ํ˜ˆ๊ด€๋ฒฝ์— ๋Œ€ํ•œ ํ˜ˆ์•ก์˜ ์••๋ ฅ์œผ๋กœ, ์‹ฌ์žฅ์ด ์ˆ˜์ถ•ํ•˜์—ฌ

    ๋™๋งฅํ˜ˆ๊ด€์œผ๋กœ ํ˜ˆ์•ก์„ ๋ณด๋‚ผ ๋•Œ ํ˜ˆ์••์„ ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••, ์‹ฌ์žฅ์ด ๋Š˜์–ด๋‚˜์„œ ํ˜ˆ์•ก์„

    ๋ฐ›์•„๋“ค์ผ ๋•Œ์˜ ํ˜ˆ์••์„ ์ด์™„๊ธฐ ํ˜ˆ์••์ด๋ผ๊ณ  ํ•œ๋‹ค82). 1999๋…„ WHO-ISH

    Guidelines83)์— ์˜ํ•˜๋ฉด ์ง„๋ฃŒ์‹ค ํ˜ˆ์•• 140/90mmHg ์ด์ƒ์„ ๊ธฐ์ค€์œผ๋กœ

    ๊ณ ํ˜ˆ์••์œผ๋กœ ๊ทœ์ •ํ•˜์˜€์œผ๋ฉฐ, 130-139/85-89mmHg์„ ๋†’์€ ์ •์ƒ, 130/85mmHg

    ์ดํ•˜๋ฅผ ์ •์ƒ 120/80mmHg ์ดํ•˜๋ฅผ ์ ์ •ํ˜ˆ์••์ด๋ผ ์ •ํ•˜์˜€๋‹ค84). 2003๋…„ ๋ฏธ๊ตญ

    ๊ตญ๋ฆฝ๋ณด๊ฑด์› ๊ณ ํ˜ˆ์•• ํ•ฉ๋™์œ„์›ํšŒ์˜ 7์ฐจ ๋ณด๊ณ ์„œ(JNC-7)๋Š” ํ˜ˆ์••์„ 4๋‹จ๊ณ„์ธ

  • 12

    ์ •์ƒํ˜ˆ์••, ๊ณ ํ˜ˆ์•• ์ „๋‹จ๊ณ„, 1๊ธฐ ๊ณ ํ˜ˆ์••, 2๊ธฐ ๊ณ ํ˜ˆ์••์œผ๋กœ ๋ถ„๋ฅ˜ํ•˜์˜€๋‹ค. ์ •์ƒํ˜ˆ์••์€

    120/80mmHg๋ฏธ๋งŒ, ๊ณ ํ˜ˆ์•• ์ „๋‹จ๊ณ„๋Š” 120/80mmHg~139/89mmHg, 1๊ธฐ

    ๊ณ ํ˜ˆ์••์€ 140/90mmHg~159/99mmHg, 2๊ธฐ ๊ณ ํ˜ˆ์••์€ 160/100mmHg

    ์ด์ƒ์œผ๋กœ ์ •์˜ํ•˜๊ณ  ์žˆ๋‹ค. ๊ทธ๋Ÿฌ๋‚˜, 2017๋…„ ๋ฏธ๊ตญ์‹ฌ์žฅํ•™ํšŒ(ACC)์™€ ์‹ฌ์žฅํ˜‘ํšŒ

    (AHA)๋Š” ํ˜ˆ์••์„ 4๋‹จ๊ณ„์ธ ์ •์ƒํ˜ˆ์••, ์ƒ์Šนํ˜ˆ์••, ๊ณ ํ˜ˆ์••1๋‹จ๊ณ„, ๊ณ ํ˜ˆ์••2๋‹จ๊ณ„๋กœ

    ๋ถ„๋ฅ˜ํ•˜์˜€๋‹ค. ์ •์ƒํ˜ˆ์••์€ 120/80mmHg๋ฏธ๋งŒ, ์ƒ์Šนํ˜ˆ์••์€ ์ˆ˜์ถ•๊ธฐํ˜ˆ์••

    120~129mmHg, ์ด์™„๊ธฐํ˜ˆ์•• 80mmHg ๋ฏธ๋งŒ, ๊ณ ํ˜ˆ์••1๋‹จ๊ณ„๋Š” 130~139

    /80~89mmHg, ๊ทธ๋ฆฌ๊ณ  ๊ณ ํ˜ˆ์•• 2๋‹จ๊ณ„๋Š” 140/90mmHg ์ด์ƒ์œผ๋กœ ์ •์˜ํ–ˆ๋‹ค85).

    ๋˜ํ•œ, ์ตœ๊ทผ์˜ ์—ฐ๊ตฌ ๋ณด๊ณ ๋“ค์€ ์‹ฌํ˜ˆ๊ด€๊ณ„ ์งˆํ™˜์˜ ๋ฐœ์ƒ๋ฅ ๊ณผ ์‚ฌ๋ง๋ฅ ์„ ๋‚ฎ์ถ”๊ธฐ

    ์œ„ํ•ด์„œ ํ˜ˆ์••์„ ์ •์ƒ ์ˆ˜์ค€์œผ๋กœ ์ฒ ์ €ํ•˜๊ฒŒ ๊ด€๋ฆฌํ•  ๊ฒƒ์„ ๊ฐ•์กฐํ•˜๊ณ  ์žˆ๋Š”๋ฐ,

    Hypertension Optimal Treatment(HOT)18)๋Š” ์ด์™„๊ธฐ ํ˜ˆ์••์„ 90mmHg

    ๋ฏธ๋งŒ๋ณด๋‹ค 80mmHg ๋ฏธ๋งŒ์œผ๋กœ ๋‚ฎ์ถ”์–ด ์‹ฌํ˜ˆ๊ด€ ์งˆํ™˜์˜ ๋ฐœ์ƒ์„ 1/2๋กœ ์ค„์ผ ์ˆ˜

    ์žˆ๋‹ค๊ณ  ๋ณด๊ณ ํ•˜์˜€๊ณ , ๋˜ํ•œ UK Prospective Diabetes Study(UKPDS)19)๋Š”

    ํ˜ˆ์••์„ ๊ฐ€๊ธ‰์  ๋‚ฎ๊ฒŒ ์กฐ์ ˆํ•˜๋ฉด ๋‹น๋‡จ๋ณ‘๊ณผ ์—ฐ๊ด€๋œ ์‚ฌ๋ง๋ฅ ์„ ๋‚ฎ์ถœ ์ˆ˜ ์žˆ๋‹ค๊ณ 

    ๋ฐํ˜”๋‹ค.

    ์‹ฌํ˜ˆ๊ด€๊ณ„ ์งˆํ™˜์˜ ๋Œ€๋‹ค์ˆ˜๊ฐ€ ๊ณ ํ˜ˆ์••๊ณผ ๊ด€๋ จ์ด ์žˆ์œผ๋ฉฐ, ์ง์ ‘์ ์ธ ์ž‘์šฉ์œผ๋กœ๋Š”

    ํ˜ˆ๊ด€ ์ˆ˜์ถ• ํšจ๊ณผ๋ฅผ ๋‚˜ํƒ€๋‚ด๋ฉฐ ๊ฐ„์ ‘์ ์œผ๋กœ๋Š” ์ฃฝ์ƒ๊ฒฝํ™” ๋“ฑ์„ ์œ ๋ฐœํ•˜๋Š” ์งˆํ™˜์œผ๋กœ

    ๋‚˜ํƒ€๋‚˜๊ฒŒ ๋œ๋‹ค86). ํ˜ˆ์••์˜ ์ƒ์Šน์€ ํ˜ˆ๊ด€์˜ ์ด์ƒ์„ ์ดˆ๋ž˜ํ•˜๋Š”๋ฐ, ํฌ๊ฒŒ ๊ตฌ์กฐ์ ์ธ

    ๋ณ€ํ™” (ํ˜ˆ๊ด€๋‚ด๊ฒฝ ๋ฐ ํ˜ˆ๊ด€ ๊ตฌ์กฐ), ๊ธฐ๋Šฅ์ ์ธ ๋ณ€ํ™”์™€ ๊ธฐ๊ณ„์ ์ธ ๋ณ€ํ™”๋กœ ๋‚˜๋ˆŒ ์ˆ˜

    ์žˆ์œผ๋ฉฐ ์œ ์ „์  ์›์ธ์€ ๋‹ค์–‘ํ•œ ์œ ์ „์  ๊ฒฐํ•จ์˜ ์ง‘ํ•ฉ์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ๋Š”๋ฐ, ๊ทธ์ค‘

  • 13

    ๋ ˆ๋‹Œ-์•ˆ์ง€์˜คํ…์‹ ๊ณ„(renin-angiotensin system, RAS)๋Š” ์•ˆ์ง€์˜คํ…์‹œ๋…ธ๊ฒ

    (angiotensinogen, AGT), ๋ ˆ๋‹Œ(renin), ์•ˆ์ง€์˜คํ…์‹  ์ „ํ™˜ํšจ์†Œ(angiotensin

    converting enzyme, ACE)๋กœ ๊ตฌ์„ฑ๋˜์—ˆ์œผ๋ฉฐ, ํ˜ˆ์••์กฐ์ ˆ๊ณผ ์ˆ˜๋ถ„ ๋ฐ ์ „ํ•ด์งˆ

    ๋Œ€์‚ฌ์— ๊ด€์—ฌํ•˜๊ณ  ํ˜ˆ๊ด€์˜ ํ‰ํ™œ๊ทผ ์„ธํฌ๋ฅผ ์ฆ์‹์‹œ์ผœ ๊ณ ํ˜ˆ์•• ๋ฐœ์ƒ์— ์ค‘์š”ํ•œ

    ์—ญํ• ์„ ํ•œ๋‹ค87). ๊ฒฐ๊ณผ์ ์œผ๋กœ RAS๋Š” ์•ˆ์ง€์˜คํ…์‹  ์ „ํ™˜ ํšจ์†Œ ์–ต์ œ์ œ(ACEI)๋‚˜

    ์•ˆ์ง€์˜คํ…์‹  II ์ˆ˜์šฉ์ฒด ๊ธธํ•ญ์ œ(ARB)์˜ ๊ฐœ๋ฐœ๊ณผ ๋”๋ถˆ์–ด ์ž„์ƒ์ ์œผ๋กœ ํ˜ˆ์••์„

    ์กฐ์ ˆํ•˜๋Š” ์ค‘์š”ํ•œ ๋Œ€์ƒ์ด ๋˜์–ด ์™”์œผ๋ฉฐ88) ํ˜ˆ์•ก ๋™๋ ฅํ•™์  ์ธก๋ฉด์—์„œ ํ˜ˆ์••๊ณผ

    ํ˜ˆ๋ฅ˜์˜ ๋ณ€ํ™”, ์ฃผ๊ธฐ์  ํ˜ˆ๊ด€์ž๊ทน ๊ทธ๋ฆฌ๊ณ  ์„ธํฌ ๋‚ด์™ธ์˜ ์‹ ๊ฒฝ ํ˜ˆ์•กํ•™์  ์š”์ธ์—

    ์˜ํ•ด ํ˜ˆ๊ด€์— ๋ณ€ํ™”๊ฐ€ ์ดˆ๋ž˜๋˜๋ฉด ๋Œ€ํ˜ˆ๊ด€์—์„œ๋Š” ๋‚ด๊ฒฝ์˜ ์ฆ๊ฐ€์™€ ๋น„๋Œ€ ๊ทธ๋ฆฌ๊ณ 

    ์ค‘๊ฒฉ์˜ ๋น„๋Œ€ํ™” ๋“ฑ ๋น„๋Œ€ํ˜• ํ˜ˆ๊ด€์žฌํ˜•์„ฑ(hypertrophic remodeling)์ด ์ผ์–ด๋‚˜๋ฉฐ

    ๋ฏธ์„ธ ํ˜ˆ๊ด€์—์„œ๋Š” ํ‰ํ™œ๊ทผ ์„ธํฌ ์žฌ๋ฐฐ์น˜, ํ˜ˆ๊ด€ ์žฌํ˜•์„ฑ ๋“ฑ ํ˜ˆ๊ด€ ๋น„๋Œ€ ์—†์ด ํ˜ˆ๊ด€

    ๋‚ด๊ฒฝ์˜ ๊ฐ์†Œ(eutrophic remodeling)๊ฐ€ ์ผ์–ด๋‚œ๋‹ค89). ๋˜ํ•œ, ํ˜ˆ๊ด€๋‚ดํ”ผ ์„ธํฌ์—์„œ

    endothelium-drived relaxing factor(EDRF)์ธ ํ˜ˆ๊ด€ ์ด์™„ ์ธ์ž nitric oxide

    (NO)์˜ ์ƒ์„ฑ์œผ๋กœ endothelin-1 (ET-1), angiotensin II (Ang-II)์™€ ๊ฐ™์€ ํ˜ˆ๊ด€

    ์ˆ˜์ถ• ์ธ์ž๋“ค๊ณผ ๊ท ํ˜•์„ ์ด๋ฃจ์ง€๋งŒ90,91) ํ˜ˆ๊ด€ํ™•์žฅ ์ธ์ž๋“ค์„ ์–ต์ œํ•˜๋Š” ์•ฝ๋ฌผ์ธ

    ์ธ๋„๋ฉ”ํƒ€์‹ (indomethacin, IDN)์€ methyl๊ธฐ๋ฅผ ๊ฐ€์ง„ indole ์œ ๋„์ฒด๋กœ

    prostaglandin, ํ˜ˆ๊ด€ํ™•์žฅํ™€๋ชฌ, ์˜ ์ƒํ•ฉ์„ฑ ํšจ์†Œ์ธ cyclooxygenase๋ฅผ ๊ฐ•๋ ฅํ•˜๊ฒŒ

    ์–ต์ œํ•˜๋Š” ์•ฝ๋ฌผ92)๊ณผ, ๋ฉ”ํ‹ธ๋ Œ๋ธ”๋ฃจ(methylene blue, MTB), cGMP(ํ˜ˆ์†ŒํŒ

    ์‘์ง‘์–ต์ œ์ œ)์˜ ์ƒ์„ฑํšจ์†Œ์ธ guanylate cyclase๋ฅผ ์–ต์ œํ•˜๋Š” ์•ฝ๋ฌผ,93)๋กœ ์ธํ•ด

    ํ˜ˆ๊ด€๊ธฐ๋Šฅ์ด ์ƒ์‹ค๋˜๊ธฐ๋„ ํ•œ๋‹ค. ๊ฒฐ๊ตญ, ํ˜ˆ๊ด€ ๋‚ดํ”ผ๋Š” ํ˜ˆ๊ด€์กฐ์ง์„ ์ด์ฒด์ ์œผ๋กœ

  • 14

    ์œ ์ง€ํ•˜๋Š”๋ฐ ์ค‘์š”ํ•œ ์กฐ์ง์œผ๋กœ ํ˜ˆ๊ด€๋‚ดํ”ผ์„ธํฌ์˜ ๊ธฐ๋Šฅ์ด ์ƒ์‹ค๋˜๋ฉด ๊ฒฐ๊ณผ์ ์œผ๋กœ

    ํ˜ˆ๊ด€์†์ƒ์ด ์ผ์–ด๋‚˜๊ฒŒ ๋œ๋‹ค94).

    ๊ณ ํ˜ˆ์•• ์น˜๋ฃŒ์˜ ๊ฐ€์žฅ ๋Œ€ํ‘œ์ ์ธ ์•ฝ๋ฌผ์น˜๋ฃŒ๋Š” ์ด๋‡จ์ œ, ฮฒ-blocker, ํ˜ˆ๊ด€์ด์™„์ œ,

    ์นผ์Š˜๊ธธํ•ญ์ œ, ์•ˆ์ง€์˜คํ…์‹  ์ „ํ™˜ ํšจ์†Œ ์–ต์ œ์ œ๋“ฑ ๋‹ค์–‘ํ•˜๋ฉฐ ์ด๋Š” ๋‹จ๊ณ„์ ์œผ๋กœ ํ•œ

    ๊ฐ€์ง€ ์ด์ƒ์„ ๋ณตํ•ฉ์ ์œผ๋กœ ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ95) ํ˜ˆ์••๊ฐ•ํ•˜์ œ๋Š” ์ž‘์šฉํ•˜๋Š” ์›๋ฆฌ์—

    ๋”ฐ๋ผ ์ด๋‡จ์ œ, ๋ฒ ํƒ€์ฐจ๋‹จ์ œ, ์นผ์Š˜์ฐจ๋‹จ์ œ, ์•ค์ง€์˜คํ…์‹  ์ „ํ™˜ํšจ์†Œ(ACE) ์–ต์ œ์ œ,

    ์•ค์ง€์˜คํ…์‹ โ…ก ์ˆ˜์šฉ์ฒด ์ฐจ๋‹จ์ œ(ARB), ์•ŒํŒŒ์ฐจ๋‹จ์ œ ๋“ฑ์ด ์–‘๋ฐฉ์น˜๋ฃŒ์ œ๋กœ ์‹œํŒ๋˜๊ณ 

    ์žˆ๋Š” ์ƒํ™ฉ์ด๋‹ค96). ์ตœ๊ทผ์—๋Š” ์—ผ์ฆ์ด ๊ณ ํ˜ˆ์•• ์ง„ํ–‰์˜ ์ค‘์š”ํ•œ ๊ธฐ์ „์œผ๋กœ ์ œ๊ธฐ๋˜์–ด

    C-๋ฐ˜์‘๋‹จ๋ฐฑ(C-reactive protein, CRP)์— ๋Œ€ํ•œ ๊ด€์‹ฌ๋„ ๋†’์•„์ง€๊ณ  ์žˆ๋‹ค97).

    ๊ทธ๋Ÿฌ๋‚˜ ์ด๋Ÿฐ ์–‘๋ฐฉ์น˜๋ฃŒ์ œ๋Š” ๊ฐ•์••์˜ ํšจ๊ณผ๋ฅผ ์ง€๋‹ˆ๊ณ  ์žˆ์ง€๋งŒ ์—ฌ๋Ÿฌ ๊ฐ€์ง€ ๋ถ€์ž‘์šฉ์„

    ์œ ๋ฐœ์‹œํ‚ค๊ธฐ๋„ ํ•œ๋‹ค. ์ด๋‡จ์ œ๋Š” ๋Œ€์‚ฌ์žฅ์• ์˜ ๋ถ€์ž‘์šฉ์ด ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๊ณ ,

    ๋ฒ ํƒ€์ฐจ๋‹จ์ œ๋Š” ํ”ผ๋กœ๊ฐ, ํ์งˆํ™˜ํ™˜์ž์—์„œ์˜ ์ฒœ์‹ ์•…ํ™” ๋“ฑ์„ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ,

    ์นผ์Š˜์ฐจ๋‹จ์ œ๋Š” ํ™์กฐ, ๋‘ํ†ต, ๊ธฐ๋ฆฝ์„ฑ ํ˜„๊ธฐ์ฆ, ์‹ฌ๊ณ„ํ•ญ์ง„ ํ˜น์€ ๋นˆ๋งฅ, ๋ฐœ๋ชฉ๋ถ€์ข… ๋“ฑ์„

    ์ผ์œผํ‚ฌ ์ˆ˜ ์žˆ๋‹ค98). ํŠนํžˆ ๋ฒ ํƒ€์ฐจ๋‹จ์ œ์˜ ๊ฒฝ์šฐ ๊ต๊ฐ ์‹ ๊ฒฝ ํ•ญ์ง„์ด ์ฃผ ๋ณ‘ํƒœ ์ƒ๋ฆฌ๊ฐ€

    ์•„๋‹Œ ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์€ ๋…ธ์ธ ํ™˜์ž์—์„œ ๊ฐ•์•• ํšจ๊ณผ๊ฐ€ ์ ๊ณ  24์‹œ๊ฐ„ ๊ฐ•์•• ํšจ๊ณผ๊ฐ€

    ์ง€์†๋˜์ง€ ์•Š๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์•„ ์ƒˆ๋ฒฝ์— ๋งŽ์ด ๋ฐœ์ƒํ•˜๋Š” ๋‡Œ์กธ์ค‘์— ๋Œ€ํ•œ ๋ฐฉ์–ด ํšจ๊ณผ๊ฐ€

    ๋‹ค๋ฅธ ์•ฝ์ œ๋ณด๋‹ค ๋–จ์–ด์ง„๋‹ค๋Š” ์šฐ๋ ค๊ฐ€ ์žˆ๋‹ค99). ๋ฐ˜๋ฉด ๋ฒ ํƒ€์ฐจ๋‹จ์ œ์™€ ์ด๋‡จ์ œ์˜

    ๋ณ‘์šฉํˆฌ์—ฌ๋Š” ๋‹น๋‡จ๋ณ‘์˜ ๋ฐœ์ƒ ์œ„ํ—˜์„ ์ฆ๊ฐ€์‹œํ‚ค๊ธฐ ๋•Œ๋ฌธ์— ๋‹น๋‡จ๋ณ‘ ๋ฐœ์ƒ์˜ ์œ„ํ—˜์ด

    ๋†’์€ ํ™˜์ž์—๊ฒŒ๋Š” ์ฃผ์˜ํ•ด์•ผ ํ•œ๋‹ค100). ์•ˆ์ง€์˜คํ…์‹  ์ฐจ๋‹จ์ œ์™€ ์•ˆ์ง€์˜คํ…์‹ 

    ์ „ํ™˜ํšจ์†Œ ์–ต์ œ์ œ ๋ณ‘์šฉ ์น˜๋ฃŒ์™€ ๊ฐ™์ด ๋‘ ๊ฐ€์ง€ ๋น„์Šทํ•œ ๊ธฐ์ „์˜ ์•ฝ์˜ ๋ฐฐํ•ฉ์€

  • 15

    ๋‹จ๋ฐฑ๋‡จ ๊ฐ์†Œ์— ์•ฝ๊ฐ„ ๋” ํšจ๊ณผ์ ์ผ ์ˆ˜ ์žˆ์œผ๋‚˜ ๋ง๊ธฐ ์ฝฉํŒฅ๋ถ€์ „, ๋‡Œ์กธ์ค‘ ๋“ฑ์˜

    ์‹ฌํ˜ˆ๊ด€ ์งˆํ™˜ ๋ฐœ์ƒ์ด ์˜คํžˆ๋ ค ๋” ์ฆ๊ฐ€ํ•˜์—ฌ ํ”ผํ•˜์—ฌ์•ผ ํ•œ๋‹ค101).

    ์ด์ฒ˜๋Ÿผ ํ˜ˆ์••์ƒ์Šน์— ๋Œ€ํ•œ ์น˜๋ฃŒ๋ฒ•์œผ๋กœ๋Š” ํ˜ˆ์••๊ฐ•ํ•˜์ œ๋ฅผ ์‚ฌ์šฉ ํ•˜๋Š”

    ์•ฝ๋ฌผ์š”๋ฒ•๊ณผ ์šด๋™, ์‹์ด์š”๋ฒ•, ์ด์™„ ์š”๋ฒ• ๋“ฑ์˜ ๋น„์•ฝ๋ฌผ์š”๋ฒ•์ด ์žˆ๋‹ค. ์ค‘๋“ฑ๋„ ๋ฐ

    ์ค‘์ฆ ๊ณ ํ˜ˆ์••์—์„œ๋Š” ์•ฝ๋ฌผ์— ์˜ํ•œ ํ˜ˆ์••๊ฐ•ํ•˜๊ฐ€ ํ•„์š”ํ•˜๋ฉฐ ๊ฒฝ๋„์˜ ๊ณ ํ˜ˆ์••์—์„œ๋„

    ์ ์ฐจ์ ์œผ๋กœ ์•ฝ๋ฌผ์š”๋ฒ•์ด ๊ถŒ์žฅ๋˜๊ณ  ์žˆ๋Š” ์ถ”์„ธ์ด๋‚˜, 50์„ธ ์ด์ƒ์˜ ํ™˜์ž์—์„œ๋Š”

    ์ด์™„๊ธฐ ํ˜ˆ์••์ด 90-94mmHg ์ธ ๊ฒฝ์šฐ ์•ฝ๋ฌผ์š”๋ฒ•์„ ์‹œํ–‰ํ•˜๊ธฐ ์ „์— ์ผ๋‹จ 6๊ฐœ์›”

    ์ •๋„ ๋น„์•ฝ๋ฌผ์š”๋ฒ•์„ ์‹œํ–‰ํ•ด ๋ณด๋Š” ๊ฒƒ์ด ๊ถŒ์žฅ๋˜๊ณ  ์žˆ๋‹ค. ๋น„์•ฝ๋ฌผ์š”๋ฒ•์€ ๊ทธ ์ž์ฒด๊ฐ€

    ํ˜ˆ์••์„ ๊ฐ์†Œ์‹œํ‚ฌ ๋ฟ ์•„๋‹ˆ๋ผ ์•ฝ๋ฌผ์น˜๋ฃŒ์™€ ๋ณ‘์šฉ ์‹œ์—๋Š” ์•ฝ๋ฌผ์˜ ํ˜ˆ์•• ๊ฐ•ํ•˜ ํšจ๊ณผ๋ฅผ

    ์ฆ๊ฐ€์‹œ์ผœ ํ•„์š”ํ•œ ์•ฝ๋ฌผ์˜ ์ข…๋ฅ˜ ๋ฐ ์šฉ๋Ÿ‰์„ ๊ฐ์†Œ์‹œํ‚ฌ ์ˆ˜ ์žˆ๊ธฐ ๋•Œ๋ฌธ์— ์ผ๋‹จ

    ๊ณ ํ˜ˆ์••์œผ๋กœ ์ง„๋‹จ๋œ ํ™˜์ž์—์„œ ๋น„์•ฝ๋ฌผ์š”๋ฒ•์„ ์‹œํ–‰ํ•˜๋Š” ๊ฒƒ์ด ๋ฐ”๋žŒ์งํ•˜๋‹ค1,102).

    ํŠนํžˆ ํ•œ์˜ํ•™์—์„œ ๊ฒฝ๋ฝ์€ ๊ธฐํ˜ˆ์ˆœํ™˜(ๆฐฃ่ก€ๅพช็’ฐ)์˜ ํ†ต๋กœ์ด๋ฉฐ ์•ˆ์œผ๋กœ๋Š”

    ์˜ค์žฅ์œก๋ถ€(ไบ”่‡Ÿ๏ง‘่…‘), ๋ฐ–์œผ๋กœ๋Š” ์‚ฌ์ง€๋ฐฑํ•ด(ๅ››่‚ข็™พ้ชธ)๋ฅผ ๊ณจ๊ณ ๋ฃจ ๊ธฐํ˜ˆ(ๆฐฃ่ก€)๋กœ์จ

    ์œ ์–‘๊ด€๊ฐœ(ๆฟก้คŠ็Œๆผ‘)ํ•˜์—ฌ ๋‚ด์™ธ(ๅ…งๅค–)๋ฅผ ์†Œํ†ต(็–้€š)ํ•˜๊ณ , ํ‘œ๋ฆฌ (่กจ่ฃ)์˜ ์ž‘์šฉ์—

    ๊ด€๊ณ„ํ•˜์—ฌ ๊ธฐ์ฒด(ๆฉŸ้ซ”)๋กœ ํ•˜์—ฌ๊ธˆ ์œ ๊ธฐ์  ์—ฐ๊ด€์˜ ์ด์ฒดํ™œ๋™ (็ธฝ้ซ”ๆดปๅ‹•)์„ ํ•˜๋„๋ก

    ์ง„ํ–‰์‹œํ‚ค๋Š” ๊ณ„ํ†ต์ด๋‹ค. ๊ทธ๋Ÿฌ๋ฏ€๋กœ ๊ฒฝ๋ฝ์€ ์šด์ˆ˜์ž‘์šฉ (้‹่ผธไฝœ็”จ),

    ๋ฐ˜์‘์ž‘์šฉ(ๅๆ‡‰ไฝœ็”จ), ์ „๋„์ž‘์šฉ(ๅ‚ณๅฐŽไฝœ็”จ)์„ ํ•˜์—ฌ ์ธ์ฒด์˜ ์ƒ๋ฆฌ์ ์ธ ๋ฉด,

    ๋ณ‘๋ฆฌ์ ์ธ ๋ฉด, ์ง„๋‹จ์ ์ธ ๋ฉด ๊ทธ๋ฆฌ๊ณ  ์น˜๋ฃŒ์ ์ธ ๋ฉด์—์„œ ๊ธฐ๋Šฅ์„ ํ•˜๊ณ  ์žˆ๋‹ค36).

    ํ•œ๋ฐฉ์—์„œ ๊ณ ํ˜ˆ์••์ด๋ผ๋Š” ๋ณ‘๋ช…์ด ๊ธฐ๋ก๋œ ๊ณ ์„œ์˜ ๋‚ด์šฉ์€ ์—†๋‹ค. ํ•˜์ง€๋งŒ ๋‘ํ†ต,

    ๋ถˆ๋ฉด, ์‹ ๊ฒฝ๊ณผ๋ฏผ, ๋ณ€๋น„, ์ฒœ์‹, ํ•˜์ง€๋ฌด๋ ฅ, ์‹œ๋ ฅ์žฅ์• , ๊ฑด๋ง, ํ”ผ๋กœ, ํ˜„ํ›ˆ, ํ•ญ๊ฐ•, ์ด๋ช…,

  • 16

    ์‹ฌ๊ณ„, ํ‰๋ฏผ ๋“ฑ์˜ ํŠน์ง•์ ์ธ ์ฆ์ƒ์œผ๋กœ ํ•œ์˜ํ•™์  ๋ณ€์ฆ์€ ๊ฐ„ํ’๋‚ด๋™ํ˜•(่‚้ขจๅ…งๅ‹•ๅฝข),

    ๊ฐ„์–‘์ƒํ•ญํ˜•(่‚้™ฝไธŠไบขๅฝข), ๋‹ด์Šต์–ดํ˜ˆํ˜•(็—ฐๆฟ•็˜€่ก€ๅฝข), ๊ธฐํ˜ˆํ—ˆ์•ฝํ˜•(ๆฐฃ่ก€่™›ๅผฑๅฝข),

    ๊ฐ„์–‘์Œํ—ˆํ˜•(่‚้™ฝ้™ฐ่™›ๅฝข) 103)๋“ฑ์ด ์žˆ์œผ๋ฉฐ ์ค‘์˜ํ•™์—์„œ๋„ ๊ณ ๋Œ€๋ฌธํ—Œ ์ค‘ ์ค‘ํ’์ฆ

    (ไธญ้ขจ็—‡), ํ˜„ํ›ˆ์ฆ(็œฉๆšˆ็—‡), ๊ฐ„ํ’์ฆ(่‚้ขจ็—‡), ๊ฐ„์–‘์ฆ(่‚้™ฝ็—‡), ํ•ญ๊ฐ•์ฆ(้ …ๅผบ็—‡)์—

    ๋ถ€๋ถ„์ ์œผ๋กœ ํ•ด๋‹นํ•œ๋‹ค๊ณ  ๋ณด๊ณ  ์žˆ๋‹ค15). ์น˜๋ฃŒ์š”๋ฒ•์œผ๋กœ๋Š” ์ž์นจ์š”๋ฒ•, ์•ฝ์นจ์š”๋ฒ•,

    ์•ฝ๋ฌผ์š”๋ฒ•, ์ด์นจ์š”๋ฒ•๋“ฑ์„ ๋“ค ์ˆ˜ ์žˆ๋‹ค. ์ž์นจ์š”๋ฒ•(ๅˆบ้ผ็™‚ๆณ•)์œผ๋กœ๋Š” ๊ณ ํ˜ˆ์••

    ํ™˜์ž์—๊ฒŒ ์ž์นจํ•˜์—ฌ ํ˜ˆ์••๊ฐ•ํ™”์˜ ์œ ์˜์„ฑ์ด ์žˆ์—ˆ๊ณ  ํ˜ˆ์••๊ฐ•ํ•˜ ํšจ๊ณผ๋„ ์ตœ์†Œ

    2์‹œ๊ฐ„๊นŒ์ง€ ์ง€์†๋˜์—ˆ์œผ๋ฉฐ 104), ๋‡Œ์กธ์ค‘ ํ™˜์ž์—๊ฒŒ ์‚ฌ์•”์นจ์˜ ํ˜ˆ์••๊ฐ•ํ•˜์— ๋Œ€ํ•œ

    ์—ฐ๊ตฌ์—์„œ ๋ฐฉ๊ด‘์ •๊ฒฉ(่†€่ƒฑๆญฃๆ ผ)์„ ์‹œํ–‰ํ•ด์„œ ์œ ์˜ํ•œ ํšจ๊ณผ๊ฐ€ ์žˆ์—ˆ๋‹ค๋Š” ๋ณด๊ณ ๋„

    ์žˆ์—ˆ๋‹ค105). Guo ๋“ฑ์€ ์นจ์ž๊ทน์‹œ 87๋ช…์˜ ํ™˜์ž์—์„œ ์ˆ˜์ถ•๊ธฐํ˜ˆ์••์ด ์œ ์˜์ ์œผ๋กœ

    ๊ฐ์†Œํ•˜์˜€์ง€๋งŒ, ์ •์ƒ์ธ์—๊ฒŒ๋Š” ์ˆ˜์ถ•๊ธฐ, ์ด์™„๊ธฐ ํ˜ˆ์••์— ์˜ํ–ฅ์„ ๋ฏธ์น˜์ง€ ์•Š์Œ์„

    ๋ณด๊ณ ํ•˜์˜€๋‹ค106). Williams ๋“ฑ์€ ํƒœ์ถฉ, ์กฑ์‚ผ๋ฆฌ, ๊ณก์ง€ ์ž๊ทน์‹œ ์ด์™„๊ธฐ ํ˜ˆ์••์„

    ๋‚ฎ์ถค์„ ๋ณด๊ณ ํ•˜์˜€๋‹ค107).

    ์•ฝ์นจ์š”๋ฒ•(่—ฅ้ผ็™‚ๆณ•)์œผ๋กœ๋Š” ์ง€ํ™ฉ(ๅœฐ้ปƒ), ํ† ์‚ฌ์ž(ๅ…Ž็ตฒๅญ), ๋‹จ์‚ผ(ไธน่”˜)์„

    ์ด์šฉํ•œ ์•ฝ์นจ(่—ฅ้ผ)์ด๋‚˜ ์ง€๋ฐฑ์ง€ํ™ฉํƒ•(ๅœฐ็™ฝๅœฐ้ปƒๆนฏ), ์œก๋ฏธ์ง€ํ™ฉํƒ•(ๅ…ญๅ‘ณๅœฐ้ปƒๆนฏ)์„

    ์ด์šฉํ•œ ์•ฝ์นจ์ด ๊ณ ํ˜ˆ์•• ๋ฐฑ์„œ(็™ฝ้ผ )์˜ ํ˜ˆ์••์—์„œ ์œ ์˜์„ฑ ์žˆ๊ฒŒ ํ•˜๊ฐ•๋˜์—ˆ๋‹ค๋Š”

    ๋ณด๊ณ ๊ฐ€ ์žˆ์—ˆ๋‹ค108,109). ์•ฝ๋ฌผ์š”๋ฒ•(่—ฅ็‰ฉ็™‚ๆณ•)์˜ ๊ฒฝ์šฐ ์ž์Œ(ๆป‹้™ฐ), ์‹ํ’(็†„้ขจ)์˜

    ์•ฝ๋ฌผ์„ ํˆฌ์—ฌํ•˜์—ฌ ์ž…์› ํ›„ ์ฒซ ๋ฒˆ์งธ ์ฃผ์˜ ์ˆ˜์ถ•๊ธฐ์™€ ํ™•์žฅ๊ธฐ ํ˜ˆ์••, ๋‘ ๋ฒˆ์งธ ์ฃผ์˜

    ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••์ด ๊ฐ๊ฐ ์œ ์˜ํ•œ ํ•˜๊ฐ• ํšจ๊ณผ๊ฐ€ ์žˆ์—ˆ๋‹ค๋Š” ๋ณด๊ณ ๊ฐ€ ์žˆ์—ˆ์œผ๋ฉฐ110),

    ํฌ๋ ด(่ฑจ่–Ÿ)์˜ ๋ณตํ•ฉ์ „ํƒ•(่ค‡ๅˆ็…Žๆนฏ)์„ ํˆฌ์•ฝํ•˜์—ฌ ํ™•์žฅ๊ธฐ ํ˜ˆ์••์˜ ๊ฐ•์•• ํšจ๊ณผ์—

  • 17

    ์œ ์˜์„ฑ์ด ์žˆ์—ˆ๋‹ค111). ์žฅ ๋“ฑ112)์€ ์ด์นจ์ž๊ทน(่€ณ้‡ๅˆบๆˆŸ), ํŠนํžˆ ์ด๊ฐ‘๊ฐ•(่€ณ็”ฒ่…”)์˜

    ๋ฏธ์ฃผ์‹ ๊ฒฝ ๋ถ„์ง€์˜์—ญ์—์˜ ์นจ ์ž๊ทน์ด ๋ฏธ์ฃผ์‹ ๊ฒฝ์˜ ํฅ๋ถ„์„ ์–ต์ œ์‹œํ‚ค๋Š” ํšจ๊ณผ๊ฐ€

    ์žˆ๋‹ค๊ณ  ํ•˜์˜€๊ณ  Eva ๋“ฑ113)์€ ์ด์นจ์ž๊ทน(่€ณ้‡ๅˆบๆˆŸ) ํŠนํžˆ ์ด๊ฐ‘๊ฐ•(่€ณ็”ฒ่…”)์˜

    ์ž๊ทน์ด ๋ถ€๊ต๊ฐ์‹ ๊ฒฝ ํ™œ์„ฑ๋„๋ฅผ ์˜๋ฏธ์žˆ๊ฒŒ ์ฆ๊ฐ€์‹œํ‚จ๋‹ค๊ณ  ํ–ˆ๋‹ค.

    ์ธ์ฒด์˜ ์–ด๋Š ๊ณณ์— ์งˆ๋ณ‘์ด ๋ฐœ์ƒํ•  ๊ฒฝ์šฐ ์ƒ๋ฆฌ์ , ๋ณ‘๋ฆฌ์  ์ž‘์šฉ์„ ํ†ตํ•ด ๋‹ค๋ฅธ

    ์‹ ์ฒด๋ถ€์œ„์— ๋…ํŠนํ•œ ํ˜„์ƒ์ด ๋ฐœํ˜„๋˜๊ณ , ํ•œ์˜ํ•™์—์„œ๋Š” ์ด๋ฅผ ํ™œ์šฉํ•˜์—ฌ ์งˆ๋ณ‘์˜

    ์น˜๋ฃŒ์— ํ™œ์šฉํ•˜๊ณ  ์žˆ๋Š”๋ฐ, ๊ฒฝ๋ฝ(็ถ“็ตก), ๊ฒฝํ˜ˆ(็ถ“็ฉด)์ด๋ก ์ด ๊ทธ ๋Œ€ํ‘œ์ ์ธ ๊ฒƒ์ด๋ฉฐ,

    ๊ทผ๋ž˜ ๋“ค์–ด ์—ฐ๊ตฌ๋˜๊ณ  ํ™œ์šฉ๋˜๋Š” ๋ถ„๊ตฌ์นจ๋ฒ•(ๅˆ†ๅ€้ผๆณ•)๋„ ๊ทธ ์˜ˆ๋ผ ํ•  ์ˆ˜ ์žˆ๋‹ค.

    ์ด์นจ์€ ์™ธ์ด(ๅค–่€ณ)์˜ ์ด๊ฐœ(่€ณไป‹)์— ๋ถ„ํฌ๋˜์–ด ์žˆ๋Š” ๊ฒฝํ˜ˆ์„ ์ž๊ทนํ•˜์—ฌ ์‹ ์ฒด์˜

    ๋‹ค๋ฅธ ๋ถ€์œ„์— ๋‚˜ํƒ€๋‚˜๋Š” ์ฆ์ƒ์„ ๊ฐœ์„ ํ•˜๋Š” ์น˜๋ฃŒ์š”๋ฒ•์ด๋‹ค64,114). ์ด์นจ์š”๋ฒ•

    (่€ณ้ผ็™‚ๆณ•)์˜ ์ •ํ™•ํ•œ ๊ธฐ์›์€ ํ™•์‹คํ•˜์ง€ ์•Š์ง€๋งŒ, ๊ณ ๋Œ€ ์ด์ง‘ํŠธ์—์„œ๋Š” ๋ถˆ์ž„์˜

    ๋ชฉ์ ์œผ๋กœ ์™ธ์ด(ๅค–่€ณ)๋ฅผ ๋ฐ”๋Š˜๋กœ ์ฐŒ๋ฅด๊ฑฐ๋‚˜ ์—ด๋กœ ์†Œ์ž‘ํ–ˆ๊ณ , ์ง€์ค‘ํ•ด์˜ ์„ ์›๋“ค์€

    ์‹œ๋ ฅ๊ฐ•ํ™” ๋ชฉ์ ์œผ๋กœ ๊ธˆ ๊ท€๊ฑธ์ด๋ฅผ ํ–ˆ์œผ๋ฉฐ, ํžˆํฌํฌ๋ผํ…Œ์Šค๋Š” ๋‹น์‹œ ์˜์‚ฌ๋“ค์ด

    ์ •๋ ฅ์„ ์ฆ๊ฐ•์‹œํ‚ค๊ณ ์ž ๊ท€ ๋’ค์— ์žˆ๋Š” ์ •๋งฅ์— ์กฐ๊ทธ๋งŒ ๊ตฌ๋ฉ์„ ๋‚ด์—ˆ๋‹ค๊ณ  ์–ธ๊ธ‰ํ–ˆ๋˜

    ์ ์œผ๋กœ ๋ฏธ๋ฃจ์–ด ๋ณผ ๋•Œ ๊ทธ ๊ธฐ์›์€ ๊ณ ๋Œ€๋กœ ๊ฑฐ์Šฌ๋Ÿฌ ์˜ฌ๋ผ๊ฐ„๋‹ค๊ณ  ์ถ”์ •๋œ๋‹ค. ๋˜ํ•œ

    1637๋…„ ํฌ๋ฅดํˆฌ๊ฐˆ์˜ ์˜์‚ฌ Zacatus Lustanus๊ฐ€ ์‚ฌํ˜ˆ (bloodletting) ๋กœ

    ์น˜๋ฃŒํ•˜์ง€ ๋ชปํ•œ ์ขŒ๊ณจ์‹ ๊ฒฝํ†ต์„ ๊ท€๋ฅผ ์†Œ์ž‘ํ•˜์—ฌ ์น˜๋ฃŒ ํ•˜์˜€๋‹ค๊ณ  ๊ธฐ์ˆ ํ•œ ๊ฒƒ์„

    ๋น„๋กฏํ•˜์—ฌ, ๊ณ ๋Œ€๋ถ€ํ„ฐ ํ˜„๋Œ€ ๊นŒ์ง€ ๋งŽ์€ ์˜์‚ฌ๋“ค์ด ์ฃผ๋กœ ํ†ต์ฆ ์งˆํ™˜๊ณผ ๊ด€๋ จ ๋œ ์ด๊ฐœ

    ์ž๊ทน์˜ ํšจ๊ณผ์— ๋Œ€ํ•ด ๊ธฐ์ˆ ํ•˜์˜€๋‹ค115).

    ํ˜„์žฌ์™€ ๊ฐ™์€ ์ด์นจ์š”๋ฒ•(่€ณ้ผ็™‚ๆณ•)์€ 1950๋…„์— ํ”„๋ž‘์Šค์˜ ์˜์‚ฌ Paul

  • 18

    Nogier๊ฐ€ ๊ท€์— ๋œธ์„ ๋– ์„œ ์ขŒ๊ณจ์‹ ๊ฒฝํ†ต์ด ์น˜๋ฃŒ๋˜์—ˆ๋‹ค๋Š” ์งˆํ™˜๋“ค์„ ์ ‘ํ•˜๊ณ 

    ์—ฐ๊ตฌ๋ฅผ ์‹œ์ž‘ํ•˜์—ฌ 1956๋…„ Marseile์—์„œ ๊ฐœ์ตœ๋œ ๊ตญ์ œ์นจ๊ตฌ์˜ํ•™ํšŒ์— ๋ณด๊ณ ํ•จ์œผ๋กœ

    ์จ ์‹œ์ž‘๋˜์—ˆ์œผ๋ฉฐ116), 1957๋…„ ๋…์ผ์˜ ์ด๋ผ๋Š” ์žก์ง€์—

    ์ด์นจ์š”๋ฒ•(่€ณ้ผ็™‚ๆณ•)์— ๊ด€ํ•œ ๋…ผ๋ฌธ์ด ๋ฐœํ‘œ๋œ ์ด๋ž˜ ๊ด€์‹ฌ์ด ์ง‘์ค‘๋˜๊ณ  ์žˆ๋‹ค.

    ์ด๊ฒƒ์€ ์ด๊ฐœ์ƒ(่€ณไป‹ไธŠ)์—์„œ ์ดํ˜ˆ(่€ณ็ฉด) ๋ฐ ๋ฐ˜์‘์ (ๅๆ‡‰้ปž)์„ ํƒ์ƒ‰ํ•˜์—ฌ

    ์ž์นจ(ๅˆบ้ผ)์œผ๋กœ ์ž๊ทน์„ ๊ฐ€ํ•˜์—ฌ ์งˆ๋ณ‘์„ ์น˜๋ฃŒํ•˜๋Š” ์ผ์ข… ์˜ ๊ฒฝ์™ธ๊ธฐํ˜ˆ(็ถ“ๅค–ๅฅ‡็ฉด)

    ์น˜๋ฃŒ๋ฐฉ๋ฒ•(ๆฒป็™‚ๆ–นๆณ•)์œผ๋กœ์„œ๏ผŒ์ ์‘์ฆ(้ฉๆ‡‰็—‡)์ด ๊ด‘๋ฒ”์œ„ํ•˜๊ณ  ์‹œ์ˆ ์กฐ์ž‘์ด

    ๊ฐ„ํŽธํ•˜๋ฉฐ ์•ฝ๋ฌผ์š”๋ฒ•์— ๋น„ํ•ด ๊ฒฝ์ œ์ ์ด๋ฉฐ, ์ฒด์นจ(้ซ”้ผ)๊ณผ ๋‹ฌ๋ฆฌ ์žฅ์‹œ๊ฐ„

    ์œ ์นจ(็•™้ผ)ํ•  ์ˆ˜ ์žˆ๊ณ  ๋ถ€์ž‘์šฉ์ด ์ ์€ ์žฅ์ ์ด ์žˆ๋‹ค116-124).

    ๊ฒฝ๋ฝํ•™์ (็ถ“็ตกๅญธ็š„)์œผ๋กœ ๊ท€์—๋Š” ๋Œ€์žฅ๊ฒฝ(ๅคง่‡Ÿ็ถ“), ์†Œ์žฅ๊ฒฝ(ๅฐ้™ฝ็ถ“),

    ์‚ผ์ดˆ๊ฒฝ(ไธ‰็„ฆ็ถ“), ๋‹ด๊ฒฝ(่†ฝ็ถ“)์ด ํ†ต๊ณผํ•˜๊ณ  ์žˆ์œผ๋ฉฐ

  • 19

    ์ดํ˜ˆ(่€ณ็ฉด)์„ ํ•ด๋ถ€ํ•™์ (่งฃๅ‰–ๅญธ็š„), ์ƒ์‘๋ถ€์œ„(็›ธๆ‡‰้ƒจไฝ), ์‹ ๊ฒฝ๊ณ„ํ†ต(็ฅž็ถ“็ณป็ตฑ),

    ๋‚ด๋ถ„๋น„๊ณ„ํ†ต(ๅ…งๅˆ†ๆณŒไฟ‚็ตฑ), ์žฅ์ƒํ•™(่‡“่ฑกๅญธ), ๊ณ ํ˜ˆ์••์˜ ํŠนํšจํ˜ˆ(็‰นๆ•ˆ็ฉด), ์ด๋ฐฐํ˜ˆ

    (่€ณ่ƒŒ็ฉด)์˜ 6๊ฐ€์ง€ ๊ธฐ์ค€์œผ๋กœ ๋ถ„๋ฅ˜ํ•˜์˜€๊ณ , ๋ณ€ ๋“ฑ126)์€ 23๋ช…์˜ ์™ธ๋ž˜

    ๊ณ ํ˜ˆ์••ํ™˜์ž์— ๋Œ€ํ•ด ๊ณ ํ˜ˆ์••์ (้ซ˜่ก€ๅฃ“้ปž), ์‹ ๋ฌธ(็ฅž้–€), ๊ฐ•์••์ (้™ๅฃ“้ปž), ๊ฐ•์••๊ตฌ

    (้™ๅฃ“ๆบ)์— ์ด์นจ(่€ณ้ผ) ์‹œ์ˆ ํ•˜์—ฌ ๊ฐ•์••์˜ ํšจ๊ณผ๋ฅผ ๋ณด๊ณ ํ•˜์˜€์œผ๋ฉฐ, ์•ˆ ๋“ฑ127)์€

    ๊ฒฝ์ฆ๊ณ ํ˜ˆ์••(่ผ•็—‡้ซ˜่ก€ๅฃ“) ์ž…์›ํ™˜์ž 22๋ช… ์— ๋Œ€ํ•ด ๊ณ ํ˜ˆ์••์ (้ซ˜่ก€ๅฃ“้ปž),

    ๋‚ด๋ถ„๋น„(ๅ…งๅˆ†ๆณŒ), ์‹ ๋ฌธ(็ฅž้–€), ๊ฐ•์••์ (้™ๅฃ“้ปž), ์‹ฌ(ๅฟƒ)์— ์ด์นจ(่€ณ้ผ)์‹œ์ˆ ํ•œ ํ›„

    1์ผ ๋™์•ˆ ๊ฐ•์•• ํšจ๊ณผ๊ฐ€ ์žˆ์Œ์„ ๋ณด๊ณ ํ•˜์˜€๋‹ค. ๋‡Œ์กธ์ค‘์œผ๋กœ ์ž…์›ํ•œ ํ™˜์ž์—๊ฒŒ

    ๊ณ ํ˜ˆ์••์ (้ซ˜่ก€ๅฃ“้ปž), ๋‚ด๋ถ„๋น„(ๅ…งๅˆ†ๆณŒ), ์‹ ๋ฌธ(็ฅž้–€), ๊ฐ•์••์ (้™ๅฃ“้ปž), ์‹ฌ(ๅฟƒ)์—

    ์ด์นจ(่€ณ้ผ)์„ 24์‹œ๊ฐ„ ๋™์•ˆ ๋งค์นจํ•˜๊ณ  ์ œ๊ฑฐํ•œ ํ›„, ๋‹ค์‹œ 24์‹œ๊ฐ„ ๋™์•ˆ

    ํ™œ๋™ํ˜ˆ์••์ธก์ •๊ธฐ (AB PM)๋กœ ํ˜ˆ์••์„ ์ธก์ •ํ•œ ๊ฒฐ๊ณผ ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••์ด 7.04 mmHg,

    ์ด์™„๊ธฐ ํ˜ˆ์••์ด 2.68 mmHg์˜ ์ฐจ์ด๋กœ ์œ ์˜์„ฑ ์žˆ๊ฒŒ ํ•˜๊ฐ•ํ–ˆ๋‹ค๋Š” ๋ณด๊ณ ๋„

    ์žˆ์—ˆ๊ณ 127), ๊ณ ํ˜ˆ์••์ (้ซ˜่ก€ๅฃ“้ปž), ์‹ ๋ฌธ(็ฅž้–€), ๊ฐ•์••์ (้™ๅฃ“้ปž), ๊ฐ•์••๊ตฌ(้™ๅฃ“ๅ€)์—

    2-4์ผ๊ฐ„ ๋งค์นจ(ๅŸ‹้ผ)ํ•˜์—ฌ ํ˜ˆ์•• ํ•˜๊ฐ•์— ํšจ๊ณผ๊ฐ€ ์žˆ์—ˆ๋‹ค๋Š” ๋˜ ๋‹ค๋ฅธ ๋ณด๊ณ ๋„

    ์žˆ์—ˆ๋‹ค128).

    ์ด ๋“ฑ129)์€ 65๋ช…์˜ ๊ณ ํ˜ˆ์•• ํ™˜์ž์—๊ฒŒ ์ด์นจ ์‹œ์ˆ  ํ›„ ํ˜ˆ์••์ด ์–ต์ œ๋˜๋Š”

    ํšจ๊ณผ๊ฐ€ ์žˆ์—ˆ๋‹ค๊ณ  ๋ณด๊ณ  ํ•˜์˜€๊ณ , ์œ  ๋“ฑ130)๋Š” 30๋ช…์˜ ๊ณ ํ˜ˆ์•• ํ™˜์ž๋ฅผ ์Œํ—ˆ์–‘ํ•ญ,

    ๊ฐ„์–‘์ƒํ•ญ, ๊ธฐ์Œ์–‘ํ—ˆ ๋“ฑ ํ˜ผํ•ฉํ˜•์˜ ํ˜•ํƒœ๋กœ ๋ณ€์ฆํ•˜์—ฌ ์‹ ๋ฌธํ˜ˆ, ๊ณ ํ˜ˆ์••์  ๋“ฑ์˜

    ํ˜ˆ์— ๊ฐ€๊ฐ์„ ํ•˜์—ฌ ์ž์นจ์„ ํ•œ ๊ฒฐ๊ณผ ๋งŽ์€ ํšจ๊ณผ๋ฅผ ์ž…์ฆํ•˜์˜€๊ณ , ๋ณ€ ๋“ฑ128)์€

    23๋ช…์˜ ์™ธ๋ž˜ ๊ณ ํ˜ˆ์•• ํ™˜์ž์— ๋Œ€ํ•ด ๊ณ ํ˜ˆ์••์ , ๊ฐ•์••์ , ์‹ฌ๋ฌธ ๋“ฑ์— ์‹œ์ˆ ํ•˜์—ฌ

  • 20

    ํšจ๊ณผ๊ฐ€ ์žˆ์—ˆ๋‹ค๊ณ  ๋ณด๊ณ ํ•˜์˜€๋‹ค. ์•ˆ ๋“ฑ131)๋„ ์ด์นจ ์‹œ์ˆ  ํ›„ 1์ผ ๋™์•ˆ ๊ฐ•์••ํšจ๊ณผ๊ฐ€

    ์žˆ์Œ์„ ๋ณด๊ณ ํ•˜์˜€๋‹ค. ํ˜ˆ์••์˜ ๊ฒฝ์ค‘์— ๋”ฐ๋ฅธ ์ž„์ƒ ์—ฐ๊ตฌ๋กœ๋Š” ์‹  ๋“ฑ129)์€ ๋Œ€์ถ”ํ˜ˆ

    ์‚ฌํ˜ˆ์— ๋Œ€ํ•œ ๊ฐ•์•• ํšจ๊ณผ๋ฅผ ๋ณด๊ณ ํ•˜์˜€๋‹ค. ์ด132)์˜ ์—ฐ๊ตฌ์—์„œ๋„ ์ดํ˜ˆ์— 3์ผ๊ฐ„

    ์œ ์นจ(็•™้‡)์„ ํ•˜๋Š” ๋™์•ˆ์— ํ˜ˆ์••์€ ๊ฐ•ํ•˜ ํšจ๊ณผ๊ฐ€ ์žˆ์—ˆ๋‹ค๊ณ  ๋ณด๊ณ ํ•˜์˜€๋‹ค. ้ปƒ

    ๋“ฑ133)์€ ์ดํ˜ˆ์ฒจ์••์™•๋ถˆ์œ ํ–‰์ž์˜ ๋ฐฉ๋ฒ•์œผ๋กœ 30๋ช…์˜ ๊ณ ํ˜ˆ์•• ํ™˜์ž์—๊ฒŒ ์‹ฌํ˜ˆ์—

    ์ž๊ทน์„ ํ•˜์—ฌ ์งง์€ ๊ธฐ๊ฐ„์—๋Š” 100%์˜ ํšจ๊ณผ์œจ๊ณผ ์žฅ๊ธฐ๊ฐ„์—๋Š” 63.3%์˜ ํšจ๊ณผ๋ฅผ

    ๋ณด๊ณ  ํ•˜์˜€๊ณ , ๊ทธ์˜ ๋˜ ๋‹ค๋ฅธ ์—ฐ๊ตฌ์—์„œ๋Š” ์ฒจ์••ํ›„ ์—ฐ์†์ ์œผ๋กœ 3โˆผ5๋ถ„์ •๋„ ๋ˆŒ๋Ÿฌ

    ์ž๊ทน์„ ์ฃผ๊ณ  83๋ช…์˜ ํ™˜์ž์—๊ฒŒ ์ ์šฉ์„ ํ•˜์—ฌ ๋ช…ํ™•ํ•œ ํšจ๊ณผ์œจ์€ 58๋ก€, ์œ ํšจ

    ํšจ๊ณผ๋Š” 23๋ก€, ๋ฌดํšจ 2๋ก€ ์ด 97.6%์˜ ๋†’์€ ํšจ๊ณผ๋ฅผ ๋ณด๊ณ ํ•˜์˜€๋‹ค. ๅ”134)์€

    ๊ณ ํ˜ˆ์••ํ™˜์ž 45๋ก€์—๊ฒŒ ์ฒจ์••ํ›„ ์ˆ˜์ถ•์•• ํ•˜๊ฐ•์ด ํ‰๊ท  3.9 mmHg, ํ™•์žฅ์•• ํ•˜๊ฐ•์ด

    ํ‰๊ท  2.1mmHg์ด์—ˆ๋‹ค. ์œ 135)๋„ ๊ฐ™์€ ๋ฐฉ๋ฒ•์œผ๋กœ 33๋ก€์˜ ํ™˜์ž์—๊ฒŒ ์ ์šฉํ•˜์—ฌ

    ์œ ํšจ์œจ์ด 97%์˜ ํšจ๊ณผ๋ฅผ ๋ณด๊ณ ํ•˜์˜€๊ณ , ํ˜ธ๋‚จ์˜ํ•™์›์ œ2๋ถ€์†์˜๊ณผ

    (ๆน–ๅ—้†ซๅญธ้™ข็ฌฌ2้™„ๅฑฌ้†ซ็ง‘)136)์€ 52๋ก€์˜ ํ˜ˆ์•• ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ๋†’์€ ํšจ๊ณผ๋ฅผ

    ๋ณด๊ณ  ํ•˜์˜€๋‹ค. ๋ช‡๋ช‡์˜ ๋ณด๊ณ ์„œ์— ์˜ํ•˜๋ฉด, ๊ท€์ง€์•• ๋ฐ ์นจ์ž๊ทน์€ ๊ณ ํ˜ˆ์•• ํ™˜์ž์—์„œ

    ํšจ๊ณผ์ ์ด์—ˆ์œผ๋ฉฐ, ํ˜ˆ์ค‘ ์ง€์งˆ๋†๋„๋„ ๊ฐ์†Œ๋˜์—ˆ๋‹ค๊ณ  ํ•˜์˜€๋‹ค137-139).

    ๊ฐ•์••์ (้™ๅฃ“้ปž)์€ ๊ณ ํ˜ˆ์••์„ ์น˜๋ฃŒํ•˜๋Š” ํŠนํšจํ˜ˆ์ด๋ฉฐ140,141), ์‹ ๋ฌธ(็ฅž้–€)์€

    ๋Œ€๋‡Œํ”ผ์งˆ์˜ ํฅ๋ถ„์„ ์–ต์ œํ•˜์—ฌ ๊ฐ•์••์˜ ํšจ๊ณผ์™€ ์•ˆ์‹ (ๅฎ‰็ฅž)์˜ ํšจ๊ณผ๊ฐ€ ์žˆ๊ณ 140-142)

    ์‹ฌ(ๅฟƒ)์€ ํ˜ˆ์••์„ ์กฐ์ ˆํ•˜๊ณ  ๊ฐ•์‹ฌ(ๅผบๅฟƒ)๏ผŒ์•ˆ์‹ (ๅฎ‰็ฅž)์˜ ํšจ๊ณผ๊ฐ€ ์žˆ๋‹ค140-142).

    ๊ต๊ฐ(ไบคๆ„Ÿ)์€ ์ž์œจ์‹ ๊ฒฝ์„ ์กฐ์ ˆํ•˜๊ณ  ํ˜ˆ๊ด€์˜ ์ˆ˜์ถ•๊ณผ ์ด์™„์„ ์กฐ์ ˆํ•˜๋Š” ๊ธฐ๋Šฅ์œผ๋กœ

    ๊ฐ•์••ํšจ๊ณผ๊ฐ€ ์žˆ๊ณ 140,142), ์ŠคํŠธ๋ ˆ์Šค์— ์˜ํ•œ ๊ณ ํ˜ˆ์•• ๋ชจ๋ธ์—์„œ Li ๋“ฑ์€ vPAG์˜

  • 21

    Nitric oxide์˜ ๋งค๊ฐœ๋กœ ์นจ์ด ํ˜ˆ์••์–ต์ œ๋ฅผ ๋ณด์ธ๋‹ค๊ณ  ํ•˜์˜€๊ณ 106), Jin ๋“ฑ์€ ์นจ์ด

    ํ˜ˆ์•ก์ ๋„ ๋ณ€ํ™” ๋ฐ ํ˜ˆ์••์— ์ง์ ‘์ ์ธ ์˜ํ–ฅ์„ ๋ฏธ์นœ๋‹ค๊ณ  ํ•˜์˜€๋‹ค143). Yu๋Š”

    ๋ณธํƒœ์„ฑ๊ณ ํ˜ˆ์•• ํ™˜์ž 291 case์—์„œ ๊ท€์ž๊ทน๊ตฐ์€ ์•ฝ์ฒ˜์น˜๊ตฐ ๋ณด๋‹ค ํšจ๊ณผ์ ์ด์—ˆ์œผ๋ฉฐ,

    ํ˜ˆ์ค‘์ง€์งˆ๋†๋„์˜ ์œ ์˜์ ์ธ ๊ฐ์†Œ์™€ ์‹ฌ๋ฐฉ์„ฑ ๋ถ€์ •๋งฅ ์กฐ์ ˆํšจ๊ณผ๋ฅผ ๋‚˜ํƒ€๋ƒˆ์œผ๋ฉฐ, ๊ท€

    ์ง€์••์€ ๋ณธํƒœ์„ฑ๊ณ ํ˜ˆ์••์— ํšจ๊ณผ์ ์ž„์„ ์ฆ๋ช…ํ•˜์˜€๋‹ค137). Ganoniuk ๋“ฑ๋„

    ๋ณธํƒœ์„ฑ๊ณ ํ˜ˆ์•• ํ™˜์ž์—์„œ ์ด์นจ๊ณผ ๊ท€ ์ „์นจ์ž๊ทน์„ ํ•˜์˜€์„ ๋•Œ, ๋‘ ๊ตฐ ๋ชจ๋‘ ๋‡Œ

    ํ˜ˆ์•ก์ˆœํ™˜ ๊ฐœ์„  ํšจ๊ณผ๋ฅผ ๋ณด์˜€์œผ๋ฉฐ, ๊ท€ ์ „์นจ์ž๊ทน์ด ๋”์šฑ ์šฐ์ˆ˜ํ•จ์„

    ๋ณด๊ณ ํ•˜์˜€๋‹ค144,145).

    ๋น„์ฆ(็—บ็—‡)์€ ๋ณ‘์‚ฌ์˜ ํŠน์„ฑ์— ๋”ฐ๋ผ์„œ ํ’(้ขจ), ํ•œ(ๅฏ’), ์Šต(ๆฟ•), ์—ด๋น„(็†ฑ็—บ)

    ๋“ฑ์œผ๋กœ ๋ถ„๋ฅ˜๋˜๊ณ , ๋ฐœ๋ณ‘๋ถ€์œ„์— ๋”ฐ๋ผ ์˜ค๋น„(ไบ”็—บ), ์˜ค์žฅ๋น„(ไบ”่‡Ÿ็—บ), ์žฅ๋น„(่…ธ),

    ํฌ๋น„(่ƒž็—บ) ๋“ฑ์œผ๋กœ ๋‚˜๋‰˜๋ฉฐ, ๊ทธ ๋ฐœ๋ณ‘์–‘์ƒ ๋ฐ ์ฆ์ƒ์— ๋”ฐ๋ผ์„œ ์ค‘๋น„(้‡็—บ),

    ์ฃผ๋น„(ๅ‘จ็—บ), ํŽธ๋น„(ๅ็—บ) ๋“ฑ์œผ๋กœ ๋ถ„๋ฅ˜ ๋œ๋‹ค146).

    ๋น„์ฆ(็—บ็—‡)์˜ ์ฆ์ƒ๋“ค์„ ๋ถ€์œ„๋ณ„๋กœ ๋‚˜๋ˆ„์–ด ๋ณด๋ฉด ํ”ผ(็šฎ), ๊ธฐ์œก(่‚Œ่‚‰) ๋ถ€์œ„์—๋Š”

    ๋งˆ๋ชฉ(็—ฒๆœจ), ๋ถˆ์ธ(๏ฅงไป)๋“ฑ์˜ ๊ฐ๊ฐ์žฅ์• ๊ฐ€ ์ฃผ๋กœ ๋‚˜ํƒ€๋‚˜๋ฉฐ ๋น„๊ต์  ์—ญ์น˜(ๆ˜“ๆฒป)์ด๊ณ 

    ๊ทผ๊ณจ(็ญ‹้ชจ)๋ถ€์œ„์—์„œ๋Š” ๊ทผ๋ จ(็ญ‹่ฎŠ), ๊ณจ์ค‘(้ชจ้‡), ๊ด€์ ˆ๋™ํ†ต(้—œ็ฏ€็–ผ็—›) ๋“ฑ์˜

    ์šด๋™์žฅ์• ๊ฐ€ ์ฃผ๋กœ ๋‚˜ํƒ€๋‚˜๋ฉฐ ๋‚œ์น˜(้›ฃๆฒป)์— ์†ํ•˜๊ณ , ์žฅ๋ถ€(่‡Ÿ่…‘)์—์„œ๋Š” ๊ฐ๊ธฐ

    ํ•ด๋‹นํ•˜๋Š” ์žฅ๋ถ€(่‡Ÿ่…‘)์˜ ๋ณ‘์ฆ๋“ค์ด ๋‚˜ํƒ€๋‚˜๋Š”๋ฐ, ์ด๋“ค์€ ๋ถˆ์น˜(๏ฅงๆฒป)์— ์†ํ•œ๋‹ค.

    ๋ผ๊ณ  ํ•˜์˜€๋‹ค147). ์ด๋Ÿฌํ•œ ๋น„์ฆ(็—บ็—‡)์€ ์„œ์–‘์˜ํ•™์—์„œ ๋งํ•˜๋Š” ๊ฐ์ข…

    ๊ด€์ ˆ์—ผ(้—œ็ฏ€็‚Ž)๊ณผ ๊ทผ์œก(็ญ‹่‚‰)๊ณผ ๊ณจ๊ฒฉ(้ชจๆ ผ)์— ํ†ต์ฆ์„ ๋‚˜ํƒ€๋‚ด๋Š” ์งˆํ™˜, ์˜ˆ๋ฅผ ๋“ค๋ฉด

    ๋ฅ˜๋งˆํ† ์ด๋“œ ๊ด€์ ˆ์—ผ(้—œ็ฏ€็‚Ž), ํ†ตํ’(็—›้ขจ), ํ‡ดํ–‰์„ฑ๊ด€์ ˆ์—ผ(้€€่กŒๆ€ง้—œ็ฏ€็‚Ž),

  • 22

    ํ์ƒˆ์„ฑ(้–‰ๅกžๆ€ง) ํ˜ˆ์ „ํ˜ˆ๊ด€์—ผ(่ก€ๆ “่ก€็ฎก็‚Ž), ๊ฒฝํ”ผ์ฆ(็กฌ็šฎ็—‡), ์ „์‹ ์„ฑํ™๋ฐ˜์„ฑ๋‚œ์ฐฝ

    (ๅ…จ่บซๆ€ง็ด…ๆ–‘ๆ€ง็‹ผ็˜ก)๏ผŒ๊ทผ์—ผ(็ญ‹็‚Ž) ๋“ฑ์˜ ์ฆ์ƒ๊ณผ ์œ ์‚ฌํ•œ ๊ฒƒ์œผ๋กœ ๋ณผ ์ˆ˜ ์žˆ๋‹ค148).

    ๋น„์ฆ(็—บ็—‡)์— ๋™ํ†ต(็–ผ็—›)์ด ์žˆ๋Š” ๊ฒƒ์€ ํ•œ๊ธฐ(ๅฏ’ๆฐฃ)๊ฐ€ ๋งŽ์€ ๊ฒƒ์ด๊ณ ,

    ๋ถˆํ†ต๋ถˆ์ธ(ไธ็—›ไธไป)ํ•œ ๊ฒƒ์€ ๋ณ‘์‹ฌ(็—…ๆทฑ)ํ•˜์—ฌ ์˜์œ„(็‡Ÿ่ก›)์˜ ์ˆœํ–‰(ๅพช่กŒ)์ด

    ์‚ฝ(ๆพ)ํ•ด์ง€๊ณ ๏ผŒ๋˜ํ•œ ๊ฒฝ๋ฝ์ด ์†Œํ™œ(็–Ž่ฑ)ํ•ด์ง„ ๊ฒƒ์ด๊ณ , ํ”ผ๋กœ(็šฎ่™œ)๊ฐ€

    ๋ถˆ์˜(ไธ็‡Ÿ)ํ•˜์—ฌ ๋ถˆ์ธ(ไธไป)ํ•˜๊ฒŒ ๋œ ๊ฒƒ์œผ๋กœ ๋ณผ ์ˆ˜ ์žˆ๋‹ค149).

    ํ•œ์˜ํ•™์—์„œ๋Š” ๊ฒฌ๋น„ํ†ต์„ ๋น„์ฆ(็—บ็—‡)์˜ ๋ฒ”์ฃผ์— ํฌํ•จ์‹œ์ผœ ๊ฒฌ๋น„(่‚ฉ็—บ),

    ๋ˆ„๋น„ํ’(ๆผ่‡‚้ขจ), ๊ฒฌ์ฃผ๋น„(่‚ฉๅ‘จ็—บ) ๋ผ ์ง€์นญํ•˜์˜€๋‹ค150). ๊ทธ ์›์ธ์„ ๋‚ด์ธ(ๅ…งๅ› )๊ณผ

    ์™ธ์ธ(ๅค–ๅ› )์œผ๋กœ ๋ถ„๋ฅ˜ํ•˜์—ฌ, ๋‚ด์ธ์„ฑ(ๅ…งๅ› ๆ€ง)์€ ๋‹ด์Œ(็—ฐ้ฃฎ)์— ๊ธฐ์ธํ•˜๋ฉฐ ๊ฒฝ๋ฝ์ง€๊ธฐ

    (็ถ“็ตกไน‹ๆฐฃ)๊ฐ€ ์‘์ฒด(ๅ‡ๆปฏ)๋˜๊ณ  ๊ธฐํ˜ˆ(ๆฐฃ่ก€)์ด ๋ถ€์ฐฝ(ไธๆšข)๋˜์–ด ๊ฒฝ๊ทผ(็ถ“็ญ‹)์˜ ์ž‘์šฉ

    ์ด์ƒ์„ ์ผ์œผํ‚ค๊ฑฐ๋‚˜ ํ˜น์€ ํ(่‚บ)์™€ ์‹ฌ(ๅฟƒ)์˜ ๋ณ‘์‚ฌ(็—…้‚ช)๊ฐ€ ์ฃผ(่‚˜)์— ์œ ์ฃผํ•˜๋Š”

    ๊ฒƒ์ด๋ผ ํ•˜์—ฌ ๊ฒฝ๋งฅ๊ณผ ์—ฐ๊ด€๋œ ์žฅ๋ถ€์—์„œ ์˜ค๋Š” ๊ฒƒ์œผ๋กœ ์„ค๋ช…ํ•˜์˜€๊ณ ,

    ์™ธ์ธ์„ฑ(ๅค–ๅ› ๆ€ง)์€ ํ’ํ•œ์Šต์‚ผ๊ธฐ(้ขจๅฏ’ๆฟ•ไธ‰ๆฐฃ)์˜ ์‚ฌ๊ธฐ(้‚ชๆฐฃ)๊ฐ€ ์ธ์ฒด์˜

    ๊ฒฌ๋น„๋ถ€(่‚ฉ่‡‚้ƒจ)์— ์นจ์ž…ํ•˜์—ฌ ๊ฒฝ๋ฝ์ง€๊ธฐ(็ถ“็ตกไน‹ๆฐฃ)์˜ ์ˆœํ™˜์žฅ์• ๋ฅผ ์ผ์œผํ‚ค๊ฑฐ๋‚˜ ํ˜น์€

    ํƒ€๋ฐ•(ๆ‰“ๆ’ฒ), ์—ผ์ขŒ(๏ฆคๆŒซ)๋“ฑ์— ์˜ํ•ด์„œ ๋ฐœ์ƒํ•œ๋‹ค๊ณ  ์„ค๋ช…ํ•˜์˜€๋‹ค151). ๊ฒฌ๋น„ํ†ต์˜

    ์น˜๋ฃŒ๋Š” ๊ฑฐํ’์‚ฐํ•œํ™”์Šต (็ฅ›้ขจๆ•ฃๅฏ’ๅŒ–ๆฟ•), ์˜จ๊ฒฝํ†ต๋ฝ(ๆบซ็ถ“้€š็ตก), ๋ณด๊ฐ„์‹ (่ฃœ่‚่…Ž),

    ๊ฐ•๊ทผ๊ณจ(ๅผบ็ญ‹้ชจ), ํ–‰๊ธฐํ™œํ˜ˆ(่กŒๆฐฃๆดป่ก€), ์‚ฐ์–ด์ง€ํ†ต(ๆ•ฃ็˜€ๆญข็—›), ์„œ๊ทผํ†ต๋ฝ(่ˆ’็ญ‹้€š็ตก),

    ์†Œํ†ต๊ธฐํ˜ˆ (็–้€šๆฐฃ่ก€), ์„ ์›์น™์œผ๋กœ ํ•˜๊ณ  ํ•œ์•ฝ, ์นจ, ๋œธ, ์•ฝ์นจ, ๋ถ€ํ•ญ์š”๋ฒ• ๋“ฑ์˜

    ๋‹ค์–‘ํ•œ ๋ฐฉ๋ฒ•์œผ๋กœ ์น˜๋ฃŒํ•  ์ˆ˜ ์žˆ๋‹ค152).

    ์š”ํ†ต(่…ฐ็—›)์ด๋ž€ ์š”๋ถ€์˜ ์ œ2, 3์š”์ถ”๋ถ€ํ„ฐ ์š”์ฒœ๊ด€์ ˆ ๋ฐ ์ฒœ์žฅ๊ด€์ ˆ๊นŒ์ง€์˜

  • 23

    ๋ถ€์œ„์— ๋‚˜ํƒ€๋‚˜๋Š” ํ†ต์ฆ์„ ์ผ๊ด„ํ•˜์—ฌ ์ง€์นญํ•˜๋Š” ๊ฒƒ์œผ๋กœ ์žฅ๋ถ€(่‡Ÿ่…‘)๋กœ๋Š”

    ๊ฐ„(่‚)โ‹…๋น„(่„พ)โ‹…์‹ (่…Ž)์— ๋”ฐ๋ผ ์ฆ์ƒ๊ณผ ์ „์‹ ์ฆ์ƒ์„ ์„ค๋ช… ํ•˜์˜€์œผ๋ฉฐ, ๊ทธ ์ค‘ ์‹ (่…Ž)๊ณผ

    ๊ด€๋ จ๋œ ์š”ํ†ต(่…ฐ็—›)์˜ ๋น„์ค‘์ด ๋งŽ๋‹ค. ๊ฒฝ๋ฝ(็ถ“็ตก)์œผ๋กœ๋Š” ์†Œ์Œ๊ฒฝ(ๅฐ‘้™ฐ็ถ“)๊ณผ

    ๋Œ€์žฅ๊ฒฝ(ๅคช้™ฝ็ถ“)๊ณผ ๊ถ์Œ๊ฒฝ(ๅŽฅ้™ฐ็ถ“)๊ณผ ๊ด€๋ จ๋œ ์š”ํ†ต(่…ฐ็—›)์ด ๋งŽ๋‹ค. ๋˜ํ•œ

    ์š”ํ†ต(่…ฐ็—›)์ด ์ฃผ์ฆ์ƒ์œผ๋กœ๋งŒ ์กด์žฌํ•˜๋Š” ๊ฒƒ์ด ์•„๋‹ˆ๋ผ, ์—ด๋ณ‘(็†ฑ็—…)โ‹… ํ•™(็˜ง)โ‹… ํ•ด(ๅ’ณ)โ‹…

    ์œ„(็—ฟ)โ‹… ์ฐฝ(่„น)โ‹… ์ƒํ•œ(ๅ‚ทๅฏ’)โ‹… ๊ถ(ๅŽฅ)โ‹… ์‚ฐ(็–)๋“ฑ์˜ ์งˆํ™˜๊ณผ ๊ด€๋ จ๋œ ๋ถ€ ์ฆ์ƒ์œผ๋กœ

    ์š”ํ†ต(่…ฐ็—›)์˜ ์ฆ์ƒ์ด ๋ฐœํ˜„๋  ์ˆ˜ ์žˆ๋‹ค153). ํ•œ์˜ํ•™์—์„œ ์‹œํ–‰๋˜๋Š” ์š”ํ†ต ์น˜๋ฃŒ๋Š”

    ์นจ๊ตฌ์š”๋ฒ•(้ผ็ธ็™‚ๆณ•), ์•ฝ๋ฌผ์š”๋ฒ•(่—ฅ็‰ฉ๏งๆณ•), ์ถ”๋‚˜์š”๋ฒ•(ๆŽจๆ‹็™‚ๆณ•), ๋ถ€ํ•ญ์š”๋ฒ•

    (้™„็ผธ็™‚ๆณ•), ์ „์นจ์š”๋ฒ•(้›ป้ผ๏งๆณ•) ๋ฐ ๊ธฐ๊ณต(๊ธฐ๊ณต)์„ ํฌํ•จํ•œ ๋ฌผ๋ฆฌ์š”๋ฒ• ๋“ฑ์„ ์ฃผ๋กœ

    ๋ณด์กด์  ์น˜๋ฃŒ๋ฐฉ๋ฒ•์œผ๋กœ ํ™œ์šฉํ•˜๊ณ  ์žˆ๋‹ค. ์š”ํ†ต(่…ฐ็—›)์— ์ƒ์šฉ(ๅธธ็”จ)ํ•˜๋Š” ๋ฐฉ๋ฒ•์œผ๋กœ

    ๊ทผ์œ„์ทจํ˜ˆ(่ฟ‘ไฝๅ–็ฉด), ์›์œ„์ทจํ˜ˆ(้ ไฝๅ–็ฉด), ์ˆ˜์ฆ์ทจํ˜ˆ(้šจ่ญ‰ๅ–็ฉด)์„ ํ†ตํ•ด

    ์™ธ๊ฐ(ๅค–ๆ„Ÿ)๊ณผ ๋‚ด์ƒ(ๅ…งๅ‚ท)์ด ์žฅ๋ถ€๊ธฐ๋Šฅ์‹ค์กฐ(่‡Ÿ่…‘ๆฉŸ่ƒฝๅคฑ่ชฟ), ๊ธฐํ˜ˆ๋ฌธ๋ž€(ๆฐฃ่ก€็ดŠไบ‚),

    ์˜์œ„์‹คํ™”(็‡Ÿ่ก›ๅคฑๅ’Œ)๋ฅผ ์ผ์œผํ‚ด์œผ๋กœ์จ ๋ฐœ์ƒ๋œ ๊ธ‰๋งŒ์„ฑ ๋™ํ†ต ์งˆํ™˜(ๆ€ฅๆ…ขๆ€ง

    ็–ผ็—›็–พๆ‚ฃ)์— ์œ ํšจ(ๆœ‰ๆ•ˆ)ํ•˜๋‹ค154).

    ํ•œ์˜ํ•™(้Ÿ“้†ซๅญธ)์—์„œ ์Šฌ๊ด€์ ˆํ†ต(่†้—œ็ฏ€็—›)์€ ์Šฌํ†ต(้Ÿ“้†ซๅญธ), ์Šฌ์ค‘ํ†ต(่†ไธญ็—›)

    , ์Šฌ์ค‘(่†่…ซ), ์Šฌ์™ธ์—ผํ†ต(่†ๅค–๏ฆข็—›), ํ•™์Šฌํ’(้ถด่†้ขจ),

    ๋“ฑ์œผ๋กœ ํ‘œํ˜„๋˜๊ณ  ์žˆ๋Š”๋ฐ, ์ฃผ๋กœ ์Šฌ๋ถ€(่†้ƒจ)์˜ ๊ทผ๊ณจ(็ญ‹้ชจ), ๊ธฐ์œก(่‚Œ่‚‰), ๊ฑด(่…ฑ),

    ๊ด€์ ˆ(้—œ็ฏ€)๋“ฑ์— ๋™ํ†ต(็–ผ็—›), ์‚ฐํ†ต(็–็—›), ์ค‘์ฐฝ(่…ซ่„น), ๋งˆ๋ชฉ(็—ฒๆœจ), ๊ด€์ ˆ์˜

    ์ข…๋Œ€(่…ซๅคง), ๊ตด์‹ ๋ถˆ๋ฆฌ(ๅฑˆไผธ๏ฅงๅˆฉ)๋“ฑ์˜ ์ฆ์ƒ์„ ์ˆ˜๋ฐ˜ํ•˜๋ฏ€๋กœ ๋น„์ฆ(็—บ็—‡)์˜ ๋ฒ”์ฃผ์—

    ์†ํ•˜๋Š” ๊ฒƒ์œผ๋กœ ๋ณด๊ณ  ์žˆ๋‹ค155). ํ•œ์˜ํ•™(้Ÿ“้†ซๅญธ)์—์„œ๋Š” ๊ฐ์ข… ์—ผ์ฆ์— ์นจ ์‹œ์ˆ ์„

  • 24

    ์ ์šฉํ•˜๋Š”๋ฐ ์ด๋Š” ์Œ์–‘์‘์ƒ๋Œ€๋ก (้™ฐ้™ฝๆ‡‰่ฑกๅคง่ซ–)์—์„œ ๊ฐ์ข…

    ์งˆ๋ณ‘(็–พ็—…) ๊ณผ์ •์— ๋‚˜ํƒ€๋‚˜๋Š” ๋™ํ†ต(็–ผ็—›)์˜ ์›์ธ๊ณผ ๊ด€๋ จํ•˜์—ฌ ๋™ํ†ต(็ถ“็ตก)์€

    ๊ฒฝ๋ฝ(็ถ“็ตก) ์ค‘ ๊ธฐํ˜ˆ(ๆฐฃ่ก€)์˜ ์šดํ–‰(้‹่กŒ)์ด ๋„๋‹ฌํ•˜์ง€ ๋ชปํ•œ ๊ฒƒ์„ ์ค‘์š” ์›์ธ์œผ๋กœ

    ๋ถ„์„ํ•จ์— ๊ทผ๊ฑฐํ•˜๊ณ  ์žˆ๋‹ค156).

    ๋ณธ ์—ฐ๊ตฌ์— ์‚ฌ์šฉ๋œ ์ „ํ†ต์นจ ํ˜ˆ์œ„(็ฉดไฝ)๋Š” ใ€Ž์ตœ์‹ ์นจ๊ตฌํ•™(ๆœ€ๆ–ฐ้ผ็ธๅญธ)ใ€์—

    ๊ธฐ์žฌ๋œ ๊ณ ํ˜ˆ์•• ์น˜๋ฃŒ์˜ ์ƒ์šฉํ˜ˆ(ๅธธ็”จ็ฉด)์ธ ํƒœ์ถฉ(ๅคช่ก), ์กฑ์‚ผ๋ฆฌ(่ถณไธ‰้‡Œ), ๊ณก์ง€

    (ๆ›ฒๆฑ ), ํ•ฉ๊ณก(ๅˆ่ฐท)๋ฅผ ์ ์šฉํ•˜์˜€๊ณ 157), ์ดํ˜ˆ(่€ณ็ฉด)์€ ใ€Ž์ตœ์‹ ์นจ๊ตฌํ•™ใ€๊ณผ

    ใ€Ž์ค‘๊ตญ์นจ๊ตฌํ•™ใ€์— ๊ธฐ์žฌ๋œ ๊ณ ํ˜ˆ์•• ๋ฐ ํ˜ˆ์•ก์งˆํ™˜ ์น˜๋ฃŒ์˜ ์ƒ์šฉํ˜ˆ์ธ ์‹ ๋ฌธ(็ฅž้–€),

    ๊ต๊ฐ(ไบคๆ„Ÿ), ๊ฐ•์••์ (้™ๅฃ“็‚น), ์‹ (่…Ž), ๊ฐ„(่‚), ๋‚ด๋ถ„๋น„(ๅ…งๅˆ†ๆณŒ)๋ฅผ ์„ ํƒํ•˜์˜€๋‹ค. ๊ฐ

    ์ดํ˜ˆ์˜ ํšจ๋Šฅ๊ณผ ์ฃผ์น˜(ไธปๆฒป)๋ฅผ ๋ณด๋ฉด, ์‚ผ๊ฐ์™€๋ถ€(ไธ‰่ง’็ชฉ้ƒจ) ์•„๋žซ๋ถ€๋ถ„์— ์ž๋ฆฌํ•œ

    ์‹ ๋ฌธํ˜ˆ์€ ๋Œ€๋‡Œํ”ผ์งˆ์˜ ํฅ๋ถ„๊ณผ ์–ต์ œ๋ฅผ ์กฐ์ ˆํ•˜๋Š” ์ž‘์šฉ ๋ฐ ์ง„์ •, ์ง„ํ†ต ํšจ๊ณผ๊ฐ€

    ์žˆ๊ณ  ์ •์‹ ์‹ ๊ฒฝ๊ณ„ ์งˆํ™˜๊ณผ ๊ณ ํ˜ˆ์••์—๋„ ์ƒ์šฉ๋˜๋ฉฐ, ๊ต๊ฐํ˜ˆ์€

    ์ž์œจ์‹ ๊ฒฝ๊ณ„(autonomic nervous system)์˜ ๊ธฐ๋Šฅ์„ ์กฐ์ ˆํ•˜๊ณ  ํ˜ˆ๊ด€์„ ํ™•์žฅํ•˜๋Š”

    ์ž‘์šฉ์ด ์žˆ๋‹ค. ๊ฐ•์••์ ์€ ๊ณ ํ˜ˆ์•• ์น˜๋ฃŒ์— ์žˆ์–ด ํŠนํšจํ˜ˆ(็‰นๆ•ˆ็ฉด)์ด๊ณ , ์‹ (่…Ž)์€

    ๊ฐ•์žฅํ˜ˆ(ๅผบๅฃฏ็ฉด)๋กœ์„œ ๋Œ€๋‡Œ(ๅคง่…ฆ)์™€ ์‹ ์žฅ(่…Ž่‡Ÿ), ์กฐํ˜ˆ๊ธฐ(้€ ่ก€ๅ™จ)์— ๋Œ€ํ•˜์—ฌ

    ๋ณด์ต์ž‘์šฉ(่ฃœ็›Šไฝœ็”จ)์ด ์žˆ์œผ๋ฉฐ ๋ถ€์ข…(ๆตฎ่…ซ) ๋“ฑ์˜ ์ˆ˜๋ถ„๋Œ€์‚ฌ(ๆฐดๅˆ†ไปฃ่ฌ) ์กฐ์ ˆ ๋ฐ

    ์‹ ๊ฒฝ์‡ ์•ฝ์—๋„ ํšจ๊ณผ๊ฐ€ ์žˆ๋‹ค. ๊ฐ„ํ˜ˆ(่‚็ฉด)์€ ํ•ด์šธ(่งฃ้ฌฑ), ์กฐ๊ธฐ(่ชฟๆฐฃ), ์กฐํ˜ˆ(่ชฟ่ก€)

    ์ž‘์šฉ์— ์ƒ์šฉ๋˜๋ฉฐ, ๋ณ‘๊ฐ„์ ˆ์ (ๅฑ›้–“ๅˆ‡่ฟน) ๋‚ด์ธก(ๅ…งๅด)์— ์ž๋ฆฌํ•œ ๋‚ด๋ถ„๋น„ํ˜ˆ์€ ์—ฌ๋Ÿฌ

    ๋‚ด๋ถ„๋น„ ์‹ค์กฐ(ๅ…งๅˆ†๏ฅจๅคฑ่ชฟ)์— ์˜ํ•œ ๊ฐ์ข… ์งˆ๋ณ‘์„ ์น˜๋ฃŒํ•˜์—ฌ ์ฒด๋‚ด ๋Œ€์‚ฌ(ไปฃ่ฌ)๋ฅผ

    ์ด‰์ง„ํ•˜๋Š” ์ž‘์šฉ์„ ํ•œ๋‹ค157-159). ๋™์”จ์นจ๋ฒ•์€ ํ˜ˆ์œ„๊ฐ€ 740 ์—ฌ๊ฐœ๋‚˜ ๋˜๊ณ ,

  • 25

    ์น˜๋ฃŒ์ด๋ก ์€ ๊ฐ๊ฐ์˜ ์ผ๋ถ€๊ฐ€ ๋ชธ ์ „์ฒด๋ฅผ ๋ฐ˜์˜ํ•˜์—ฌ ๊ทธ ์ผ๋ถ€์—์„œ ์ทจํ˜ˆํ•˜์—ฌ ์ „์ฒด๋ฅผ

    ์น˜๋ฃŒํ•  ์ˆ˜ ์žˆ๋‹ค๋Š” ์ด๋ก  ์ฆ‰ ์ƒ๋ณ‘ํ•˜์น˜, ์ขŒ๋ณ‘์šฐ์น˜, ์šฐ๋ณ‘์ขŒ์น˜๋“ฑ์„ ์ฃผ์น˜๋ฒ•์œผ๋กœ

    ์‚ฌ์šฉํ•˜๊ณ  ์žˆ๋‹ค. ๋˜ํ•œ ์ทจํ˜ˆ์ด ์šฉ์ดํ•˜๊ณ , ์‹ค์šฉ์ ์ด๋ฉฐ, ์›์œ„ ์ทจํ˜ˆ์„ ํ•˜๋ฏ€๋กœ

    ๋น„๊ต์  ์‹œ์ˆ ์ด ๊ฐ„ํŽธํ•˜๋‹ค. ๋‚ด์™ธ๊ณผ ์งˆํ™˜ ์งˆ๋ณ‘๊ณผ ๊ด€๊ณ„์—†์ด ์น˜๋ฃŒ ํšจ๊ณผ๊ฐ€ ์šฐ์ˆ˜ํ•˜๋ฉฐ

    ํŠนํžˆ ์ž์นจ ํ›„ ์ฆ‰์‹œ ์ง€ํ†ต ํšจ๊ณผ๊ฐ€ ๋‚˜ํƒ€๋‚˜ ํ†ต์ฆ์น˜๋ฃŒ์— ํ˜„์žฌ ๋งŽ์ด ์‚ฌ์šฉ๋˜์–ด์ง€๋Š”

    ์นจ ๋ฒ• ์ค‘ ํ•˜๋‚˜์ด๋‹ค160).

    ๊ฒฌ๋น„ํ†ต์˜ ์นจ์น˜๋ฃŒ์‹œ ์‚ฌ์šฉ๋˜๋Š” ํ˜ˆ์œ„๋กœ ๊ฒฌ์šฐ(่‚ฉ้ซƒ), ์ˆ˜์‚ผ๋ฆฌ(ๆ‰‹ไธ‰้‡Œ),

    ๊ณก์ง€(ๆ›ฒๆฑ ), ์™ธ๊ด€(ๅค–้—œ), ์ฒœ์ •(ๅคฉๅบญ), ๋…ธํšŒ(่‡‘ๆœƒ), ๊ฒฌ์ •(่‚ฉ่ฒž), ์ฒœ๋ฃŒ(ๅคฉ้ซŽ),

    ๊ฑฐ๊ณจ(ๅทจ้ชจ), ์ฒ™ํƒ(ๅฐบๆพค)์ด ์žˆ์œผ๋ฉฐ ์ฃผ๋กœ ์ˆ˜์–‘๋ช…๋Œ€์žฅ๊ฒฝ(ๆ‰‹้™ฝๆ˜Žๅคง่…ธ็ถ“),

    ์ˆ˜์†Œ์–‘์‚ผ์ดˆ๊ฒฝ(ๆ‰‹ๅฐ‘้™ฝไธ‰็„ฆ็ถ“)์˜ ํ˜ˆ์ด๋‹ค152). ๋™์”จ์นจ ์ž„์ƒ๊ฐ€๋“ค์ด ๊ฒฌ๋น„ํ†ต ์น˜๋ฃŒ์—

    ์ฃผ๋กœ ์‚ฌ์šฉํ•˜๋Š” ํ˜ˆ์œ„๋กœ๋Š” ๊ฒฌํ†ต์— ์‹ ๊ด€, ์กฑ์ฒœ๊ธˆ, ์กฑ์˜ค๊ธˆ, ๊ฒฌ์ค‘, ๋น„๊ด€, ํ™”๊ณจ ๊ณก๋ฆ‰,

    ์‚ฌํ™”์ค‘, ์ค‘๊ตฌ๋ฆฌ ๋“ฑ์˜ ๋™์”จ๊ธฐํ˜ˆ๊ณผ ๊ทธ ์™ธ ์ข…์ฐฝ์„ ๋™๋ฐ˜ํ•œ ๊ฒฌ๋ด‰ํ†ต์— ์‹ ๊ด€์„

    ๋น„๋กฏํ•˜์—ฌ ํ†ต์‹ , ํ†ต์œ„, ํ†ต๋ฐฐ์™€ ์ค‘๊ตฌ๋ฆฌ, ์ธกํ•˜์‚ผ๋ฆฌ, ์ค‘์ž, ์ค‘์„ ์„ ์ƒ๋น„ํ†ต์— ์ธก์‚ผ๋ฆฌ,

    ์œก์™„, ์Šฌ์•ˆ์„ ์‚ฌ์šฉํ•˜์˜€์œผ๋ฉฐ ๋ฐฉํ˜ˆ๋„ ์ž์ฃผ ๋ณ‘์šฉํ•˜์˜€๋‹ค161).

    ์š”ํ†ต์˜ ๊ณตํ†ต์  ์ฃผ์น˜ํ˜ˆ์€ ์‹ ์ˆ˜(่…Žๅ…ช), ๊ธฐํ•ด์ˆ˜(ๆฐฃๆตทๅ…ช), ๋Œ€์žฅ์ˆ˜(ๅคง่…ธๅ…ช),

    ๊ด€์›์ˆ˜(้—œๅ…ƒๅ…ช), ํ™˜๋„(็’ฐ่ทณ), ์€๋ฌธ(ๆฎท้–€), ์œ„์ค‘(ๅง”ไธญ), ์Šน์‚ฐ(ๆ‰ฟๅฑฑ), ๊ณค๋ฅœ(ๅด‘ๅด™),

    ํŒ”๋ฃŒ(ๅ…ซ้ซŽ)็ฉด๋“ฑ์ด๋ฉฐ, ์‹ ํ—ˆ์š”ํ†ต(่…Ž่™›่…ฐ็—›)์—๋Š” ์ต์‹ (็›Š่…Ž)์‹œํ‚ค๋Š” ์‹ ์ˆ˜(่…Žๅ…ช),

    ๊ด€์›์ˆ˜(้—œๅ…ƒๅ…ช), ๋ช…๋ฌธ(ๅ‘ฝ้–€), ์œ„์ค‘(ๅง”ไธญ), ์ง€์‹ค(ๅฟ—ๅฎค), ํƒœ๊ณ„(ๅคชๆบช)็ฉด์„,

    ํ•œ์Šต์š”ํ†ต(ๅฏ’ๆฟ•่…ฐ็—›)์—๋Š” ์š”์–‘๊ด€(่…ฐ้™ฝ้—œ), ๋ช…๋ฌธ(ๅ‘ฝ้–€), ์Œ๋ฆ‰์ฒœ(้™ฐ้™ตๆณ‰),

    ํ’๋ถ€(้ขจๅบœ), ์œ„์ค‘(ๅง”ไธญ)์„, ์Šต์—ด์š”ํ†ต(ๆฟ•็†ฑ่…ฐ็—›)์—๋Š” ์กฑ์‚ผ๋ฆฌ(่ถณไธ‰้‡Œ),

  • 26

    ์Œ๋ฆ‰์ฒœ(้™ฐ้™ตๆณ‰), ํ•ฉ๊ณก(ๅˆ่ฐท), ๋‚ด์ •(ๅ…งๅบญ), ์‚ผ์Œ๊ต(ไธ‰้™ฐไบค)๋ฅผ, ์ขŒ์„ฌ์š”ํ†ต

    (ๆŒซ้–ƒ่…ฐ็—›)์ธ ๊ฒฝ์šฐ ์ธ์ค‘(ไบบไธญ), ์žฅ๊ฐ•(้•ทๅผบ), ํ›„๊ณ„(ๅพŒ่ฐฟ), ์œ„์ค‘(ๅง”ไธญ)์„ ์ฃผ๋กœ

    ์‚ฌ์šฉํ•œ๋‹ค162).

    ์Šฌ๊ด€์ ˆํ†ต(่†้—œ็ฏ€็—›)์— ๋Œ€ํ•œ ์นจ๊ตฌ์น˜๋ฃŒ์— ์žˆ์–ด์„œ๋Š” ๊ฐ ๊ฒฝํ˜ˆ(็ถ“็ฉด)์ค‘

    ๊ทผ์œ„ํ˜ˆ์€ ์–‘๋ฆ‰์ฒœ(GB34), ์กฑ์‚ผ๋ฆฌ(ST36), ๋…๋น„(ST35), ์œ„์ค‘(UB40),

    ํ˜ˆํ•ด(SP10), ์–‘๊ตฌ(ST34), ๊ณก์ฒœ(LV8), ์Šฌ์–‘๊ด€(GB33), ์Šฌ์•ˆ(Xyian,

    EX36)๋“ฑ์˜ ์Šฌ๊ด€์ ˆ ์ฃผ์œ„์˜ ๊ฒฝํ˜ˆ๋“ค์ด ๋‹ค์šฉ๋˜๊ณ , ์›์œ„ํ˜ˆ์€ ์นจ๊ตฌ๋Œ€์„ฑ์—์„œ

    ๊ฐ„์ˆ˜(BL18), ์‹ ์ˆ˜(BL18), ๊ณค๋ฅœ(UB60), ํ˜„์ข…(GB39), ์‚ผ์Œ๊ต(SP10),

    ํ–‰๊ฐ„(LV2), ํ•ด๊ณ„(ST41), ํƒœ๊ณ„(K3)๋ฅผ ์‚ฌ์šฉํ•œ๋‹ค๊ณ  ํ–ˆ๋‹ค163).

  • 27

    IV. MATERIALS AND METHODS

    ๋ณธ ์—ฐ๊ตฌ๋Š” ๋น„์ฆ์ฆ์ƒ๊ณผ ํ•จ๊ป˜ ๊ณ ํ˜ˆ์••์„ ์ง„๋‹จ๋ฐ›๊ณ  ์•ฝ์„ ๋ณต์šฉ

    ์ค‘์ด๊ฑฐ๋‚˜๏ผŒ์ธก์ • ํ˜ˆ์••์ด 140/90 mmHg ์ด์ƒ ๋˜๋Š” ํ™˜์ž 7๋ช… ์ด์ƒ์„ ๋Œ€์ƒ์œผ๋กœ

    ๋น„์ฆ์น˜๋ฃŒ๊ฐ€ ๊ณ ํ˜ˆ์•• ์น˜๋ฃŒ์— ์“ฐ์ด๋Š” ์ „ํ†ต์นจ๊ณผ ์ด์••์š”๋ฒ•์ด ํ˜ˆ์••์— ๋ฏธ์น˜๋Š” ์น˜๋ฃŒ

    ํšจ๊ณผ๋ฅผ ๋ถ„์„ํ•˜๋Š” ์ž„์ƒ ์—ฐ๊ตฌ์ด๋‹ค. 2018๋…„ 1์›”๋ถ€ํ„ฐ 4์ฃผ๊ฐ„ ์ฃผ 2ํšŒ ์ด 8ํšŒ์˜

    ๋น„์ฆ์น˜๋ฃŒ์™€ ์นจ์น˜๋ฃŒ์™€ ์ด์••์น˜๋ฃŒ๊ฐ€ ์ด์–ด์ง€๊ณ , ๋น„์ฆ์น˜๋ฃŒ๊ฐ€ ๊ณ ํ˜ˆ์•• ์น˜๋ฃŒ์˜

    ๊ฐ•์••ํšจ๊ณผ์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ์„ ๋ถ„์„ํ•˜๊ณ ์ž ํ•˜์˜€๋‹ค. ํ™˜์ž๋“ค์—๊ฒŒ ์—ฐ๊ตฌ์˜ ๋ชฉ์ ๊ณผ

    ์ ˆ์ฐจ๋ฅผ ์ž์„ธํžˆ ์„ค๋ช…ํ•˜๊ณ , ์ž๋ฐœ์ ์œผ๋กœ ์ฐธ์—ฌ ์˜์‚ฌ๋ฅผ ํ‘œํ•œ ํ™˜์ž๋ฅผ ์„ ๋ณ„ํ•˜์—ฌ

    Informed Consent Form์„ ์ž‘์„ฑํ•˜๊ณ  ์—ฐ๊ตฌ์— ์ฐธ์—ฌํ•˜๊ฒŒ ํ•˜์˜€๋‹ค. ์—ฐ๊ตฌ์— ์ฐธ์—ฌ ํ•œ

    ํ™˜์ž๋Š” ์น˜๋ฃŒ ์ „ ๊ณผ ํ›„๏ผŒ ์ตœ์ข… ์น˜๋ฃŒ ํ›„ ํ†ต์ฆ์ •๋„์™€ ํ˜ˆ์••์„ ์ธก์ • ํ•˜์—ฌ ์น˜๋ฃŒ

    ํšจ๊ณผ๋ฅผ ๋น„๊ต๋ถ„์„ ํ•˜์˜€๋‹ค.

    4.1. Materials

    4.1.1. ํ˜ธ์นจ

    ๋ณธ ์—ฐ๊ตฌ์— ์‚ฌ์šฉ๋˜ ๋Š” ํ˜ธ์นจ์€ (์ฃผ) ๋™๋ฐฉ๋ฉ”๋””์ปฌ (Dong Bang Acupuncture

    Incorporated.) ์—์„œ ์ œ์กฐํ•œ Stainless Steel ์˜ ๊ทœ๊ฒฉ 0.25X40mm ์˜

    ๋ฉธ๊ท ์ฒ˜๋ฆฌ๋œ ๊ฒƒ์„ ์‚ฌ์šฉ ํ•˜์˜€์œผ๋ฉฐ, Figure l ๊ณผ ๊ฐ™์€ ๊ฒƒ์„ ์‚ฌ์šฉํ•˜์˜€๋‹ค. ๊ทธ๋ฆฌ๊ณ 

    ์‚ฌ์šฉ๋œ ์นจ์€ ๋ฏธ๊ตญ ์˜๋ฃŒ๊ธฐ๊ธฐ ํ๊ธฐ๋ฌผ ์ฒ˜๋ฆฌ ๊ทœ์ •์— ๊ทผ๊ฑฐํ•˜์—ฌ ํ๊ธฐ ์ฒ˜๋ฆฌํ•˜์˜€๋‹ค.

  • 28

    Figure 1. Dng Bang Sterilized Needles

    4.1.2. ์™•๋ถˆ๋ฅ˜ํ–‰์ž

    ์—ฐ๊ตฌ์— ์‚ฌ์šฉ๋˜๋Š” ์ด์นจ์€ 2mm ์˜ ์™•๋ถˆ๋ฅ˜ํ–‰์ž์— 0.4" x 0.4"๊ทœ๊ฒฉ์˜

    surgical ์Šคํ‹ฐ์ปค๋ฅผ ๋ถ€์ฐฉํ•˜์—ฌ ์ œ์กฐํ•˜๊ณ  ๋ฉธ๊ท ๋œ ๊ฒƒ์œผ๋กœ์„œ Health Body World

    Supply, Inc์‚ฌ์˜ ์ œํ’ˆ์„ ์‚ฌ์šฉํ•˜์˜€๋‹ค.

    Figure 2. Vaccaria Press Seeds

  • 29

    4.1.3. ์†Œ๋…์šฉ ์•Œ์ฝ”์˜ฌ ์Šค์™‘

    ๋ณธ ์—ฐ๊ตฌ์— ์‚ฌ์šฉ๋˜๋Š” ์†Œ๋…์šฉ ์•Œ์ฝ”์˜ฌ ์Šค์™‘(alcohol prep pad)์€

    Covidien์‚ฌ(๋ฏธ๊ตญ์‚ฐ)์˜ 1 inch X 1 inch (๊ฐ€๋กœ X ์„ธ๋กœ), ๊ฐœ๋ณ„ํฌ์žฅ์˜ ๋ฉธ๊ท ์ฒ˜๋ฆฌ๋œ

    ์ผํšŒ์šฉ ์•Œ์ฝ”์˜ฌ ์Šค์™‘(์ œํ’ˆ๋ฒˆํ˜ธ: 5750)์œผ๋กœ 70%์˜ ์ด์†Œํ”„๋กœํ•„

    ์•Œ์ฝ”์˜ฌ(isopropyl alcohol)์„ ํ•จ์œ ํ•˜๊ณ  ์žˆ๋Š” ๊ฒƒ์„ ์‚ฌ์šฉํ•˜์˜€๋‹ค. ์ž์นจ ๋ฐ”๋กœ ์ „๊ณผ

    ์™•๋ถˆ๋ฅ˜ํ–‰์ž ๋ถ€์ฐฉ ์ „ ํ•ด๋‹น ํ˜ˆ์œ„์— ์ผํšŒ ์‚ฌ์šฉ ํ›„ ํ๊ธฐํ•˜์˜€๋‹ค.

    4.1.4. ํ˜ˆ์••๊ณ„

    ๋ณธ ์—ฐ๊ตฌ์— ์‚ฌ์šฉ ๋˜๋Š” ํ˜ˆ์•• ์ธก์ • ๊ธฐ๊ตฌ๋Š” ํ‘œ์ค€ ์ „์ž์‹ ํ˜ˆ์••๊ณ„๋กœ ์ œ์กฐํ•œ

    ๊ฒƒ์œผ๋กœ ์ œํ’ˆ๋ช… Omron BP742N ์ด๋ฉฐ๏ผŒCuff ๊ทœ๊ฒฉ์€ ์ƒ์™„์šฉ ํ‘œ์ค€ํ˜•์œผ๋กœ

    ์‚ฌ์šฉํ•˜์˜€๋‹ค.

    Figure 3. Upper Arm Blood Pressure Monitor

    VAS๋Š” Cline el al(1992)์ด ๊ฐœ๋ฐœํ•œ ์ฃผ๊ด€์ ์ธ ํ†ต์ฆ ๊ฐ•๋„๋กœ์„œ164) 10cm์˜

  • 30

    ์ˆ˜ํ‰์„  ์™ธ์ชฝ ๋์€ 0, ์˜ค๋ฅธ์ชฝ ๋์€ 10์œผ๋กœ ํ•˜์—ฌ ๋Œ€์ƒ์ž๋กœ ํ•˜์—ฌ๊ธˆ ๋Š๋ผ๋Š”

    ํ†ต์ฆ์ •๋„๋ฅผ ํ‘œ์‹œํ•˜๋„๋ก ํ•˜๊ณ , ํ‘œ์‹œํ•œ ์ง€์ ๊นŒ์ง€๋ฅผ ์žฐ ๊ธธ์ด๋ฅผ ์ ์ˆ˜ํ™”ํ•˜์—ฌ

    ์ ์ˆ˜๊ฐ€ ๋†’์„์ˆ˜๋ก ํ†ต์ฆ์ •๋„๊ฐ€ ๊ฐ•ํ•จ์„ ๋‚˜ํƒ€๋‚ด์—ˆ๋‹ค.

    Figure 4. Visual Analogue Scale (VAS)

    4.2. Methods

    4.2.1. ์—ฐ๊ตฌ๋Œ€์ƒ

    ๋ณธ ์—ฐ๊ตฌ๋Š” 2018๋…„ 1์›” 1์ผ๋ถ€ํ„ฐ 2018๋…„ 3์›” 30์ผ๊นŒ์ง€ ์ž„์ƒ ์—ฐ๊ตฌ ๋ชจ์ง‘์—

    ์ฐธ์—ฌํ•œ 7๋ช… ์ด์ƒ์˜ ๋น„์ฆ์„ ๋™๋ฐ˜ํ•œ ๊ณ ํ˜ˆ์•• ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ํ•˜์˜€๋‹ค.

    ์ž„์ƒ์—ฐ๊ตฌ๋ฅผ ์ฐธ์—ฌํ•˜๋Š” ๋ชจ๋“  ํ™˜์ž์—๊ฒŒ ์—ฐ๊ตฌ์˜ ๋ชฉ์ ๊ณผ ๋ฐฉ๋ฒ•์„ ์ž์„ธํžˆ ์„ค๋ช…ํ•˜๊ณ ,

    Informed Consent Form์„ ์ž‘์„ฑํ•œ ํ›„์— ์—ฐ๊ตฌ์— ์ฐธ์—ฌํ•˜์˜€๋‹ค. ๊ณ ํ˜ˆ์••์„ ์ง„๋‹จ

    ๋ฐ›๊ณ  ์•ฝ์„ ๋ณต์šฉํ•˜๊ณ  ์žˆ๋Š” ํ™˜์ž ์ค‘ ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์•• 130mmHg ๋˜๋Š” ์ด์™„๊ธฐ ํ˜ˆ์••

    90mmHg ์ด์ƒ์— ํ•ด๋‹นํ•˜๊ฑฐ๋‚˜, ๊ณ ํ˜ˆ์•• ์ง„๋‹จ์€ ๋ฐ›์ง€ ์•Š์•˜์ง€๋งŒ ๋ถ€๋™ํ•œ ์‹œ๊ฐ„์—

    3๋ฒˆ์˜ ํ˜ˆ์•• ์ธก์ •์—์„œ ๋ชจ๋‘ ์ธก์ • ํ˜ˆ์••์ด ์ˆ˜์ถ•๊ธฐ 140mmHg ๋˜๋Š” ์ด์™„๊ธฐ 90

  • 31

    mmHg ์ด์ƒ์ธ ํ™˜์ž 7๋ช… ์ด์ƒ ์„ ๋ฐœํ•˜์—ฌ, ์ด์ค‘์—์„œ ํ†ต์ฆ์„ ๋™๋ฐ˜ํ•œ ๋น„์ฆํ™˜์ž๋ฅผ

    ๋Œ€์ƒ์œผ๋กœ ํ•˜์˜€๋‹ค. ๊ฒฌ๋น„ํ†ต, ์š”ํ†ต, ์Šฌํ†ต์˜ ์„ ๋ฐœ๊ธฐ์ค€์€ ๋‹ค์Œ๊ณผ ๊ฐ™๋‹ค.

    โ€ข ๊ฒฌ๋น„ํ†ต

    i. ๊ธ‰๋งŒ์„ฑ ์–ด๊นจํ†ต์ฆ์„ ํ˜ธ์†Œํ•˜๋Š” ๋‚จ๋…€ ํ™˜์ž ์ค‘ VAS ๊ฐ€ 5 ์ด์ƒ์ธ ํ™˜์ž

    ii. ์ˆ˜๋™์ , ๋Šฅ๋™์ ์šด๋™ ์‹œ ๊ฒฌ๋ฐฐ๋ถ€๋ฅผ ํฌํ•จํ•œ ๊ฒฌ๋น„์ฃผ์— ๋ถ„๋ช…ํ•œ ํ†ต์ฆ์ด ์žˆ๋Š”

    ํ™˜์ž

    โ€ข ์š”ํ†ต

    i. ๊ธ‰๋งŒ์„ฑ ์š”ํ†ต์„ ํ˜ธ์†Œํ•˜๋Š” ๋‚จ๋…€ ํ™˜์ž ์ค‘ VAS ๊ฐ€ 5 ์ด์ƒ์ธ ํ™˜์ž

    โ€ข ์Šฌํ†ต

    i. ์Šฌ๊ด€์ ˆํ†ต์ด ์ž„์ƒ์ ์œผ๋กœ ์ž์ฃผ ์žˆ์–ด ์ผ์ƒ์ƒํ™œ์— ์–ด๋ ค์›€์„ ํ˜ธ์†Œํ•˜๋Š” ํ™˜์ž

    ์ค‘ VAS ๊ฐ€ 5 ์ด์ƒ์ธ ํ™˜์ž

    ii. ์ž„์ƒ๊ธฐ๊ด€์—์„œ ํ‡ดํ–‰์„ฑ๊ด€์ ˆ์—ผ, ๋ฅ˜๋งˆํ‹ฐ์Šค ๊ด€์ ˆ์—ผ๋“ฑ ์Šฌ๊ด€์ ˆ ๊ด€๋ จ ์ง„๋‹จ์„

    ๋ฐ›์€ ํ™˜์ž

    iii. 50์„ธ ์ด์ƒ, ์กฐ์กฐ๊ฐ•์ง 30๋ถ„ ์ด๋‚ด, ์—ผ๋ฐœ์Œ(crepitus)์ฆ์ƒ์„ ๊ฐ€์ง€๊ณ  ์žˆ๋Š”

    ํ™˜์ž

    ๋ณธ ์—ฐ๊ตฌ์— ๊ด€ํ•œ ๋ชจ๋“  ์‚ฌํ•ญ์€ South Baylo University์˜ IRB(Institutional

    Review Board)์˜ ์‹ฌ์˜, ์Šน์ธ์„ ๋ฐ›์€ ํ›„ ์‹œํ–‰ํ•˜์˜€๋‹ค.

    4.2.1.1. ์ œ์™ธ๊ธฐ์ค€

    ๋Œ€์ƒ์ž์˜ ์ œ์™ธ ๊ธฐ์ค€์œผ๋กœ ์™ธ๋ž˜๋ณ€์ˆ˜๋ฅผ ์ œ๊ฑฐํ•˜๊ธฐ ์œ„ํ•˜์—ฌ 18์„ธ ๋ฏธ๋งŒ์˜

  • 32

    ๋ฏธ์„ฑ๋…„์ž ๋ฐ ์‹ฌํ˜ˆ๊ด€๊ณ„ ์งˆํ™˜์œผ๋กœ ์ธํ•œ ์ˆ˜์ˆ ์„ ๋ฐ›์€ ๊ฒฝํ—˜์ด ์žˆ๋Š” ์ž, ๊ณ ํ˜ˆ์••์„ฑ

    ์œ„๊ธฐ์˜ ๊ฒฝ๊ณ  ์ฆ์ƒ์ด ์žˆ๋Š” ์ž, ๋ฉด์—ญ๊ณ„ ์งˆํ™˜ ๋ฐ ์ •์‹ ์‹ ๊ฒฝ๊ณ„ ์งˆํ™˜ ๊ด€๋ จ ์•ฝ๋ฌผ์„

    ๋ณต์šฉ ์ค‘์ธ ์ž, ์ฃผ์น˜์˜์— ์˜ํ•ด ํ•„์š”์— ๋”ฐ๋ผ ๊ณ ํ˜ˆ์•• ์ฒ˜๋ฐฉ์•ฝ์„ ๋ณ€๊ฒฝํ•œ ์ž,

    ์ž„์‚ฐ๋ถ€ ๋ฐ ์ˆ˜์œ  ์ค‘์ธ ์ž, ์ž์นจ ๋ถ€์œ„์™€ ์™ธ์ด์˜ ์ฒฉ์•• ๋ถ€์œ„์— ์Šต์ง„, ๊ถค์–‘์„ฑ

    ํ”ผ๋ถ€๋ณ‘, ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••์ด 180 mmHg ์ด์ƒ ์ด๊ฑฐ๋‚˜ ์ด์™„๊ธฐ ํ˜ˆ์••์ด 110 mmHg

    ์ด์ƒ์ธ ์ž ๋“ฑ์˜ ์ด์ƒ์†Œ๊ฒฌ์ด ์žˆ๋Š” ์ž๋Š” ์—ฐ๊ตฌ๋Œ€์ƒ์—์„œ ์ œ์™ธํ•˜์˜€๋‹ค. ์ฒด์งˆ์ด

    ๊ทน๋„๋กœ ํ—ˆ์•ฝํ•˜๊ฑฐ๋‚˜ ์‹ฌ๊ฐํ•œ ์งˆ๋ณ‘์„ ์•“๊ณ  ์žˆ๋Š”์ž. ๊ฒฌ๋น„ํ†ต, ์š”ํ†ต, ์Šฌํ†ต์˜

    ์ œ์™ธ๊ธฐ์ค€์€ ๋‹ค์Œ๊ณผ ๊ฐ™๋‹ค.

    โ€ข ๊ฒฌ๋น„ํ†ต

    i. ๋ฐฉ์‚ฌ์„  ์†Œ๊ฒฌ์ƒ ์„ํšŒํ™” ๋ฐ ์—ผ์ฆ์„ฑ ๊ด€์ ˆ์—ผ์„ ๋™๋ฐ˜ํ•œ ํ™˜์ž

    ii. ์ข…์–‘ํ™˜์ž, ๊ธ‰์„ฑ ์™ธ์ƒ, ๊ณจ์ ˆ ๋ฐ ํƒˆ๊ตฌํ™˜์ž

    iii. ๊ฒฝ์ถ”์‹ ๊ฒฝ์˜ ๋ณ‘๋ณ€ ๋ฐ ๋งˆ๋น„๊ฐ€ ์žˆ๋Š” ํ™˜์ž

    โ€ข ์š”ํ†ต

    i. ์„ ์ฒœ์  ์ฒ™์ถ”์งˆํ™˜์ด๋‚˜ ์ฒ™์ถ”์ˆ˜์ˆ ์„ ๋ฐ›์€ ์ ์ด ์žˆ๋Š” ํ™˜์ž

    ii. ์ฒ™์ถ”์†์ƒ์ด ์–‘๋ฐฉ์—์„œ ์ง„๋‹จ๋œ ํ™˜์ž

    iii. ๊ธฐ์กด์— ์ด๋ฏธ ์š”ํ†ต์น˜๋ฃŒ๋ฅผ ๋ฐ›๊ณ  ์žˆ๋Š” ํ™˜์ž

    โ€ข ์Šฌํ†ต

    i. ํ‡ดํ–‰์„ฑ ๊ด€์ ˆ์—ผ, ๋ฅ˜๋งˆํ‹ฐ์Šค ๊ด€์ ˆ์—ผ๋“ฑ ์–‘๋ฐฉ์  ์ง„๋‹จ์ด ์žˆ๊ณ  ์ˆ˜์ˆ ์ด๋‚˜

    ์•ฝ๋ฌผ์š”๋ฒ•์œผ๋กœ ์–‘๋ฐฉ์  ์น˜๋ฃŒ๋ฅผ ๋ฐ›๊ณ  ์žˆ๋Š” ํ™˜์ž

  • 33

    4.2.2. ์—ฐ๊ตฌ์„ค๊ณ„

    ๋ณธ ์—ฐ๊ตฌ์˜ ์„ค๊ณ„๋Š” Figure 5 ์—์„œ์™€ ๊ฐ™์ด Screening์„ ํ†ต๊ณผํ•œ 7๋ช…์˜

    ๋น„์ฆ์„ ๋™๋ฐ˜ํ•œ ๊ณ ํ˜ˆ์•• ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ๋น„์ฆ์น˜๋ฃŒ๊ฐ€ ์ „ํ†ต์นจ๊ณผ ์ด์••์š”๋ฒ•์˜

    ํ˜ˆ์••๊ฐ•ํ•˜์น˜๋ฃŒ์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ์„ ์—ฐ๊ตฌํ•˜๊ธฐ ์œ„ํ•œ ์ž„์ƒ์‹คํ—˜์ด๋‹ค. ๋ชจ์ง‘๋œ 7๋ช…์˜

    ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ Informed Consent Form์— ์„œ๋ช…์„ ๋ฐ›๊ณ ๏ผŒ ์ฃผ 2ํšŒ ์ด 8ํšŒ์˜

    ์นจ์น˜๋ฃŒ, ์ด์••์น˜๋ฃŒ๋ฅผ ์‹œํ–‰ํ•˜๊ธฐ ์ „๊ณผ ์น˜๋ฃŒ ํ›„์˜ ํ†ต์ฆ๊ณผ ํ˜ˆ์••์„ ์ธก์ •ํ•˜์—ฌ ๋ณ‘ํ–‰

    ์น˜๋ฃŒ๊ฐ€ ํ˜ˆ์••๊ฐ•ํ•˜์— ๋ฏธ์น˜๋Š” ํšจ๊ณผ๋ฅผ ํ™•์ธํ•˜๊ณ , ๊ฐ•์••ํšจ๊ณผ๋ฅผ ์•Œ์•„๋ณด๊ณ ์ž ํ•˜์˜€๋‹ค.

  • 34

    Figure 5. ์—ฐ๊ตฌ ์„ค๊ณ„๋„ (Schemetic Diagram of Study Design)

  • 35

    4.2.3. ์น˜๋ฃŒ๋ฐฉ๋ฒ•

    ๋น„์ฆ์น˜๋ฃŒ์™€ ํ•จ๊ป˜ ์ „ํ†ต์นจ ์น˜๋ฃŒ์™€ ์ด์••์š”๋ฒ•์„ 4์ฃผ ๋™์•ˆ ์ฃผ 2ํšŒ ์‹œํ–‰ํ•˜์—ฌ

    ์น˜๋ฃŒ ์ „๊ณผ ์น˜๋ฃŒ ํ›„์˜ ํ˜ˆ์••๊ฐ•ํ•˜ ํšจ๊ณผ๋ฅผ ๋น„๊ตํ•˜๊ณ , ๋น„์ฆ์น˜๋ฃŒ๊ฐ€ ์ „ํ†ต์นจ์น˜๋ฃŒ์™€

    ์ด์••์š”๋ฒ• ๋ณ‘ํ–‰ ์น˜๋ฃŒ์˜ ๊ณ ํ˜ˆ์••์น˜๋ฃŒ์— ๋Œ€ํ•œ ์˜ํ–ฅ๋ ฅ ๊ด€๊ณ„๋ฅผ ๋น„๊ตํ•˜์˜€๋‹ค. ๋งค ์น˜๋ฃŒ

    ์ „ ํ˜ˆ์••์ธก์ • ์œ„ํ•ด 10๋ถ„๊ฐ„ ์•ˆ์ • ํ›„ ์ƒ์™„๋™๋งฅ์—์„œ ํ˜ˆ์••์„ ์ธก์ •ํ•˜์˜€๋‹ค. ์น˜๋ฃŒ ํ›„

    ์ฆ‰์‹œ ๋™์ผํ•œ ๋ฐฉ๋ฒ•์œผ๋กœ ํ˜ˆ์••์„ ์ธก์ •ํ•˜์—ฌ ๊ฒฐ๊ณผ๋ฅผ ๋น„๊ต ๋ถ„์„ํ•˜์˜€๋‹ค. ์ด์•• ์š”๋ฒ•์€

    ํ•ด๋‹น ํ˜ˆ์œ„์— ๋งค ์น˜๋ฃŒ์‹œ ํ•œ์ชฝ ๊ท€์— ๋ถ€์ฐฉํ•˜์—ฌ ํ•ด๋‹น ์ดํ˜ˆ ๋ถ€์œ„๋ฅผ ์ž๊ทนํ•˜๋„๋ก

    ํ•˜์˜€๋‹ค.

    ๊ณ ํ˜ˆ์••์„ ์ง„๋‹จ ๋ฐ›๊ณ  ํ˜ˆ์••์•ฝ์„ ๋ณต์šฉํ•˜๊ณ  ์žˆ๋Š” ํ™˜์ž์—๊ฒŒ๋Š” ๊ณ„์†์ ์œผ๋กœ ์•ฝ์„

    ๋ณต์šฉํ•˜๊ฒŒ ํ•˜์˜€๋‹ค.

    4.2.3.1. ์น˜๋ฃŒํ˜ˆ์œ„

    ๊ณ ํ˜ˆ์•• ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ ํ˜ˆ์œ„๋Š” ๊ณ ํ˜ˆ์•• ์น˜๋ฃŒ์— ์ž„์ƒํšจ๋Šฅ์ด ์žˆ๋Š” ํ˜ˆ์œ„์ธ74,75)

    ํƒœ์ถฉ(LV3), ์กฑ์‚ผ๋ฆฌ(ST36), ๊ณก์ง€(LI11), ํ•ฉ๊ณก(LI4) ํ˜ˆ์„ ์–‘์ชฝ์— ์ž์นจํ•˜๊ณ ,

    30๋ถ„๊ฐ„ ์œ ์นจํ•˜์˜€๋‹ค. ์ด์••์š”๋ฒ• ์œผ๋กœ๋„ ๊ณ ํ˜ˆ์••์— ์ž„์ƒํšจ๋Šฅ์ด ์žˆ๋Š”74,75) ์‹ ๋ฌธ,

    ๊ต๊ฐ, ๊ฐ•์••์ , ์‹ , ๊ฐ„, ๋‚ด๋ถ„๋น„ ํ˜ˆ์„ ๋ฐฐํ•ฉํ•˜์—ฌ ๋งค ์น˜๋ฃŒ์‹œ ํ•œ์ชฝ ๊ท€์— ๋ถ€์ฐฉํ•˜์—ฌ

    ํ•ด๋‹น ์ดํ˜ˆ ๋ถ€์œ„๋ฅผ ์ž๊ทนํ•˜์˜€๊ณ  ๋งค ์น˜๋ฃŒ ๋งˆ๋‹ค ๋ฐ˜๋Œ€ํŽธ ๊ท€๋กœ ๊ต์ฒดํ•˜์˜€๋‹ค.

    ํ™˜์ž์—๊ฒŒ๋Š” ๋งค์ผ 4ํšŒ ์ด์ƒ ํ•œ ์ž๋ฆฌ ๋งˆ๋‹ค 10์ดˆ์”ฉ ์ž๊ทนํ•˜๋„๋ก ํ•˜์˜€๋‹ค.

    ๋น„์ฆ์น˜๋ฃŒ์˜ ํ˜ˆ์ž๋ฆฌ๋Š” ์š”ํ†ต, ๊ฒฌํ†ต, ์Šฌํ†ต์— ๋”ฐ๋ผ ํ˜ˆ์ž๋ฆฌ๋ฅผ ๊ตฌ๋ณ„ํ•˜์—ฌ ์‚ฌ์šฉํ•˜์˜€๋‹ค.

    ์š”ํ†ต ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ ํ˜ˆ์œ„๋Š” ์ž„์ƒํšจ๋Šฅ์ด ์žˆ๋Š”165) ๊ณค๋ฅœ(UB60), ์™„์ˆœ1, 2, ์ง„์ •ํ˜ˆ,

  • 36

    ๋งˆ๊ด˜์ˆ˜ ํ˜ˆ์„ ์–‘์ชฝ์— ์ž์นจํ•˜๊ณ , 30๋ถ„๊ฐ„ ์œ ์นจํ•˜์˜€๋‹ค. ๊ฒฌํ†ต ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ ํ˜ˆ์œ„๋Š”

    ์ž„์ƒํšจ๋Šฅ์ด ์žˆ๋Š”166) ์กฐ๊ตฌ(ST38), ์‹ ๊ด€, ์กฑ์ฒœ๊ธˆ, ์กฑ์˜ค๊ธˆ ํ˜ˆ์„ ์–‘์ชฝ์— ์ž์นจํ•˜๊ณ ,

    30๋ถ„๊ฐ„ ์œ ์นจํ•˜์˜€๋‹ค. ์Šฌํ†ต ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ ํ˜ˆ์œ„๋Š” ์ž„์ƒํšจ๋Šฅ์ด ์žˆ๋Š”167) ๋…๋น„, ์Šฌ์•ˆ,

    ํ˜ˆํ•ด, ์–‘๊ตฌ, ๊ณก์ฒœ, ์Šฌ์–‘๊ด€ ํ˜ˆ์„ ํ™˜์ธก์— ์ž์นจํ•˜๊ณ , 30๋ถ„๊ฐ„ ์œ ์นจํ•˜์˜€๋‹ค.

    Table 1. Location and Indication of Acupuncture Points

    Acupuncture point

    Function

    Anatomical location

    ํƒœ์ถฉ(LR3)

    ๋‘ํ†ต, ํ˜„ํ›ˆ, ์‹ค๋ฉด, ๋ชฉ์ ์ข…ํ†ต

    ์กฑ๋ฐฐ ์ œ 1,2 ์ค‘์กฑ๊ณจ ์ ‘ํ•ฉ๋ถ€ ์•ž ์š”ํ•จ๋ถ€

    ์กฑ์‚ผ๋ฆฌ(ST36)

    ์œ„ํ†ต, ์ˆ˜์ข…, ์ค‘ํ’, ๋‘ํ›ˆ, ์‹ค๋ฉด

    ๋…๋น„ ์•„๋ž˜ 3์ดŒ, ์ „๊ฒฝ๊ณจ๋ฆ‰์˜ ์™ธ์ธก 1ํšก์ง€, ์ „๊ฒฝ๊ณจ๊ทผ ์†

    ํ•ฉ๊ณก(LI4)

    ๋‘ํ†ต, ์ƒ์ง€๋™ํ†ต, ์œ„๋น„, ํ๊ฒฝ, ๊ตฌ์•ˆ์™€์‚ฌ

    ์ˆ˜๋ฐฐ ์ œ 1๊ณผ ์ œ 2 ์ค‘์ˆ˜๊ณจ ์‚ฌ์ด, ๋Œ€๋žต ์ œ2์ค‘์ˆ˜๊ณจ์˜ ์š”์ธก ์ค‘์•™

    ๊ณก์ง€(LI11)

    ๋‘ํ†ต, ๋ฐ˜์‹ ๋ถˆ์ˆ˜, ์ƒ์ง€๋ถˆ์ˆ˜, ๋‚˜๋ ฅ, ํ’์ง„

    ์ฒ™ํƒœ๊ณผ ์ƒ์™„๊ณจ ์™ธ์ธก์ƒ๊ณผ ์—ฐ๊ฒฐ์„  ์œ„ ์ค‘์•™

  • 37

    Table 2. Location and Indication of Auricular Points

    Auricular point

    Function

    Anatomical location

    Neurogate(์‹ ๋ฌธ)

    ์ง„์ •, ์•ˆ์‹ , ์ง€ํ†ต, ์ฒญ์—ด

    ๋Œ€์ด๋ฅœ์ƒ, ํ•˜๊ฐ๋ถ„๊ณ„์ฒ˜, ์‚ผ๊ฐ์™€์˜ ์™ธ์ธก 1/3์ฒ˜

    Sympathetic(๊ต๊ฐ)

    ํ•ด๊ฒฝ์ง„ํ†ต, ์ž์Œ๋ถ€์–‘, ๋‚ด์žฅ๋™ํ†ต, ์‹ฌ๊ณ„, ์žํ•œ, ๋„ํ•œ (์ž์œจ์ง„๊ฒฝ๊ธฐ๋Šฅ๋ฌธ๋ž€)

    ํ•˜์ด๋ฅœ๊ฐ์ƒ๋ จ๊ณผ ์ด๋ฅœ๋‚ด์ธก์ด ๊ต์ฐจ๋˜๋Š”๊ณณ

    Kidney(์‹ )

    ์‹ ์—ผ, ์š”ํ†ต, ์ด๋ช…, ์–‘์œ„

    ๋Œ€์ด๋ฅœํ•˜๊ฐ์˜ ์ƒ๋ จ, ์†Œ์žฅํ˜ˆ์˜ ์ง์ƒ๋ฐฉ

    Liver(๊ฐ„)

    ๊ธ‰๋งŒ์„ฑ ๊ฐ„์—ผ, ๋‘ํ†ต, ํ˜„ํ›ˆ, ํ˜ผ์ˆ˜, ์•ˆ๋ณ‘

    ์œ„์™€ ์‹ญ์ด์žฅํ˜ˆ์˜ ํ›„๋ฐฉ

    Lower Blood Pressure(๊ฐ•์••์ )

    ํ‰๊ฐ„์‹ํ’ / ๊ณ ํ˜ˆ์•• ์‚ผ๊ฐ์™€์˜ ๋ฐ”๊นฅ ์ƒ๊ฐ

    Endocrine(๋‚ด๋ถ„๋น„)

    ๋‚ด๋ถ„๋น„๊ณต๋Šฅ๋ฌธ๋ž€๋ณ‘์ฆ ์ด๊ฐ‘๊ฐ•์˜ ์ €๋ถ€, ๋ณ‘๊ฐ„์ ˆํ” ๋‚ด

  • 38

    Table 3. Acupuncture Points Used for the Treatment of Lower Back Pain

    Acupuncture point

    Function

    Anatomical location

    ๊ณค๋ฅœ(UB60)

    ๋‘ํ†ต, ํ•ญ๊ฐ•, ๋ชฉํ˜„, ๋น„๋‰ต, ๊ฒฌ๋ฐฐ์š”ํ‡ดํ†ต, ๊ฐ๊ทผ์ข…ํ†ต 168)

    ์™ธ๊ณผ์™€ ์กฑ๊ทผ๊ฑด ์‚ฌ์ด์˜ ์š”ํ•จ๋ถ€

    ์™„์ˆœ 1, 2

    ์‹ (่…Ž)์„ฑ๋‘ํ†ต, ์ขŒ๊ณจ์‹ ๊ฒฝํ†ต, ์‹ ์žฅ์—ผ, ๋ฐฐํ†ต, ์š”ํ†ต 169)

    ํ›„๊ณ„ํ˜ˆ์ด ์™„์ˆœ 1ํ˜ˆ์ด๊ณ , ๊ทธ 1์ดŒ ๋’ค๊ฐ€ ์™„์ˆœ2ํ˜ˆ

    ์ง„์ •ํ˜ˆ

    ์ฒ™์ถ”์งˆ๋ณ‘์ด๋‚˜ ์š”ํ†ต, ์†Œ์•„๋ชฝ๊ฒฝ, ๋ถˆ๋ฉด, ์‚ฌ์ง€์‹ ๊ฒฝ๋งˆ๋น„, ์–‘ํ‡ด์‚ฐ๋ฌด๋ ฅ, ์‚ฌ์ง€๊ฒฝ๋ จ 169)

    ์ธ๋‹นํ˜ˆ ์ง์ƒ๋ฐฉ์— ์œ„์น˜ํ•˜๋ฉฐ, ๋…๋งฅ๊ฒฝ๋ฝ์ƒ์— ์œ„์น˜

    ๋งˆ์พŒ์ˆ˜

    ๋ฐฉ๊ด‘๊ฒฐ์„, ๋ฐฉ๊ด‘์—ผ, ์†Œ๋ณ€๋นˆ์‚ญ, ์š”์ฒ™์ถ”๊ณจํ†ต, ๋น„์—ผ 169)

    ์•ˆ๋ฉด์˜ ๊ถŒ๊ณจ ์ฆ‰ ๊ด‘๋Œ€๋ผˆ ์•„๋ž˜

  • 39

    Table 4. Acupuncture Points Used for the Treatment of Shoulder Pain

    Acupuncture point

    Function

    Anatomical location

    ์กฐ๊ตฌ(ST38)

    ์Šฌ๊ฒฝ๋งˆ๋ชฉ ๋ฐ ์‚ฐํ†ต, ์กฑ์™„๋ถˆ์ˆ˜,

    ๊ฒฌํ†ต๋ถˆ๊ฑฐ, ์™„๋ณต๋„ํ†ต168)

    ์ƒ๊ฑฐํ—ˆ ์งํ•˜ 2์ดŒ, ๋…๋น„์™€

    ํ•ด๊ณ„ ์—ฐ๊ฒฐ์„ ์ƒ์˜ ์ค‘์•™

    ์‹ ๊ด€

    ์œ„์‚ฐ๊ณผ๋‹ค, ๋„์‹์ฆ, ์•ˆ๊ตฌ์™œ์‚ฌ,

    ์‚ฐ๊ด‘, ๋นˆํ˜ˆ, ์ „๊ฐ„๋ณ‘, ์‹ ๊ฒฝ๋ณ‘,

    ๋‘ํ†ต, ์š”์‚ฐ, ๋ฏธ๋ฆ‰๊ณจํ†ต, ๋น„๊ณจํ†ต,

    ๋‘ํ›ˆ, ๋ฐฐํ†ต, ์ขŒ๊ณจ์‹ ๊ฒฝํ†ต, ๋ฐ

    ์–‘์ˆ˜์˜ ๋ฐœ๋งˆ, ๋™ํ†ต๊ณผ ๊ฒฌ๋น„ํ†ต ๋ฐ

    ๊ฒฌ๋น„๋ถˆ๊ฑฐ์— ํŠนํšจ170)

    ์Œ๋ฆ‰์ฒœ ์งํ•˜ 1.5์ดŒ

    ์กฑ์ฒœ๊ธˆ

    ๊ธ‰์„ฑ์žฅ์—ผ, ์–ด๊ณจ์ž์ฃผํ›„๊ด€,

    ํŽธ๋„์„ ์—ผ, ํ›„ํ†ต์ƒ์ฐฝ, ํ›„์—ผ,

    ๊ฐ‘์ƒ์„ ์ข…, ๊ฒฌ๋ฐฐํ†ต170)

    ์ธกํ•˜์‚ผ๋ฆฌ ์™ธ๋ฐฉ 5ํ‘ผ ์—์„œ

    ์งํ•˜ 2์ดŒ

    ์กฑ์˜ค๊ธˆ

    ๊ธ‰์„ฑ์žฅ์—ผ, ์–ด๊ณจ์ž์ฃผํ›„๊ด€,

    ํŽธ๋„์„ ์—ผ, ํ›„ํ†ต์ƒ์ฐฝ, ํ›„์—ผ,

    ๊ฐ‘์ƒ์„ ์ข…, ๊ฒฌ๋ฐฐํ†ต170)

    ์กฑ์ฒœ๊ธˆ ์งํ•˜ 2์ดŒ

  • 40

    Table 5. Acupuncture Points Used for the Treatment of Knee Pain168)

    Acupuncture point

    Function

    Anatomical location

    ๋…๋น„(ST35)

    ์Šฌํ†ต, ๋งˆ๋ชฉ, ๊ฐ๊ธฐ, ๊ตด์‹ ๋ถˆ๋ฆฌ

    ์Šฌ๊ฐœ๊ณจํ•˜์—ฐ, ์Šฌ๊ฐœ์ธ๋Œ€์™ธ์ธก ์š”ํ•จ๋ถ€

    ์Šฌ์•ˆ(EX36)

    ์Šฌํ†ต, ํ•˜์ง€๋ฌด๋ ฅ

    ์Šฌ๊ฐœ์ธ๋Œ€์–‘์ธก์š”ํ•จ๋ถ€

    ํ˜ˆํ•ด(SP10)

    ๋Œ€ํ‡ด๋‚ด์ธกํ†ต ์Šฌ๊ฐœ๊ณจ๋‚ด์ƒ์—ฐ์œ„2์ดŒ

    ์–‘๊ตฌ(ST34)

    ์Šฌ๊ฒฝ๋น„ํ†ต, ํ•˜์ง€๋ถˆ์ˆ˜ ์Šฌ๊ฐœ๊ณจ์™ธ์ƒ๋ฐฉ2์ดŒ

    ๊ณก์ฒœ(LV8) ์Šฌ๊ฒฝ๋‚ด์ธกํ†ต ๋ฐ˜๋ง‰์–‘๊ทผ๊ณผ ๋ฐ˜๊ฑด์–‘๊ทผ์˜ ์ •์ง€๋ถ€์˜ ์ „์—ฐ

    ์Šฌ์–‘๊ด€(GB33)

    ์Šฌ์ค‘ํ†ต, ํ•˜ํ‡ด๋งˆ๋ชฉ,

    ์–‘๋ฆ‰์ฒœ ์ƒ3์ดŒ, ์Šฌ๊ด€์ ˆ ์™ธ์ธก์˜ ๊ทผ๊ณผ ๊ณจ ์‚ฌ์ด

  • 41

    Figure 6. Ear Acupuncture Points168)

  • 42

    Figure 7. Ear Nerve Distribution71,125)

    4.2.3.2. ์‹œ์ˆ ๋ฐฉ๋ฒ•

    ์ƒ๊ธฐ์— ๋ช…์‹œํ•œ ํ˜ˆ์ž๋ฆฌ ํƒœ์ถฉ(LV3), ์กฑ์‚ผ๋ฆฌ(ST36), ๊ณก์ง€(LI11),

    ํ•ฉ๊ณก(LI4)๋“ค์— ํ˜ˆ์œ„์— ๋”ฐ๋ผ 20mm์ด๋‚ด์˜ ๊นŠ์ด๋กœ ํ‰๋ณดํ‰์‚ฌ๋กœ ์ทจํ˜ˆํ•˜๊ณ , 30๋ถ„๊ฐ„

    ์œ ์นจํ•˜์˜€๋‹ค. ์œ„ ํ˜ˆ์ž๋ฆฌ๋“ค์„ ์ทจํ˜ˆ ํ›„ ํŠน์ • ์ดํ˜ˆ์— ์ผํšŒ์šฉ ์™•๋ถˆ๋ฅ˜ํ–‰์ž๋ฅผ

    ๋ถ€์ฐฉํ•˜์—ฌ 1๋ถ„๊ฐ„ ์ž๊ทน์„ ์ฃผ์—ˆ๋‹ค. ์ดํ›„ ๋‹ค์Œ ์น˜๋ฃŒ ์ผ๊นŒ์ง€ ํ™˜์ž์—๊ฒŒ ๊ฐ ์ดํ˜ˆ์˜

    ๋ถ€์œ„๋ฅผ ๋งค์ผ 4ํšŒ ์ด์ƒ ๊ฐ ํ˜ˆ ์ž๋ฆฌ๋งˆ๋‹ค 1๋ถ„๊ฐ„ ์•„ํ”„์ง€ ์•Š์„ ์ •๋„๋กœ ์••๋ ฅ์„

    ๊ฐ€ํ•˜์—ฌ ์ž๊ทนํ•˜๋„๋ก ํ•˜์˜€๋‹ค.

  • 43

    4.2.3.3 ์น˜๋ฃŒ ์ฐธ๊ฐ€์ž

    ๋ณธ ์—ฐ๊ตฌ์˜ ์น˜๋ฃŒ๋Š” ํ•œ์˜์‚ฌ 1์ธ์ด ๋ชจ๋‘ ์‹œํ–‰ํ•˜์˜€๋‹ค.

    4.2.4. ์ธก์ •๋ฐฉ๋ฒ•

    ๋ณธ ์—ฐ๊ตฌ์—์„œ ์น˜๋ฃŒํšจ๊ณผ ์ธก์ • ๋ฐฉ๋ฒ•์œผ๋กœ ๋Œ€์ƒ์ž์˜ ์ƒ์™„์—์„œ ์ „์ž์‹ ์ƒ์™„ํ˜•

    ํ˜ˆ์••๊ณ„๋ฅผ ์ด์šฉํ•˜์—ฌ ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••๏ผŒ์ด์™„์ด ํ˜ˆ์••์„ ์น˜๋ฃŒ ์ „๊ณผ ์น˜๋ฃŒ ํ›„

    ์ธก์ •ํ•˜์˜€๋‹ค. ์น˜๋ฃŒ์ „ ์ธก์ •์‹œ ๋Œ€์ƒ์ž๋ฅผ 10๋ถ„๊ฐ„ ๋ฐ˜๋“ฏ์ด ๋ˆ„์šด ์ƒํƒœ์—์„œ ํœด์‹ํ•˜๊ฒŒ

    ํ•œ ํ›„ ์•ˆ์ •์ƒํƒœ์—์„œ ํ˜ˆ์••์„ ์ธก์ • ํ•˜๊ณ  ์น˜๋ฃŒ ํ›„์—๋Š” ๋ฐ”๋กœ ์ธก์ •ํ•˜์˜€๋‹ค.

    4.2.5. ํ†ต๊ณ„๋ถ„์„

    ์น˜๋ฃŒ ํšจ๊ณผ๋ฅผ ๋น„๊ต ๋ถ„์„ ํ•˜๊ธฐ ์œ„ํ•ด ์น˜๋ฃŒ ์ „ํ›„์˜ ํ˜ˆ์•• ์ธก์ • ๊ฒฐ๊ณผ๋ฅผ (ํ‰๊ท )

    ยฑ (ํ‘œ์ค€ํŽธ์ฐจ)๋กœ ํ‘œ์‹œํ•˜๊ณ , ํ†ต๊ณ„ ๋ถ„์„์€ Statistical Program for Social

    Science (SPSS) Version 22.0 Window ์šฉ์„ ์‚ฌ์šฉํ•˜์˜€๋‹ค. ๋ชจ๋“  ํ†ต๊ณ„ ๋ถ„์„์€

    ์‹ ๋ขฐ๋„ 95% ์ˆ˜์ค€์—์„œ p

  • 44

    V. RESULTS AND DISCUSSION

    ๋ณธ ์—ฐ๊ตฌ๋Š” ๋น„์ฆ์„ ๊ฒธํ•œ ๊ณ ํ˜ˆ์•• ํ™˜์ž์—์„œ ๋น„์ฆ ์น˜๋ฃŒ๊ฐ€ ์ „ํ†ต์นจ๊ณผ

    ์ด์••์š”๋ฒ•๋ฅผ ๋ณ‘์šฉํ•œ ํ˜ˆ์•• ๊ฐ•ํ•˜ ์น˜๋ฃŒ์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ์„ ํ‰๊ฐ€ํ•˜๊ธฐ ์œ„ํ•˜์—ฌ ์น˜๋ฃŒ

    ๋‹จ๊ณ„๋ณ„ ํ˜ˆ์••์„ ์ธก์ •ํ•˜์—ฌ ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••, ์ด์™„๊ธฐ ํ˜ˆ์••, ๊ทธ๋ฆฌ๊ณ  ํ†ต์ฆ ๋ณ€ํ™”์˜ ์น˜๋ฃŒ

    ์ง€์† ํšจ๊ณผ ๋ฐ 8ํšŒ ์น˜๋ฃŒ ํ›„์˜ ์ตœ์ข… ์—ฐ๊ตฌ ๊ฒฐ๊ณผ๋ฅผ ๋น„๊ต ๋ถ„์„ํ•˜์˜€๋‹ค. ๋ถ„์„ ๊ฒฐ๊ณผ๋Š”

    ์ˆ˜์ง‘ํ•œ ์ž๋ฃŒ์— ๋Œ€ํ•˜์—ฌ ๊ฐ ๋‹จ๊ณ„๋ณ„๋กœ ์ •๊ทœ์„ฑ ๊ฒ€์ •์„ ์‹œํ–‰ํ•œ ํ›„ ์‚ฐ์ถœํ•˜์˜€์œผ๋ฉฐ,

    ๋ชจ๋“  ํ†ต๊ณ„๋ถ„์„์€ ฮฑ=0.05 ์ˆ˜์ค€์—์„œ ํ‰๊ท ๊ฐ„ ์ฐจ์ด์— ๋Œ€ํ•œ ์œ ์˜์„ฑ(statistical

    significance)์„ ๊ฒ€์ •ํ•˜์˜€๋‹ค.

    5.1. ์—ฐ๊ตฌ ๋Œ€์ƒ์ž์˜ ์ผ๋ฐ˜ ํŠน์„ฑ

    ๋ณธ ์—ฐ๊ตฌ์— ์ฐธ์—ฌํ•œ ์ด 7๋ช…์˜ ์—ฐ๊ตฌ ๋Œ€์ƒ๋“ค์˜ ๋‚˜์ด, ์„ฑ๋ณ„, ์ธ์ข…, ๊ฐ€์กฑ๋ ฅ,

    ๊ฒฐํ˜ผ, ์ง์žฅ, ํก์—ฐ, ์œ ๋ณ‘๊ธฐ๊ฐ„ ๋ฐ ์•ฝ๋ฌผ ๋ณต์šฉ์˜ ๋‚ด์šฉ์„ Table 6 ์™€ ๊ฐ™์ด

    ๋‚˜ํƒ€๋‚ด์—ˆ๋‹ค. 7๋ช…์˜ ์—ฐ๋ น ๋ถ„ํฌ๋Š” 34์„ธ์—์„œ 85์„ธ ์‚ฌ์ด๋กœ ํ‰๊ท ์—ฐ๊ฒฝ์€ 57์„ธ

    ์ด์—ˆ์œผ๋ฉฐ ๋‚จ์„ฑ์ด 4์ธ, ์—ฌ์„ฑ์ด 3์ธ ์ด์—ˆ๋‹ค. ์œ ๋ณ‘๊ธฐ๊ฐ„์€ 2๋…„์—์„œ 10๋…„

    ์ด์ƒ์ด์—ˆ์œผ๋ฉฐ ํ‰๊ท  ์œ ๋ณ‘๊ธฐ๊ฐ„์€ 7๋…„ ์ด์—ˆ๋‹ค. 7์ธ ์ค‘ 2์ธ ์€ ๊ณ ํ˜ˆ์•• ๊ฐ€์กฑ๋ ฅ์ด

    ์žˆ๊ณ  5์ธ์€ ์—†์–ด 29%์˜ ๊ฐ€์กฑ๋ ฅ์„ ๋ณด์˜€๋‹ค.

    ๋”ฐ๋ผ์„œ ํ–ฅํ›„์˜ ๋ณ€์ˆ˜์— ๋Œ€ํ•œ ๋ถ„์„์€ ์ •๊ทœ์„ฑ ๋ถ„์„์„ ํ†ตํ•ด์„œ ๋น„๋ชจ์ˆ˜ ํ†ต๊ณ„๋ฅผ

    ์‹œํ–‰ํ•˜์˜€๋‹ค.

  • 45

    Table 6. Demographic Characteristics of the Subjects

    Characteristic Score

    Mean Age(years) 57

    Gender Male

    Female

    4

    3

    Married/ Living together 5 out of 7

    Employed 5 out of 7

    Smoking 0

    Mean Duration of HTN 7 years

    Medication use Yes

    No

    3 out of 7

    4 out of 7

    Family History in HTN 29 %

    Ethnicity

    Hispanic

    Asian

    2

    5

    5.2. ์ธก์ •์น˜ ๋ณ€ํ™” ๋ฐ ๋ถ„์„

    5.2.1. ๊ฐ ํšŒ์ˆ˜๋ณ„ ์น˜๋ฃŒ ์ „ํ›„ ํ˜ˆ์•• ์ธก์ •๊ฐ’์˜ ๋ณ€ํ™” ๋ฐ ๋ถ„์„

    ํ˜ˆ์•• ๊ฐ•ํ•˜ ํšจ๊ณผ๋ฅผ ์•Œ์•„๋ณด๊ธฐ ์œ„ํ•˜์—ฌ ๋งคํšŒ ์น˜๋ฃŒ ์ „ ํ›„์˜ ํ˜ˆ์••์„ ์ธก์ •ํ•œ

    ๊ฐ’์— ๋Œ€ํ•ด์„œ ์ •๊ทœ์„ฑ ๊ฒ€์ •์„ ์‹ค์‹œ ํ•˜์˜€๋‹ค. ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••์—์„œ๋Š” 6์ฐจ ์น˜๋ฃŒ์—์„œ

    ์ •๊ทœ์„ฑ(normality)์„ ๋งŒ์กฑํ•˜์ง€ ๋ชปํ•˜์˜€์œผ๋ฏ€๋กœ ๋น„๋ชจ์ˆ˜์  ๊ฒ€์ • ๋ฐฉ๋ฒ•

    (nonparametric test)์ธ Wilcoxon Signed-Rank Test ๋ฅผ ์ ์šฉํ•˜์—ฌ p=0.018

    ์˜ ๊ฒฐ๊ณผ๋ฅผ ์–ป์—ˆ๋‹ค. ์ด์™ธ์˜ ์น˜๋ฃŒ์—์„œ๋Š” ์ •๊ทœ์„ฑ์ด ์ธ์ •๋˜์—ˆ์œผ๋ฏ€๋กœ Paired t-

  • 46

    Test๋กœ ๊ฐ•์•• ํšจ๊ณผ์˜ ์œ ์˜์„ฑ์„ Table 7์— ๋‚˜ํƒ€๋‚ด์—ˆ๊ณ  ์ด์™„๊ธฐ ํ˜ˆ์••์˜ ์œ ์˜์„ฑ์€

    Table 8์— ๋‚˜ํƒ€๋‚ด์—ˆ๋‹ค. ๋˜ํ•œ ์น˜๋ฃŒ ์ „ ํ›„์˜ ๋ณ€ํ™”๋ฅผ Figure 7 ๊ณผ Figure 8 ์—

    ๋‚˜ํƒ€๋‚ด์—ˆ๋‹ค. ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••์˜ ๋งค์ฐจ ์น˜๋ฃŒ์‹œ ํ‰๊ท  ๋ณ€ํ™”๋Ÿ‰(๊ฐ์†Œ๋Ÿ‰)์„ ๋ถ„์„ํ•ด ๋ณด๋ฉด,

    1์ฐจ ์น˜๋ฃŒ ํ›„ ์ˆ˜์ถ•๊ธฐ์••์€ ๊ฐ๊ฐ 153.6 ยฑ 6.5 mmHg ์—์„œ142.4 ยฑ 12.7 mmHg

    (p=0.022), 2์ฐจ ์น˜๋ฃŒ์ „ ์น˜๋ฃŒ ํ›„ ๊ฐ๊ฐ 153.6 ยฑ 12.8 mmHg ์—์„œ 142.3 ยฑ

    12.7 mmHg (p=0.001), 3์ฐจ ์น˜๋ฃŒ ์ „ 146.4 ยฑ 13.6 mmHg ์—์„œ ์น˜๋ฃŒ ํ›„

    139.0 ยฑ 14.1 mmHg (p=0.004), 4์ฐจ, 5์ฐจ, 6์ฐจ, 7์ฐจ, ๋ฐ 8์ฐจ ์น˜๋ฃŒ ์ „ ํ›„์˜

    ์ˆ˜์ถ•๊ธฐ ์••์€ ๊ฐ๊ฐ 144.1 ยฑ 13.4 mmHg ์—์„œ 137.9 ยฑ 13.4 mmHg

    (p=0.003), 141.9 ยฑ 12.5 mmHg ์—์„œ 134.1 ยฑ 13.9 mmHg (p=0.005), 139.7

    ยฑ 13.8 mmHg ์—์„œ 134.9 ยฑ 12.7 mmHg (p=0.018), 138.6 ยฑ 12.4 mmHg

    ์—์„œ 132.9 ยฑ 14.0 mmHg (p=0.029), 137.4 ยฑ 12.7 mmHg ์—์„œ 130.6 ยฑ

    8.2 mmHg (p=0.043) ๋กœ ๋งคํšŒ ๊ฐ์†Œ ํ•˜์˜€์œผ๋ฉฐ ๋ชจ๋‘ ์œ ์˜์„ฑ์„ ๋ณด์˜€๋‹ค.

    ์ด์™„๊ธฐ ํ˜ˆ์••๋„ ๋งˆ์ฐฌ๊ฐ€์ง€๋กœ 1์ฐจ ์—์„œ 8์ฐจ๊นŒ์ง€ ์น˜๋ฃŒ ์ „ ํ›„์˜ ํ˜ˆ์•• ๋ณ€ํ™”๋Š”

    ๊ฐ๊ฐ 89.7 ยฑ 4.9 mmHg ์—์„œ 81.7 ยฑ 3.8 mmHg (p=0.000), 84.9 ยฑ 4.6

    mmHg ์—์„œ 76.3 ยฑ 6.2 mmHg (p=0.002), 81.0 ยฑ 4.7 mmHg ์—์„œ 74.6 ยฑ

    6.1 mmHg (p=0.001), 78.1 ยฑ 7.8 mmHg ์—์„œ 73.6 ยฑ6.0 mmHg (p=0.019),

    76.7 ยฑ 5.2 mmHg ์—์„œ 72.0 ยฑ 5.9 mmHg (p=0.002), 75.9 ยฑ 5.3 mmHg

    ์—์„œ 72.6 ยฑ 3.6 mmHg (p=0.012), 74.3 ยฑ 3.7 mmHg ์—์„œ 71.3 ยฑ 4.4

    mmHg (p=0.018), ๋ฐ 74.6 ยฑ 4.1 mmHg ์—์„œ 71.9 ยฑ 5.2 mmHg (p=0.034)

    ๋กœ ๊ฐ์†Œ๋ฅผ ๋ณด์ด๋ฉฐ ๋ชจ๋“  ํšŒ์ฐจ์—์„œ ๋งค ์น˜๋ฃŒ ์ „๊ณผ ์น˜๋ฃŒ ํ›„ ๋ณ€ํ™” ๊ฐ’์ด p

  • 47

    ์œผ๋กœ ์œ ์˜์„ฑ์„ ๋‚˜ํƒ€๋ƒˆ๋‹ค.

    Table 7. Change of Systolic Blood Pressure

    No. of Tx (Days of Interval)

    Before After Difference p-value*

    1st(0d) 153.6 ยฑ 6.5 142.4 ยฑ 12.7 11.1 ยฑ 9.6 0.022

    2nd(3d) 153.6 ยฑ 12.8 142.3 ยฑ 12.7 11.3 ยฑ 4.4 0.001

    3rd(4d) 146.4 ยฑ 13.6 139.0 ยฑ 14.1 7.4 ยฑ 4.4 0.004

    4th(3d) 144.1 ยฑ 13.4 137.9 ยฑ 13.4 6.3 ยฑ 3.5 0.003

    5th(4d) 141.9 ยฑ 12.5 134.1 ยฑ 13.9 7.7 ยฑ 4.8 0.005

    6th(3d) 139.7 ยฑ 13.8 134.9 ยฑ 12.7 4.9 ยฑ 4.7 0.018**

    7th(4d)

    8th(3d)

    138.6 ยฑ 12.4

    137.4 ยฑ 12.7

    132.9 ยฑ 14.0

    130.6 ยฑ 8.2

    5.7 ยฑ 5.3

    6.9 ยฑ 7.1

    0.029

    0.043

    *Paired Sample T-Test **Wilcoxon Signed-Rank Test

  • 48

    Table 8. Change of Diastolic Blood Pressure

    No. of Tx (Days of Interval)

    Before After Difference p-value*

    1st(0d) 89.7 ยฑ 4.9 81.7 ยฑ 3.8 8.0 ยฑ 3.1 0.000

    2nd(3d) 84.9 ยฑ 4.6 76.3 ยฑ 6.2 8.6 ยฑ 2.6 0.002

    3rd(4d) 81.0 ยฑ 4.7 74.6 ยฑ 6.1 6.4 ยฑ 2.6 0.001

    4th(3d) 78.1 ยฑ 7.8 73.6 ยฑ 6.0 4.6 ยฑ 3.8 0.019

    5th(4d) 76.7 ยฑ 5.2 72.0 ยฑ 5.9 4.7 ยฑ 2.3 0.002

    6th(3d) 75.9 ยฑ 5.3 72.6 ยฑ 3.6 3.3 ยฑ 2.4 0.012

    7th(4d)

    8th(3d)

    74.3 ยฑ 3.7

    74.6 ยฑ 4.1

    71.3 ยฑ 4.4

    71.9 ยฑ 5.2

    3.0 ยฑ 2.4

    2.7 ยฑ 2.6

    0.018

    0.034

    *Paired Sample T-Test

  • 49

    Figure 8. Change of Systolic Blood Pressure

    Figure 9. Change of Diastolic Blood Pressure

  • 50

    5.2.2. ๊ฐ ํšŒ์ˆ˜๋ณ„ ์น˜๋ฃŒ ์ „ํ›„ ํ†ต์ฆ ์ธก์ •๊ฐ’์˜ ๋ณ€ํ™” ๋ฐ ๋ถ„์„

    1 ์ฐจ์—์„œ 8 ์ฐจ์— ๊ฑธ์นœ ์น˜๋ฃŒ ์ „ํ›„ VAS (Visual Analogue Scale) ์ธก์ •์น˜๋ฅผ

    ๋น„๊ตํ•˜์˜€์„ ๋•Œ ๋งคํšŒ ํ‰๊ท  1.0 ยฑ 0.7 ์˜ ๊ฐ์†Œ ํญ์„ ๋‚˜ํƒ€๋‚ด์—ˆ๋‹ค. ํ‘œ๋ณธ์ˆ˜์˜

    ํ•œ๊ณ„์ƒ ์ •๊ทœ์„ฑ ๊ฒ€์ •์„ ๊ฑฐ์นœ ๊ฒฐ๊ณผ, 1์ฐจ ์—์„œ 4์ฐจ๊นŒ์ง€ ์ •๊ทœ์„ฑ์ด ์ธ์ •๋˜์—ˆ์œผ๋ฏ€๋กœ

    Paired t-Test ๋ฅผ ์‹ค์‹œํ•˜์—ฌ ์น˜๋ฃŒ ์ „ ํ›„์˜ ํ†ต์ฆ์— ๋Œ€ํ•œ ์œ ์˜์„ฑ์„ ๊ฒ€์ •ํ•˜์˜€๊ณ ,

    ์ •๊ทœ๋ถ„ํฌ๊ฐ€ ์ธ์ •๋˜์ง€ ์•Š์€ 5์ฐจ ์—์„œ 8์ฐจ ์น˜๋ฃŒ์— ์žˆ์–ด์„œ๋Š” Wilcoxon Signed-

    rand test ์˜ ๋น„๋ชจ์ˆ˜ ๊ฒ€์ •(nonparametric analysis)์„ ์‚ฌ์šฉํ•˜์—ฌ ๊ฐ ๋‹จ๊ณ„๋ณ„

    ์‹คํ—˜ ์ „ ํ›„์˜ ์น˜๋ฃŒํšจ๊ณผ์— ๋Œ€ํ•œ ์œ ์˜์„ฑ์„ ๊ฒ€์ •ํ•œ ๊ฒฐ๊ณผ๋ฅผ ๋‚˜ํƒ€๋‚ด์—ˆ๋‹ค. ํ†ต์ฆ์˜

    ๋งคํšŒ ํ‰๊ท  ๋ณ€ํ™”๋Ÿ‰(๊ฐ์†Œ๋Ÿ‰)์„ ๋ถ„์„ํ•ด ๋ณด๋ฉด, 1์ฐจ ์น˜๋ฃŒ์ „ ํ†ต์ฆ์€ 7.1 ยฑ 1.1 ๋กœ

    ์น˜๋ฃŒํ›„ 5.1 ยฑ 1.3 (p=0.000) ๊ณผ ๋น„๊ตํ•ด์„œ 2.0 ยฑ 0.7 ์˜ ๊ฐ์†Œ ํญ์„

    ๋‚˜ํƒ€๋‚ด์—ˆ๊ณ , 2์ฐจ ์น˜๋ฃŒ ์ „ํ›„์˜ ํ†ต์ฆ์€ 6.0 ยฑ 1.4 ์™€ 4.7 ยฑ 1.0 ๋กœ 1.3 ยฑ 0.9

    (p=0.004)์˜ ๊ฐ์†Œ๋Ÿ‰์„ ๋ณด์˜€๋‹ค. ๋˜ํ•œ 3์ฐจ ์™€ 4์ฐจ ์น˜๋ฃŒ์—์„œ 5.4 ยฑ 1.1 ์—์„œ

    4.6 ยฑ 1.1 ๋กœ 0.9 ยฑ 0.9 (p=0.045) ์™€ 5.1 ยฑ 1.1 ์—์„œ 4.0 ยฑ 1.0 ๋กœ 1.1 ยฑ

    0.7 (p=0.005)์˜ ์œ ์˜์„ฑ์„ ๋ณด์˜€๋‹ค. ํ•œํŽธ, ๋น„๋ชจ์ˆ˜ ๊ฒ€์ •์„ ํ†ตํ•œ 5์ฐจ ์น˜๋ฃŒ์—์„œ

    8์ฐจ ์น˜๋ฃŒ์˜ ๊ฒฐ๊ณผ๋ฅผ ๋ถ„์„ํ•ด ๋ณด๋ฉด 5์ฐจ ์น˜๋ฃŒ์—์„œ๋Š” 4.7 ยฑ 1.4 ์—์„œ 4.1 ยฑ

    1.1๋กœ 0.6 ยฑ 0.5 (p=0.046), 6์ฐจ ์—์„œ๋Š” 4.3 ยฑ 1.1 ์—์„œ 3.7 ยฑ 1.1๋กœ 0.6 ยฑ

    0.5 (p=0.046), 7์ฐจ ์—์„œ๋Š” 4.0 ยฑ 1.2 ์—์„œ 3.3 ยฑ 1.1๋กœ 0.7 ยฑ 0.5

    (p=0.025), ๋งˆ์ง€๋ง‰ ์น˜๋ฃŒ์ธ 8์ฐจ ์—์„œ๋Š” 3.2 ยฑ 1.1 ์—์„œ 1.9 ยฑ 1.8 ๋กœ 1.4 ยฑ

    0.9 (p=0.017)๋กœ ๋ชจ๋‘ ์œ ์˜์„ฑ์ด ์ธ์ •๋˜์—ˆ๋‹ค.

  • 51

    Table 9. The Effect of Treatment on the Change of VAS

    No. of Tx (Days of Interval)

    Before After Difference p-value*

    1st(0d) 7.1 ยฑ 1.1 5.1 ยฑ 1.3 2.0 ยฑ 0.7 0.000

    2nd(3d) 6.0 ยฑ 1.4 4.7 ยฑ 1.0 1.3 ยฑ 0.9 0.004

    3rd(4d) 5.4 ยฑ 1.1 4.6 ยฑ 1.1 0.9 ยฑ 0.9 0.045

    4th(3d) 5.1 ยฑ 1.1 4.0 ยฑ 1.0 1.1 ยฑ 0.7 0.005

    5th(4d) 4.7 ยฑ 1.4 4.1 ยฑ 1.1 0.6 ยฑ 0.5 0.046**

    6th(3d) 4.3 ยฑ 1.1 3.7 ยฑ 1.1 0.6 ยฑ 0.5 0.046**

    7th(4d)

    8th(3d)

    4.0 ยฑ 1.2

    3.2 ยฑ 1.1

    3.3 ยฑ 1.1

    1.9 ยฑ 1.8

    0.7 ยฑ 0.5

    1.4 ยฑ 0.9

    0.025**

    0.017** *Paired Sample T-Test **Wilcoxon Signed-Rank Test

  • 52

    Figure 10. Change of VAS (Visual Analogue Scale)

  • 53

    5.2.3. ๊ฐ ํšŒ์ˆ˜๋ณ„ ์น˜๋ฃŒ ์ „ํ›„ ํ˜ˆ์•• ๋ˆ„์  ์น˜๋ฃŒ ํšจ๊ณผ ๋ณ€ํ™” ๋ฐ ๋ถ„์„

    1์ฐจ ์น˜๋ฃŒ์ „ ํ˜ˆ์•• ์ธก์ •๊ฐ’์—์„œ ๊ฐ ํšŒ์ฐจ๋ณ„ ์น˜๋ฃŒ ํ›„ ํ˜ˆ์••์˜ ์ฐจ์ด๋ฅผ ํ†ตํ•˜์—ฌ

    ๋ˆ„์  ํšจ๊ณผ๋ฅผ ๋ถ„์„ ํ•œ ๊ฒฐ๊ณผ, 1์ฐจ ์น˜๋ฃŒํ›„ ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••์˜ ๋ณ€ํ™” 11.1 ยฑ 9.6

    mmHg (p=0.022), 2์ฐจ ์น˜๋ฃŒ ํ›„ ์ˆ˜์ถ•๊ธฐ์••๊ณผ ์ดˆ๊ธฐ ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••์˜ ์ฐจ๋Š” 11.3 ยฑ

    11.1 mmHg (p=0.015) ๋กœ ๋šœ๋ ทํ•œ ์ฐจ์ด๊ฐ€ ๋‚˜ํƒ€๋‚ฌ๊ณ , 3์ฐจ ์น˜๋ฃŒํ›„ ์ˆ˜์ถ•๊ธฐ์••๊ณผ

    ์ดˆ๊ธฐ์˜ ์ˆ˜์ถ•๊ธฐ์••์˜ ๋ณ€ํ™”๋Š” 14.6 ยฑ 11.1 mmHg (p=0.013), 4์ฐจ ์น˜๋ฃŒํ›„ ์ˆ˜์ถ•๊ธฐ

    ์••์˜ ๋ณ€ํ™”๋Š” 15.7 ยฑ 10.0 mmHg (p=0.006)๋กœ ์ธก์ •๋˜์–ด ์œ ์˜ํ•œ ์ˆ˜์ถ•๊ธฐ

    ํ˜ˆ์••์ด ๊ฐ์†Œ๋ฅผ ํ™•์ธํ•  ์ˆ˜ ์žˆ์—ˆ๋‹ค. 5์ฐจ ์น˜๋ฃŒํ›„ ์ˆ˜์ถ•๊ธฐ ์••์˜ ๋ณ€ํ™”๋Š” 19.4 ยฑ

    10.9 mmHg (p=0.003), 6์ฐจ ์น˜๋ฃŒํ›„ ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••์˜ ๋ณ€ํ™” ํญ์€ 18.7 ยฑ 9.7

    mmHg (p=0.002) ๋กœ ์ˆ˜์ถ•๊ธฐ ์••์˜ ๊ฐ์†Œ๊ฐ€ ๋šœ๋ ทํ•˜๊ฒŒ ์œ ์ง€๋˜๊ณ  ์žˆ์Œ์„ ์•Œ ์ˆ˜

    ์žˆ์—ˆ๋‹ค. ๋˜ํ•œ 7์ฐจ ์น˜๋ฃŒ ํ›„ ์ˆ˜์ถ•๊ธฐ์••์˜ ๋ณ€ํ™”๋Š” 20.7 ยฑ 10.8 mmHg (p=0.002)

    ๊ณผ 8์ฐจ ์น˜๋ฃŒ ํ›„ ์ˆ˜์ถ•๊ธฐ์••์˜ ๋ณ€ํ™”์ธ 23.0 ยฑ 2.2 mmHg (p=0.000) ๋„ ๋šœ๋ ทํ•œ

    ์œ ์˜์ฐจ๋ฅผ ๋ณด์˜€๋‹ค.

    ์ด์™„๊ธฐ ํ˜ˆ์••์˜ ์ตœ์ดˆ ์ธก์ •๊ฐ’๊ณผ ๋งค ์น˜๋ฃŒํ›„ ์ธก์ •๋œ ์ด์™„๊ธฐ ํ˜ˆ์••์˜ ๊ฐ•์••์€

    1ํšŒ ์น˜๋ฃŒ ํ›„ 8.0 ยฑ 3.1 mmHg (p=0.000)๋กœ ๋‚˜ํƒ€๋‚ฌ๊ณ , 2์ฐจ ์น˜๋ฃŒํ›„ ์ด์™„๊ธฐ์••์˜

    ๋ณ€ํ™”๋Š” 13.4 ยฑ 5.8 mmHg (p=0.002)๋กœ ๋šœ๋ ทํ•œ ๊ฐ์†Œ๋ฅผ ๋ณด์˜€๋‹ค. 3์ฐจ ์น˜๋ฃŒํ›„

    ์ด์™„๊ธฐ ๊ฐ•์••ํญ์€ 15.1 ยฑ 5.8 mmHg (p=0.000), 4์ฐจ ์น˜๋ฃŒํ›„ ์ด์™„๊ธฐ ๊ฐ•์••ํญ์€

    16.1 ยฑ 5.8 mmHg (p=0.000) ๋กœ ์œ ์˜ํ•œ ๊ฐ์†Œ๋ฅผ ํ™•์ธ ํ•  ์ˆ˜ ์žˆ์—ˆ๋‹ค. ์ด์™ธ์—๋„

    5์ฐจ ์น˜๋ฃŒํ›„ ์ด์™„๊ธฐ ๊ฐ•์••ํญ์€ 17.7 ยฑ 4.6 mmHg (p=0.000), 6์ฐจ ์น˜๋ฃŒํ›„

    ์ด์™„๊ธฐ ๊ฐ•์••ํญ์€ 17.1 ยฑ 3.7 mmHg (p=0.000)๋กœ ์ธก์ •๋˜์–ด ์œ ์˜ํ•œ ๊ฐ์†Œ๋ฅผ

  • 54

    ๋ณด์˜€์œผ๋ฉฐ 7์ฐจ ์น˜๋ฃŒํ›„ ์ด์™„๊ธฐ ๊ฐ•์••ํญ์€ 10.4 ยฑ 2.4 mmHg (p=0.000)๊ณผ 8์ฐจ

    ์น˜๋ฃŒํ›„ ์ด์™„๊ธฐ ๊ฐ•์••ํญ์€ 17.9 ยฑ 3.8 mmHg (p=0.000)๋กœ ๋ˆ„์  ์น˜๋ฃŒ ํšจ๊ณผ๊ฐ€

    ๊ฐ์†Œํ•˜์—ฌ ๋šœ๋ ทํ•œ ์œ ์˜์„ฑ์„ ๋ณด์˜€๋‹ค.

    ์ด์ƒ๊ณผ ๊ฐ™์€ ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••๊ณผ ์ด์™„๊ธฐ ํ˜ˆ์••์˜ ๋ˆ„์  ์น˜๋ฃŒ ํšจ๊ณผ๋ฅผ ๋น„๊ตํ•œ ๊ฒฐ๊ณผ

    ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••๊ณผ ์ด์™„๊ธฐ ํ˜ˆ์••์—์„œ ์•„์ฃผ ํ˜„์ €ํ•œ ๊ฐ์†Œ ํšจ๊ณผ(p

  • 55

    ๋ณด์˜€๋‹ค.

    Table 10. Cumulative Effect of Systolic Blood Pressure

    No. of Treatment

    (Days of Interval)

    Mean of after Nth

    Treatment

    Difference p-value*

    1st(0d) First_B - First_A 142.4 ยฑ 12.7

    11.1 ยฑ 9.6

    0.022

    2nd(3d) First_B โ€“ Second_A 142.3 ยฑ 12.7

    11.3 ยฑ 11.1

    0.015

    3rd(4d) First_B โ€“ Third_A 139.0 ยฑ 14.1

    14.6 ยฑ 11.1

    0.013

    4th(3d) First_B โ€“ Fourth_A 137.9 ยฑ 13.4

    15.7 ยฑ 10.0

    0.006

    5th(4d) First_B โ€“ Fifth_A 134.1 ยฑ 13.9

    19.4 ยฑ 10.9

    0.003

    6th(3d) First_B โ€“ Sixth_A 134.9 ยฑ 12.7

    18.7 ยฑ 9.7

    0.002

    7th(4d) First_B โ€“ Seventh_A

    8th(3d) First_B โ€“ Eighth_A

    32.9 ยฑ 14.0

    130.6 ยฑ 8.2

    20.7 ยฑ 10.8

    23.0 ยฑ 2.2

    0.002

    0.000

    *Paired Sample T-Test

  • 56

    Table 11. Cumulative Effect of Diastolic Blood Pressure

    No. of Treatment

    (Days of Interval)

    Mean of after Nth

    Treatment

    Difference p-value*

    1st(0d) First_B - First_A 81.7 ยฑ 3.8

    8.0 ยฑ 3.1

    0.000

    2nd(3d) First_B โ€“ Second_A 76.3 ยฑ 6.2

    13.4 ยฑ 5.8

    0.002

    3rd(4d) First_B โ€“ Third_A 74.6 ยฑ 6.1

    15.1 ยฑ 5.8

    0.000

    4th(3d) First_B โ€“ Fourth_A 73.6 ยฑ 6.0

    16.1 ยฑ 5.8

    0.000

    5th(4d) First_B โ€“ Fifth_A 72.0 ยฑ 5.9

    17.7 ยฑ 4.6

    0.000

    6th(3d) First_B โ€“ Sixth_A 72.6 ยฑ 3.6

    17.1 ยฑ 3.7

    0.000

    7th(4d) First_B โ€“ Seventh_A

    8th(3d) First_B โ€“ Eighth_A

    71.3 ยฑ 4.4

    71.9 ยฑ 5.2

    10.4 ยฑ 2.4

    17.9 ยฑ 3.8

    0.000

    0.000

    *Paired Sample T-Test

  • 57

    Table 12. SYS Treatment Rate (%)

    No. of Treatment

    (Days of Interval)

    Mean of after Nth

    Treatment

    Difference (%) p-value*

    1st(0d) First_B - First_A 142.4 ยฑ 12.7

    7.4 ยฑ 6.2

    0.020

    2nd(3d) First_B โ€“ Second_A 142.3 ยฑ 12.7

    7.4 ยฑ 6.1

    0.016

    3rd(4d) First_B โ€“ Third_A 139.0 ยฑ 14.1

    4.8 ยฑ 6.1

    0.084

    4th(3d) First_B โ€“ Fourth_A 137.9 ยฑ 13.4

    10.3 ยฑ 6.7

    0.006

    5th(4d) First_B โ€“ Fifth_A 134.1 ยฑ 13.9

    12.7 ยฑ 7.2

    0.003

    6th(3d) First_B โ€“ Sixth_A 134.9 ยฑ 12.7

    12.3 ยฑ 6.4

    0.002

    7th(4d) First_B โ€“ Seventh_A

    8th(3d) First_B โ€“ Eighth_A

    32.9 ยฑ 14.0

    130.6 ยฑ 8.2

    13.6 ยฑ 7.2

    15.0 ยฑ 1.9

    0.002

    0.000

    *Paired Sample T-Test

  • 58

    Table 13. DI Treatment Rate (%)

    No. of Treatment

    (Days of Interval)

    Mean of after Nth

    Treatment

    Difference (%) p-value*

    1st(0d) First_B - First_A 81.7 ยฑ 3.8

    8.9 ยฑ 3.2

    0.000

    2nd(3d) First_B โ€“ Second_A 76.3 ยฑ 6.2

    14.8 ยฑ 6.2

    0.002

    3rd(4d) First_B โ€“ Third_A 74.6 ยฑ 6.1

    9.6 ยฑ 6.2

    0.006

    4th(3d) First_B โ€“ Fourth_A 73.6 ยฑ 6.0

    17.9 ยฑ 6.2

    0.000

    5th(4d) First_B โ€“ Fifth_A 72.0 ยฑ 5.9

    19.7 ยฑ 5.0

    0.000

    6th(3d) First_B โ€“ Sixth_A 72.6 ยฑ 3.6

    19.0 ยฑ 3.6

    0.000

    7th(4d) First_B โ€“ Seventh_A

    8th(3d) First_B โ€“ Eighth_A

    71.3 ยฑ 4.4

    71.9 ยฑ 5.2

    20.5 ยฑ 3.3

    19.9 ยฑ 4.0

    0.000

    0.000

    *Paired Sample T-Test

  • 59

    Figure 11. Cumulation Effect of Systolic Blood Pressure

    Figure 12. Cumulation Effect of Systolic Blood Pressure

  • 60

    Figure 13. Cumulative Effect of Diastolic Blood Pressure

    Figure 14. Cumulative Effect of Diastolic Blood Pressure

  • 61

    Figure 15. SYS Treatment Rate (%)

    Figure 16. DI Treatment Rate (%)

  • 62

    Figure 17. SYS Treatment Rate (%)

    Figure 18. DI Treatment Rate (%)

  • 63

    5.2.4. ๊ฐ ํšŒ์ˆ˜๋ณ„ ์น˜๋ฃŒ ์ „ํ›„ ํ†ต์ฆ ๋ˆ„์  ์น˜๋ฃŒ ํšจ๊ณผ ๋ณ€ํ™” ๋ฐ ๋ถ„์„

    1์ฐจ ์น˜๋ฃŒ์ „ ํ†ต์ฆ ์ธก์ •๊ฐ’์—์„œ ๊ฐ ํšŒ์ฐจ๋ณ„ ์น˜๋ฃŒ ํ›„ ํ†ต์ฆ์˜ ์ฐจ์ด๋ฅผ ํ†ตํ•˜์—ฌ

    ๋ˆ„์  ํšจ๊ณผ๋ฅผ ๋ถ„์„ ํ•œ ๊ฒฐ๊ณผ 1์ฐจ ์น˜๋ฃŒํ›„ ํ†ต์ฆ์˜ ๋ณ€ํ™” 2.0 ยฑ 0.7 (p=0.000), 2์ฐจ

    ์น˜๋ฃŒ ํ›„ ํ†ต์ฆ์˜ ์ฐจ๋Š” 2.4 ยฑ 0.5 (p=0.016) ์œผ๋กœ ์ •๊ทœ์„ค ๊ฒ€์ • ๊ฒฐ๊ณผ p-value

    ๊ฐ€ 0.05 ๋ณด๋‹ค ์ž‘์•„ ์ •๊ทœ์„ฑ(normality)์„ ๋งŒ์กฑํ•˜์ง€ ๋ชป์•„์˜€์œผ๋ฏ€๋กœ ๋น„๋ชจ์ˆ˜ ๊ฒ€์ •

    ๋ฐฉ๋ฒ•์ธ Wilcoxon Signed Rank Test๋ฅผ ์ ์šฉํ•˜์—ฌ ๊ฒฐ๊ณผ๋ฅผ ์–ป์—ˆ๋‹ค. 3์ฐจ ๋˜ํ•œ

    ๋น„๋ชจ์ˆ˜ ๊ฒ€์ •์„ ํ†ตํ•ด์„œ 2.5 ยฑ 0.5 (p=0.016)์˜ ์œ ์˜ํ•œ ํ†ต์ฆ์˜ ๊ฐ์†Œ๋ฅผ ํ™•์ธํ• 

    ์ˆ˜ ์žˆ์—ˆ๋‹ค. 4์ฐจ ์น˜๋ฃŒํ›„ ํ†ต์ฆ์˜ ๋ณ€ํ™”๋Š” 3.1 ยฑ 0.8 (p=0.000), ๋น„๋ชจ์ˆ˜ ๊ฒ€์ •์„

    ํ†ตํ•œ 5์ฐจ ์น˜๋ฃŒํ›„ ํ†ต์ฆ์˜ ๋ณ€ํ™” ํญ์€ 2.9 ยฑ0.4 (p=0.014), 6์ฐจ ์น˜๋ฃŒํ›„ ํ†ต์ฆ์˜

    ํญ์€ 3.4 ยฑ 0.7 (p=0.000), ๋น„๋ชจ์ˆ˜ ๊ฒ€์ •์„ ํ†ตํ•œ 7์ฐจ ์น˜๋ฃŒํ›„๋Š” 3.8 ยฑ 0.6

    (p=0.016), ๋งˆ์ง€๋ง‰ 8์ฐจ ์น˜๋ฃŒํ›„๋Š” 5.2 ยฑ 1.3 (p=0.000)๋กœ ๋šœ๋ ทํ•œ ์œ ์˜ํ•œ

    ์ฐจ์ด๋ฅผ ๋ณด์˜€๋‹ค.

    ๋˜ํ•œ, VAS ๋ˆ„์ ์น˜๋ฃŒ์œจ์„ ๋น„๊ตํ•œ ๊ฒฐ๊ณผ 1์ฐจ ์น˜๋ฃŒ ํ›„์— 28.9 ยฑ 11.6 (%)

    (p=0.001), 2์ฐจ ์น˜๋ฃŒ ํ›„์— 33.6 ยฑ 5.9 (%) (p=0.000), 3์ฐจ ์น˜๋ฃŒ ํ›„์— 23.1 ยฑ

    12.8 (%) (p=0.003), 4์ฐจ ์น˜๋ฃŒ ํ›„์— 43.5 ยฑ 10.8 (%) (p=0.000), 5์ฐจ ์น˜๋ฃŒ

    ํ›„์— 42.0 ยฑ 7.9 (%) (p=0.000), 6์ฐจ ์น˜๋ฃŒ ํ›„์— 48.0 ยฑ 11.8 (%) (p=0.000),

    7์ฐจ ์น˜๋ฃŒ ํ›„์— 54.3 ยฑ 10.4 (%) (p=0.000), ๊ทธ๋ฆฌ๊ณ  8์ฐจ ์น˜๋ฃŒ ํ›„


Recommended